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Abstract 
 
‘Characterisation of the Regulation of Growth by Nitric Oxide Signalling in Drosophila 
melanogaster’ 
A thesis submitted to the University of Sussex for the degree of Doctor of Philosophy 
By Anna Scott 
School of Life Sciences 
September 2009 
 
 
 
The molecular mechanisms that control growth appear to be conserved across the animal 
kingdom, with nitric oxide regulation of cell proliferation and growth being found to be very 
significant. Indeed, in Drosophila larval development and mammalian systems NO has been 
shown to be particularly important in these processes, and previous work in our laboratory has 
identified the Drosophila forkhead transcription factor dFOXO as a critical target through 
which NO signalling exerts its regulatory effects on growth, although little is currently known 
concerning the precise mechanisms involved.  
 
Accordingly, in this thesis, we investigate the processes through which NO may modulate 
growth and demonstrate that targeted expression of a constitutively active NO Synthase to 
whole larval salivary glands or clones of cells within the glands, results in reduced 
endoreplication and growth as measured by nuclear size. Targeted over expression of dFOXO 
itself is shown to result in similar phenotypes, and subsequent molecular analysis of potential 
signalling targets required for this inhibition of growth reveals that dFOXO, Thor and Myc 
expression are regulated in vivo by NO. 
 
To elucidate if NO acts directly on dFOXO, the genetic interaction of components of the 
insulin signalling pathway is analysed, exploiting RNA interference to assay what components 
are necessary for the NO signal to be effectively transduced, and it is demonstrated that NO 
control of growth is not through sGC, one of the most significant known targets for NO-
mediated regulation in other organisms 
 
We subsequently investigated the roles of Thor, a Drosophila 4E-binding protein, and the 
kinase, Lk6, homologues of which are known to be important in growth regulation in other 
organisms,  and thus potential effectors of NO and dFOXO. However our data demonstrated 
that neither Thor nor Lk6 are required for the inhibition of growth by NO. 
 
Interestingly a potential anti-oncogenic effect of NO signalling was also revealed following 
analysis of interactions between NO and Ras or Myc induced growth in which NO was able 
reduce the overgrowth produce by both these oncogenes. 
 
Overall this research confirms dFOXO as an essential target for NO induced inhibition of 
growth. The work also eliminates two dFOXO transcription targets, Thor and Lk6, as necessary 
for NO to regulate growth.  
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Chapter 1:  General Introduction 
1.1. Nitric Oxide 
Nitric oxide (NO) is a reactive free radical gas, which is known to have many important 
physiological roles (Bruckdorfer 2005). NO acts as a short-lived intracellular and transcellular 
messenger, and has been seen to have many functions within vertebrates as well as 
invertebrates, acting as a major regulator in nervous, immune and cardiovascular systems 
(Schmidt & Walter 1994).  
In this chapter I will give a basic introduction to NO focusing on its role in cell signaling 
within the fruit fly Drosophila melanogaster.  
1.1.2. Nitric Oxide Synthase 
In living systems, NO is synthesized from L-arginine in a reaction catalysed by nitric oxide 
syntheses (NOS) (Fig. 1.1) (Stuehr 1997). NOS acts by oxidising the guanidine group of L-
arginine in a process which uses several cofactors and consumes five electrons, resulting in the 
formation of NO and L-citrulline (Bredt & Snyder 1994).  Three different isoforms of NOS 
have been identified in mammals:  neuronal (nNOS), inducible (iNOS) and endothelial (eNOS) 
(Bruckdorfer 2005). Although these nomenclature is used for the 3 isoforms, most mammalian 
cell types and tissues express one or more isoforms of NOS (Bruckdorfer 2005). 
 
 
 
 
 
 
 
 
Figure 1.1. NO biosynthesis from L-arginine. The intermediate in the formation of NO, the enzyme 
bound N-hydroxy-L-arginine is shown. The dotted line shows recycling of L-citrulline back to L-
arginine. Figure from (Bruckdorfer 2005).  
       L-arginine        N
ω
-hydroxy L-arginine      L-citrulline 
L-arginosuccinate 
                                     
Fumarate 
ATP 
Aspartate 
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1.1.3. Nitric Oxide function in vertebrate systems 
In mammalian systems NO is known to modulate a range of physiological functions. These 
include: control of vascular tone (Palmer et al 1987), the functionality of neurons (Meffert et al 
1994)  reviewed in (Prast & Philippu 2001) and the immune response (Nathan & Hibbs 1991) 
reviewed in (Bogdan 2001). However, although NO has many roles as a biological messenger 
for the purpose of this thesis I intend to focus on its role in cell proliferation.  
NO has been shown to inhibit the proliferation of many cell types, tumours and tumour cell 
lines in a wide variety of organisms. This action of NO on cell proliferation is reviewed in 
Villalobo 2006. Thirty nine cell types of differing tissue origin have demonstrated sensitivity to 
the inhibitory effect of exogenous NO. These tissues include muscle, endothelial, epithelial, 
lymphocyte and neural progenitor cells (Villalobo 2006). As well as these normal cell types, 
exogenous NO can also inhibit the proliferation of tumor cell lines that include those derived 
from breast cancer (Pervin et al 2001), colon cancer (Jarry et al 2004) and neuroblastoma cells 
(Murillo-Carretero et al 2002).   
The inhibitory effect on proliferation by NO has been shown many times but the mechanism(s) 
by which NO is inducing this effect is not clearly understood. To date, many studies have 
focused on how NO blocks the progression of the cell cycle. In many cell types NO has been 
shown to inhibit the G1 to S transition there by resulting in G1 arrest (Fig. 2.) (Gansauge et al 
1998, Wanga et al 2007) 
However, previous work has demonstrated that NO does not solely control proliferation, but 
that it also acts to balance cell proliferation and differentiation events (Kuzin et al 1996) 
(Peunova & Enikolopov 1995). For example, in brain development in the African clawed toad, 
Xenopus laevis, transitions of neural precursor cells from proliferation to differentiation 
determine the distinct anatomical features of the brain. It is thought that NO may mediate this 
transition as an area of NOS-expressing
 
cells lies adjacent to the zone of dividing neuronal 
precursors, and when NOS is inhibited, larger brains which are not correctly organized, are 
produced (Peunova et al 2001). 
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Figure 1.2.  Major effects of NO inhibition of the G1/S transition of the cell cycle (adapted from 
Villalobo 2006). During normal cell cycle progression, up-regulation of cyclins D1 and D2 (CycD1/2) 
prepares the stage for activation of Cdk4/6 during the G1 phase. Cdk4/6, activated by CycD1/2, plus 
Cdk2, in turn activated by cyclin E (CycE), phosphorylate the retinoblastoma protein (pRb) at multiple 
sites, releasing the repressor activity exerted on transcription factors of the E2F family. These 
transcription factors control, among others, the expression of cyclin A (CycA), which by activating 
Cdk2 is required for the progression of the cell cycle to its S phase. The inhibitory action of p16Ink4a, 
acting on the CycD1/2–Cdk4/6 complexes, plus p27Kip1 and p21Cip1/Waf1, both acting on the CycE–
Cdk2 complex, are also indicated. Major targets of NO relevant to inhibition of cell cycle progression at 
the G1/S transition, including the down-regulation of cyclin D and cyclin A expression, the up-
regulation of the expression of both the inhibitory protein p21Cip1/Waf1 and the transcription factor 
E2F, and the dephosphorylation of pRb, are also shown (Villalobo 2006). 
 
 
1.1.4. NO activity and soluble guanylate cyclase 
Some of the molecular actions of NO are known to be due to the formation of complexes 
between NO and the metallo prosthetic groups of various proteins/enzymes, for example, with 
the haem group of soluble guanylate cyclase (sGC) (Stamler 1994). sGC is responsible for the 
formation of cyclic GMP from the nucleotide GTP. cGMP acts a secondary messenger, which 
NO 
Cdk 4/6 
CycD1/2 
CycE 
Cdk 2 
p21 
Kip1 
p21 
Cip1 
p16 
Ink4a 
CycD1/2 
E2F 
CycA 
CycA 
Cdk 2 
pRb 
E2F 
 
S phase 
 
G1 phase 
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goes on to signal through cGMP-dependent protein kinases or PKGs. Active forms of PKG can 
phosphorylate many substrates including the IP3 receptor and subunits of myosin light chain 
phosphatase (Krumenacker et al 2004). The basal activity of sGC can be increased up to 200-
fold by the binding of NO, but the NO-heme complex has a half-life around 0.2s (Bruckdorfer 
2005).  
1.1.5. NOS in Drosophila melanogaster 
The Drosophila melanogaster NOS gene was cloned and characterised by screening a phage 
library of the Drosophila genome using a fragment of rat nNOS gene (Regulski & Tully 1995). 
In Drosophila, NOS is encoded by a single dNOS gene, found on the second chromosome at 
the position 32B (Regulski & Tully 1995). The major product of the gene is the dNOS1protein, 
which bears extensive homology to all three of the mammalian NOS isoforms but shows 
highest homology with the neuronal NOS (nNOS) with 43% amino acid sequence identity 
(Regulski & Tully 1995). As with all mammalian NOS enzymes, the dNOS protein contains 
putative binding sites for calmodulin, FMN, FAD, and NADPH, and dNOS activity is 
Ca2+/calmodulin dependent when expressed in cell culture (Regulski & Tully 1995). 
 
1.1.6. NOS expression in Drosophila 
Across a variety of insect species the NADPH-diaphorase reaction has been widely used as a 
histochemical marker for NOS. The basis of this assay is the detection of an insoluble 
formazan precipitate formed by the NADPH diaphorase enzyme. Using NADPH-diaphorase, 
the activity of NOS has been followed through Drosophila larval development (Kuzin et al 
1996). NOS activity is seen in high levels in the developing imaginal discs with staining 
becoming more intense as development proceeds. The wing, eye, haltere, and genital discs in 
the third instar show distinct and reproducible patterns of intense staining which then gradually 
decreases in a specific spatial pattern during early pupal development (Kuzin et al 1996). 
 
1.1.7. NO function in development 
NO has also been shown to inhibit cell proliferation in other organisms, as well as in 
mammalian systems. In 1995, Peunova and Enikolopov (Peunova & Enikolopov 1995) 
observed that the growth arrest and differentiative effect of nerve growth factor (NGF) on 
 17 
 
PC12 cells was mediated by NO.  It was shown that NOS expression was induced by NGF 
along side differentiation, that NO acted as a cytostatic agent in neural cells and that if NOS 
was inhibited it stopped the NGF-induced proliferation decrease, and in turn prevented 
differentiation of cells towards neuronal phenotype (Peunova & Enikolopov 1995). This 
finding indicated that NO act as a negative regulator of proliferating neuroblasts, with a role in 
neuronal differentiation. This role results in neuroblasts being able to escape from their state of 
proliferation, thereby allowing their differentiation towards a neuronal phenotype (Contestabile 
& Ciani 2004). The antiproliferative action of NO has not only been demonstrated in neuronal 
precursor cells. Kuzin et al. (1996) showed that in Drosophila, NO negatively regulates cell 
proliferation of imaginal discs in late larval stages, with an increase in NOS activity levels, 
coinciding with temporal cytostasis. In this instance NOS inhibition results in excess cell 
proliferation and hypertrophy of organs. In contrast, ectopic expression of NOS was seen to 
have the opposite effect, causing hypotrophy (Kuzin et al 1996). These results together have 
shown NO acts as an antiproliferative agent, playing an important role in development, 
allowing cell differentiation to occur by halting proliferation. This function of NO is further 
supported by its action on DNA replication. NO has been identified as acting on DNA 
synthesis by Garg and Hassid 1989, with NO-generating vasodilators effectively inhibiting 
DNA synthesis and proliferation of rat aortic smooth muscle cells. Similarly, Kuzin et al saw 
that regions of developing imaginal tissue with high levels of NOS, showed reduced DNA 
synthesis as determined by BrdU incorporation (Kuzin et al 1996). Kuzin et al also found that 
manipulation of endogenous or transgenic NOS activity in imaginal discs during eye disc 
development was able to enhance or suppress the effects of RBF and E2F on development of 
the eye. This suggested a role for NO in the developing imaginal eye disc via interaction with 
the retinoblastoma (Rb) pathway (Kuzin et al 2000). 
Drosophila NOS nulls created have been reported to be homozygous late embryonic and larval 
lethal, showing the essential role of NOS within Drosophila development (Regulski et al 
2004).  
NO has been also been identified as playing a role in visual system development through 
another pathway (Gibbs et al 2001). During the development of photoreceptors within 
Drosophila, there is a period of NO-sensitive soluble guanylate cyclase (sGC) production (just 
before functional connections with the optic lobe interneurons are made), which in turn 
stimulates production of cGMP that can then interact with other molecular targets (Gibbs et al 
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2001). The inhibition of either NO or sGC during this time results in disorganisation in retinal 
projection pattern, and leads to the overgrowth of the retinal axons.  
NO has also been shown to be involved in development in other insect species. In the moth  
Manduca sexta the suppression or the removal of NO effects cell proliferation and optic lobe 
development (Champlin & Truman 2000). 
 
1.2. Cell Proliferation and Growth Control 
Although much is known about NO and its mediation of cell proliferation, little is known about 
the mechanism involved (Villalobo 2006).  
In this thesis the molecular and cellular mechanisms by which NO induces growth inhibition 
will be investigated. Accordingly, the nature of cell proliferation and growth control within the 
context of Drosophila will first be introduced. 
 
It can be seen that body plans between different species can vary considerably, but growth 
control is an evolutionarily conserved process with many similarities across different 
organisms. An understanding of growth control is important, not only to help better understand 
how genes are able to control animal size, but also in the context of disease, as when regulation 
of growth goes wrong it can result in numerous diseases including cancer (Weinkove & 
Leevers 2000).  
A simple definition of growth is as an accumulation of mass which can be either an increase in 
cell number or size or both. Cell proliferation is the increase in cell number, whereas increase 
in cell size requires biosynthesis. Cells are able to couple both the control of growth and cell 
proliferation, in order for tissues to develop. Cells multiply under the control of the cell cycle, 
which acts to ensure DNA is replicated before mitosis. Usually an accumulation of mass is 
followed by subsequent cell division, with animal and organ growth being generally 
accompanied by increases in cell number, not cell size (Weinkove & Leevers 2000). However, 
this is not the case with certain larval tissues of Drosophila. 
 
Drosophila is useful model organism for the study of growth. Drosophila has a short 
generation time, as well as being easily and inexpensively cultured. As a consequence much 
work has been done with Drosophila which has considerably contributed to our knowledge on 
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growth regulation and elucidation of many of the cell-signalling components required. 
Drosophila larvae contain imaginal discs, which are epithelia organs that reorganize to 
generate adult epidermal structures, these include wings, eyes and legs (Demerec 1950). The 
imaginal discs have been utilised to study growth control providing a model of proliferating 
tissue for research. Drosophila imaginal discs accumulate mass and cell number and can be 
studied during the larval instar phases before metamorphosis. Imaginal discs not only provide a 
cellular model system but also a model which incorporates the types of cell-cell 
communication networks that occur in other tissues. This results in a significantly more 
sophisticated model than would be provided by a homogenous population of tissue culture 
cells. Using Drosophila imaginal wing discs, proliferation and growth have been extensively 
studied. An example of such work is that of Neufeld et al where stimulatory and inhibitory 
components of the cell cycle were over-expressed. They then found that within the wing disc 
tissue, compensatory mechanisms exist to keep growth and cell proliferation regulated 
(Neufeld et al 1998).  
 
Growth and cell cycle progression can also be studied using endoreplicating cells in tissues 
whose patterning has already been established. Endoreplicating cells undergo a modified cell 
cycle, in which cellular DNA synthesis occurs without subsequent mitosis. The continued 
DNA replication increases nuclear size and cell size throughout larval development. 
Endoreplicated cells in which the sister chromatids remain closely associated are referred to as 
polytene (Edgar & Orr-Weaver 2001). In Drosophila larvae, salivary gland cells are 
endoreplicating which results in large cells with polytene chromosomes which have up to 2048 
copies of the euchromatic genome neatly aligned in parallel arrays (Edgar & Orr-Weaver 
2001). Endoreplicating cells have been shown to be sensitive to nutritional control with 
numerous genes required for protein synthesis being vital for endocycling (Britton & Edgar 
1998, Galloni & Edgar 1999). Salivary glands can be used to study growth in Drosophila as 
due to the large cell size, any change in protein expression and change in size is relatively 
easily determined. 
 
In order to properly consider Nitric Oxide signaling in the context of growth control, an 
understanding of the components of cellular signaling pathways known to regulate growth is 
important. These are discussed below. 
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1.2.1. Ras  
Ras is a proto-oncogene, and it has been estimated that 30% of all human tumors contain an 
activating mutation in Ras (Vojtek & Der 1998). Ras is a guanine nucleotide binding protein, a 
GTPase. As with all GTPases, it is controlled by the GDP/GTP
 
cycle. Ras is inactive when 
bound to GDP but becomes active when bound to GTP. Ras in the active GTP bound form acts 
in signal transduction pathways to transmit extracellular signals from receptor tyrosine kinases 
to downstream serine/threonine kinase targets. These serine/threonine kinases include Raf (c-
Raf-1, A-Raf, and B-Raf), MEK (MAPK/ERK kinases 1 and 2), and ERK1/2 (Vojtek & Der 
1998).  
 
In Drosophila, Ras 85D has been found to promote growth in several tissues. Clones of cells in 
wing discs expressing activated Ras (Ras
V12) 
have increased cell and clone size when compared 
to wild type controls (Prober & Edgar 2000). In the Drosophila eye disc Ras has been shown to 
mediate growth, survival and differentiation through MAPK activity (Halfar et al 2001). Ras is 
also capable of controlling levels of other growth effectors such as dMyc, another proto-
oncogene (Prober & Edgar 2000). The transcription factor dMyc has similar effects on growth 
to Ras, and wing disc cells expressing Ras
V12
, an activated form of Ras, show increased levels 
of dMyc protein (Prober & Edgar 2000). Ras has effects on multiple pathways, including those 
involving phosphoinositide 3-kinase (PI3K) (Prober & Edgar 2000). However, Ras is not 
required for dPI3K signaling although it is required to maintain normal levels of dMyc protein. 
In salivary glands Ras
 V12
 has also been seen to cause significant cell growth, which results in 
large over-grown salivary glands (Berry & Baehrecke 2007). 
1.2.2. Myc 
Myc is part of a network of transcription factors which act in a wide variety of processes 
including growth and proliferation, differentiation, apoptosis and oncogenesis (Pierce et al 
2004). This transcription network is known as the Max transcription factor network, it is made 
up of a group transcription factors that share two common features. Firstly they contain a 
basic-helix-loop-helix-leucine zipper (bHLHZ) motif which mediates protein-protein binding 
and DNA binding (Grandori et al 2000). Secondly, they all form individual heterodimers with 
Max which is also a bHLHZ protein (Grandori et al 2000). Myc acts in this Max network by 
binding with Max, and in turn the heterodimer formed binds DNA and activates transcription. 
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Myc target genes include those involved in cell metabolism, ribosome biogenesis and 
translation control. Myc can also act to repress transcription by forming an inhibitory complex 
with Miz-1 (Pierce et al 2004). The Max network also includes the Mxd family of proteins. 
Mxd proteins can also bind to Max and DNA, acting as antagonists of the Myc function 
(Grandori et al 2000). 
 
Drosophila has one ortholog to the mammalian Myc transcription factor dMyc. dMyc is 
encoded by the diminutive gene (dm) (Secombe et al 2004). In Drosophila, as in mammalian 
cells, dMyc acts as regulator of growth and proliferation. When the expression of dMyc is 
reduced in Drosophila it results in a reduction in the size of both cells and animals (Neufeld et 
al 1998, Pierce et al 2004). Conversely, when dMyc is over expressed in Drosophila it results 
in an increase in size of cells with both mitotic and endoreplicating cells, including those of the 
salivary gland, being larger than normal (Grewal et al 2005, Neufeld et al 1998, Pierce et al 
2004). dMyc has also been shown to be a regulator of rRNA synthesis and ribosome biogenesis 
during larval development (Grewal et al 2005).  
Myc has been identified as both a direct and indirect target for the transcription factor dFOXO, 
with myc mRNA levels being controlled by dFOXO in a tissue-specific manner. dFOXO can 
inhibit or increase myc expression (Teleman et al 2008). FOXO has been shown to suppress 
Myc driven proliferation (Bouchard et al 2007) and Myc dependent gene expression in cell 
culture (Delpuech et al 2007).  
1.2.3. Insulin Signaling Pathway 
The insulin pathway is one of the most intensively studied growth-regulatory signaling 
pathways and is conserved from C. elegans to mammals (Nelson & Padgett 2003). Insulin is 
categorised as an IGF-1 growth factor. The binding of insulin to the insulin receptor activates 
the insulin-signaling pathway. The binding of insulin initiates a cascade of events which results 
in phosphorylation of several adaptor proteins, including the insulin receptor substrates (IRS) 
(Casas-Tintoa et al 2007). 
Reduction in the insulin signal in Drosophila tissues has been shown to result in reduced disc 
growth, disc size and reduce size and DNA content of endoreplicating cell. Also mutants in the 
insulin signaling pathway have both reduced larval and adult fly size (Britton et al 2002). In 
contrast, if the pathways activity is enhanced, growth and cell size are increased.  
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Unsurprisingly, it is easier to get a clear idea of how each individual step works by breaking 
the insulin pathway down into individual components. 
The components of insulin signaling in the context of Drosophila are shown in Figure 1.3. and 
will be outlined below. It is important to note that the insulin pathway is highly conserved 
between Drosophila and mammals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Insulin signaling pathway in Drosophila (adapted from(Neufeld 2003)). The dFOXO 
protein mediates a transcriptional response to insulin signaling. Under conditions of abundant nutrients, 
dFOXO is phosphorylation by Akt and retained in an inactive state in the cytoplasm. When insulin 
levels fall, dFOXO is dephosphorylated and translocated into the nucleus (pink arrow), where it 
stimulates transcription of Thor and presumably other negative regulators of growth. In addition, active 
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dFOXO increases expression of the insulin receptor gene, which may result in increased insulin 
sensitivity under low insulin conditions (Neufeld 2003). 
 
1.2.3.1. Drosophila Insulin receptor and Peptides 
The Drosophila homolog of the insulin/IGF1 receptor (dInR) is essential for normal growth 
(Brogiolo et al 2001, Fernandez et al 1995). dInR is a tyrosine kinase receptor which, on 
binding with Drosophila insulin-like peptides (DILPs), results in the autophosphorylation of 
the dInR which then phosphorylates insulin receptor substrate (IRS) proteins. Drosophila has 
seven insulin like peptides, dilp1 to 5 show the most significant homology to mouse and 
human insulins (Rulifson et al 2002). Dilp2 has been demonstrated to have a genetic 
interaction with dInR (Brogiolo et al 2001). 
The sequence similarity between the human and Drosophila receptors is also high, and dInR is 
able to bind mammalian insulin with high affinity (Garofalo 2002). All described alleles of 
dInR are recessive, and homozygous embryonic or early larval lethal. It has been shown only 
weak heteroallelic combinations of dInR alleles were found to be viable and yield adults, 
although these animals are developmentally delayed, with small body size, and female sterility 
(Brogiolo et al 2001, Fernandez et al 1995). dInR expression is regulated by a feedback 
mechanism whereby the transcription factor, dFOXO, which lies downstream of dInR in the 
insulin signaling pathway can stimulate its expression (Casas-Tintoa et al 2007, Puig et al 
2003, Puig & Tjian 2005).  
A Drosophila IRS protein, called Chico, has been described by Böhni et al, 1999, and Chico 
mutant flies, like dInR mutants, are smaller in size due to a reduction in cell size and cell 
number (Böhni et al 1999). 
Targeted ablation of the dilp expressing neurons in the larval brain results in an undergrowth 
phenotype similar to that found with Chico mutants (Rulifson et al 2002). Similarly 
overexpression of dilps results in significant increase in body size (Ikeya et al 2002). 
1.2.3.2. PI3K and PTEN 
Binding of DILPs to dInR induces phosphorylation of the insulin receptor substrates, activating 
phospho-inositide 3–kinase (P13K). Activated PI3Ks phosphorylate inositol lipids at the 3′ 
position, generating a variety of secondary messengers. The most critical secondary messenger 
produced by PI3K is generated when phosphatidylinositol-4,5-P2 (PIP2, mostly found in lipid 
 24 
 
membranes) is phosphorylated in the third position, producing phosphatidylinositol-3,4,5-P3 
(PIP3) (Britton et al 2002). 
PI3K is a heterodimer made up of a catalytic subunit (Dp110) and an adaptor subunit (Dp60) 
(Leevers et al 1996). Dp110 protein is homologous to class I mammalian PI3Ks, p110α and 
p110β. Overexpression of Dp110 in wing or eye imaginal discs of Drosophila larvae results in 
flies with enlarged wings or eyes respectively. Overexpression of mutated Dp110 containing a 
mutation predicted to result in the loss of catalytic activity results in smaller wings and eyes 
(Leevers et al 1996). 
A fusion protein called tGPH (tubulin-GPH) was developed during a study looking at PI3K 
activity in vivo in Drosophila. The fusion protein contains the pleckstrin homology (PH) 
domain of the Drosophila homolog of the general receptor for phosphoinositides-1 (GRP1) 
fused to green fluorescent protein (GFP), generating a protein called GPH (GFP-PH domain) 
(Britton et al 2002). PH domains bind specifically the secondary messenger, PIP3. PIP3 
generally resides in lipid membranes, particularly the plasma membrane, GRP1 is recruited to 
membranes when PI3-kinase activity raises cellular levels of PIP3. Accordingly high PI3K 
activity typically results in movement of GPH to the cell membranes (Britton et al 2002). 
The effects of PI3K activity are counteracted by the action of the tumour suppressor gene 
PTEN (phosphatase and tensin homolog on chromosome 10) (Gao et al 2000, Goberdhan et al 
1999, Huang et al 1999). PTEN acts to regulate the effects of PI3K, as PTEN dephosphorylates 
PIP3 back to PIP2 (Goberdhan et al 1999). 
Another regulator of PI3K in Drosophila, Susi, has also been identified. Susi directly binds to 
dP60, the regulatory subunit of dPI3K. Susi has no overt similarity to known inhibitors of 
PI3K/PKB signaling in other systems, it thus defines a novel mechanism by which this 
signaling cascade is kept in check, and may be involved in insulin signaling during fasting 
(Wittwer et al 2005). 
1.2.3.3. Akt and dTor 
Once the secondary messenger PIP3 has been produced, it activates Akt. Akt is a 
serine/threonine kinase (also known as protein kinase B or PKB). Elevated levels of PIP3 
recruit the PH-domain-containing Akt protein to the plasma membrane, and thereby facilitating 
its further activation by phosphoinositide-dependent kinase 1 (PDK1). Akt loss-of-function 
mutants show reduction in cell size. Conversely, Akt overexpression results in an increase in 
cell size, without altering proliferation (Verdu et al 1999). When Akt is active it 
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phosophorylates the transcription factor dFOXO, which causes its retention in the cytoplasm. 
However, when there is low activity of Akt, dFOXO can enter the nucleus (Neufeld 2003). The 
role and regulation of dFOXO in controlling growth will be discussed in detail below 
(1.2.3.4.). 
TOR (Target of Rapamycin) represents a second branch of the insulin signaling pathway, 
downstream of Akt. It is a conserved Ser/Thr kinase (Wullschleger et al 2006), and is 
designated as mTOR/FRAP/RAFT1 in mammals and TOR1 and TOR2 in yeast.. In mammals 
TOR is capable of promoting cellular proliferation as a response to growth factors and the TOR 
pathway is known to act as a nutrient-sensitive growth pathway. In Drosophila, a homologue 
dTOR, has been described (Zhang et al 2000). The kinase activity of dTOR is required for 
growth factor-dependent phosphorylation of S6 kinase. Loss of dTOR produces phenotypes 
characteristic of starvation, in particular amino acid deprivation. Cell cycle arrest associated 
with dTOR loss of function can be suppressed by the overexpression of cyclin E (Zhang et al 
2000). dTOR activity is regulated through TSC1 and TSC2 (tuberous sclerosis complex genes 
1 and 2) which together act to inhibit dTOR (Gao et al 2002). TSC2 activity itself is thought to 
be directly inhibited following phosphorylation by Akt (Potter et al 2002). Although this 
regulatory mechanism has been questioned as, Tsc2 mutants in which the Akt phosphorylation 
sites were changed to nonphosphorylatable or phospho-mimicking residues expressed in Tsc2-
null mutants could completely rescue the lethality and cell growth defects of Tsc2-null mutants 
(Dong & Pan 2004). 
dTOR links to the insulin signalling pathway not only through Akt, but in that dTOR acts to 
regulate Thor activity. Upon phosphorylation by dTOR, Thor dissociates from the translational 
regulator, eIF4e, allowing assembly of the initiation complex at the mRNA cap structure, 
ribosome recruitment, and subsequent translation (Lachance et al 2002). Thor and its 
regulation will be discussed in more detail below. 
1.2.3.4. dFOXO 
dFOXO, a downstream target of Akt, is a transcriptional regulator of the Forkhead-box type O 
(FOXO) class of Forkhead-related factors (Neufeld 2003). Four FOXO species, encoded by 
four distinct genes, have been identified in mammals: FOXO1 (previously known as FKHR), 
FOXO3 (previously known as FKHRL1), FOXO4 (previously known as Afx), and FOXO6 
(Jacobs et al 2003), whereas in the nematode, Caenorhabditis elegans, a single FOXO 
transcription factor, DAF-16 is found. In Drosophila, dFOXO was identified as a homolog of 
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Caenorhabditis elegans DAF-16 and mammalian FOXO4 (Jünger et al 2003, Puig et al 2003), 
and the sole FOXO protein present in the species. The DNA binding domain of dFOXO, which 
lies in the N-terminal region, shows 45% identity with FOXO4, and the amino acid sequence 
that forms the motif for recognition by Akt (RXRXXS/T) is conserved (Puig et al 2003). The 
three specific sites at which FOXO4 is regulated by Akt-dependent phosphorylation are also 
conserved in dFOXO, with the dFOXO residues T44, S190 and S259, corresponding to 
mammalian FOXO4 T28, S193 and S258 respectively (Puig et al 2003). dFOXO is inhibited 
by dAkt-mediated phosphorylation when insulin is present, which results in it being retained in 
the cytoplasm and thereby unable to regulate transcription. However, following a reduction in 
insulin signalling, dFOXO becomes dephosphorylated and accumulates in the nucleus. where it 
can act to stimulate transcription of target genes (Neufeld 2003). FOXO proteins may also be 
regulated at the point of translation or by the stability of the protein (Harvey et al 2008, Mattila 
et al 2008). In a Drosophila cell line expressing a constitutively active dFOXO, 227 genes 
were seen to be up regulated (Puig et al 2003). Of these 227 genes, two were identified that are 
also know to be active within the insulin signalling pathway. These were the translational 
repressor eukaryotic initiation factor 4E-binding protein (d4EBP) (also known as Thor, and 
discussed below) and dInR (Puig et al 2003). The transcriptional activation of Thor by dFOXO 
also corresponds with dAkt activation of dTOR which acts to inhibit Thor activity (Miron 
2001). As mentioned above, dFOXO also activates transcription of dInR (Puig et al 2003) this 
provides a feedback loop in which dFOXO can act to increase dInR levels. It has been 
suggested that this increase in dInR, under conditions where insulin levels are low, means that 
the system will be able to respond rapidly when nutrients are again available (Puig & Tjian 
2005).  
A recently identified transcriptional target of dFOXO is Lk6, a Drosophila Mnk-like kinase 
(Teleman et al 2008) Lk6, like Thor, acts to regulate eukaryotic initiation factor 4E (eIF4E) 
activity (eIF4E will be discussed below). In this same study Myc, itself a transcription factor 
(section 1.2.2), was also identified as a dFOXO target, although in a tissue specific manner 
(Teleman et al 2008). Accordingly, it has been suggested that Myc is the convergent point for 
regulation by dFOXO and TOR branches of the insulin pathway (Teleman et al 2008). 
Although dFOXO can act to inhibit growth, dFOXO null mutants appear to be wild type, 
growing to normal size (Jünger et al 2003). However, when dInR, Chico, PI3K or Akt are 
mutated in a dFOXO null mutant background, the reduced growth phenotypes seen in these 
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mutants in a dFOXO 
+/+
 background are suppressed. This demonstrates that dFOXO can act to 
inhibit growth under conditions of reduced insulin signalling (Jünger et al 2003). dFOXO has 
also been seen to suppress growth when there is increased activity of the TOR pathway 
(Harvey et al 2008, Jünger et al 2003). dFOXO has also recently been shown to regulate cAMP 
signalling by inducing expression of an adenylate cyclase, ac76e,  and this has been shown to 
increase starvation resistance and limit growth (Mattila et al 2009). 
Together all these data point to dFOXO having an important role in growth control. However, 
under normal laboratory conditions, where food is plentiful, dFOXO seems to be inactive as 
high levels of insulin mean that dFOXO is phosphorylated and therefore inactive.    
1.2.3.5. Thor 
Thor is a member of the 4E-binding
 
protein (4E-BP) family, which in mammals have been 
defined as critical
 
regulators in a pathway that controls initiation of translation
 
through 
interaction with eukaryotic initiation factor 4E (eIF4E) (Bernal & Kimbrell 2000).  
The role of Thor as a regulator is dependent on its binding of eIF4E. The sequestration of 
eIF4E in this way preventing it from forming the translation initiation complex. However, 
phosphorylation of Thor then results in the release of eIF4E and translation (Bernal & Kimbrell 
2000). The regulation and function of this translation initiation complex and eIF4E will be 
described in more detail below.  
As mentioned above, Thor is a downstream target of the insulin signaling pathway (Miron 
2001). As a function of its involvement with this pathway, Thor phosphorylation occurs as a 
result of insulin treatment, with the subsequent release of eIF4E allowing translation to occur 
(Lachance et al 2002, Miron 2001). This phosphorylation event is thought to be (as in 
mammalian systems) regulated by TOR (Miron et al 2003). TOR can also act to phosphorylate 
S6K but in contrast to the mechanism of Thor phosphorylation, in a PI3K- and Akt-
independent manner (Miron et al 2003). 
Thor can also be regulated at the transcriptional level, through the insulin signaling pathway 
via dFOXO (Jünger et al 2003, Puig et al 2003).  
Expression within the wing-imaginal disc of a Thor mutant that will bind deIF4E most strongly 
Thor
LL
, has been shown to result in a decrease in wing size. However, this reduction in wing 
size was not seen if wild type Thor was expressed (Miron 2001). Null mutants of Thor are 
viable and do not exhibit increased growth, although their immune response is compromised 
(Bernal & Kimbrell 2000). Teleman et al (2005) demonstrated that Thor did not function under 
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normal growth conditions but instead acts as a metabolic ‘brake’ that is activated under 
conditions of environmental stress in order to control fat metabolism (Teleman et al 2005). 
This role for Thor is also supported by the work of Tettweiler et al (2005) where Thor was 
shown to be critical for survival under conditions of dietary restriction or oxidative stress 
(Tettweiler et al 2005). 
1.2.3.6. Lk6 
Mammalian cells respond to a variety of extracellular stimuli via activation of specific 
mitogen-activated protein (MAP) kinase cascades. A subfamily of murine serine/threonine 
kinases, whose members bind tightly to the growth factor-regulated MAP kinases are known as 
MAP kinase-interacting kinases (Mnk) (Waskiewicz et al 1997).The Drosophila Lk6 protein is 
the functional homolog of the mammalian Mnk kinases (Arquier et al 2005).  Lk6 has been 
identified as a transcriptional target of dFOXO (Teleman et al 2008) and has been shown to 
regulate the activity of translation initiation factor eIF4E (Fig. 1.4.) (Arquier et al 2005, Parra-
Palau et al 2005, Reiling et al 2005). The regulation of eIF4E activity by Lk6 induced 
phosphorylation has also been demonstrated (Arquier et al 2005, Reiling et al 2005) although 
the exact role of this phosphorylation event on eIF4E activity is unclear. Lk6 has been shown 
in one study to be vital for normal growth and development (Arquier et al 2005). In Lk6 null 
mutants, slower development and reduced viability and adult size has been observed (Arquier 
et al 2005). These results were comparable to that seen in animals expressing a non-
phosphorylatable form of eIF4E (Lachance et al 2002). These data suggest that Lk6 acts to 
positively phosphorylate eIF4E which is then able to activate protein synthesis, although 
results in mammalian studies have been contradictory, with it being shown that 
phosphorylation of eIF4E reduces its affinity for the capped mRNA (Scheper et al 2002). It 
should also be noted that even in the studies showing that phosphorylation of eIF4E through 
Lk6 acted to activate translation (Arquier et al 2005), overexpression of Lk6 in the eye disc 
resulted in subtle growth impairments (Arquier et al 2005).  
So even in studies where Lk6-mediated activation of translation is seen, the opposite effect was 
also observed in some tissues. Growth inhibition due to Lk6 overexpression in an eIF4E 
phosphorylation-dependent manner was also seen in another study (Reiling et al 2005). In this 
work, Reiling et al also had contradictory results to that of Arquier et al main results as their 
Lk6 null animals were viable and fertile without obvious growth defects when grown under 
standard conditions. Although in the Reiling et al study, when Lk6 null mutants were raised 
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under conditions of poor nutrient supply a reduction in size of flies was observed. This 
reduction in the amino acid supply also abolished the negative effects of Lk6 overexpression 
on growth, which suggests that the activity of Lk6 is also regulated in response to nutrient 
availability (Reiling et al 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.   PI3K-dependent regulation of protein biosynthesis: Convergent regulation by TOR 
and FOXO in muscle. (adapted from Teleman et al 2008).  Myc is transcriptionally repressed by 
FOXO and posttranscriptionally activated by TOR. Both inputs cause Myc activity to increase upon 
increased insulin signaling, leading to the expression of a set of E box-containing genes involved in 
ribosome assembly. Insulin signaling also regulates translation initiation via eIF4E. Thor and Lk6 are 
direct transcriptional targets of FOXO that are induced under conditions of low insulin signaling. Both 
inhibit eIF4E activity either by direct binding and sequestration (4E-BP/Thor) or by phosphorylation 
(Lk6). 4E-BP/Thor binding to eIF4E is regulated by TOR (Teleman et al 2008). 
 
 
 
 
Thor 
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1.2.3.7. eIF4E and the initiation of translation complex 
As mentioned previously, eIF4E is a downstream target in the insulin signaling pathway of 
Thor and Lk6. Cellular eukaryotic messenger RNAs (except those in organelles) possess a cap 
structure at their 5′ terminus comprising, m
7
GpppX (where X is any nucleotide) (Gingras et al 
1999). This cap is one of the structural features of eukaryotic mRNAs involved in the 
modulation of ribosome binding to the mRNA. eIF4E is a translation initiation factor which is 
involved in the recognition of and binding to the cap (Hernández & Sierra 1995). eIF4E is part 
of a protein complex, eIF4F, made up of eIF4A (RNA helicase), eIF4G (a large scaffold 
protein), and eIF4E (Miron & Sonenberg 2001). The interaction of eIF4E with the cap 
structure, positions the eIF4F complex at the 5' end of the mRNA. The action of the complex is 
to unwind
 
the inhibitory secondary structures present in the 5' untranslated
 
region of the mRNA 
(Miron & Sonenberg 2001).  
As mentioned above, in Drosophila, the activity of eIF4E is modulated through Thor and Lk6.  
1.3. Previous research from the laboratory 
As the work in this thesis carries on from research previously completed in our laboratory 
(Kimber 2005), a brief summary of what was has previously been found regarding Nitric Oxide 
signaling will be given below. 
Previous work on NO in the lab has identified modulation of the insulin signalling pathway as 
providing a possible mechanism by which NO may act to inhibit growth.  
Following microarray analysis on tissue culture cells that had been treated with a NO donor, S-
nitroso-N-acetyl-penicillamine (SNAP), Thor was identified as one of seven transcripts up-
regulated 4hrs after NO treatment, and it continued to be up-regulated over the next two time 
points (8 and 12hrs). As Thor is part of the insulin signalling pathway and is known to suppress 
growth under some conditions, it was therefore considered possible that this pathway may 
provide a relevant mechanism by which NO inhibits growth.  
In order to analyse NO function in vivo, the mouse macrophage NOS gene (NOS2) was utilised 
to express NO under control of the UAS GAL4 system. When NOS2 was expressed in salivary 
glands there was a reduction in size and an increase in Thor-LacZ expression. However when 
NOS2 was expressed in a dFOXO loss-of-function mutant background, it resulted in the 
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suppression of the NOS2-induced phenotypes and a reduction in Thor-LacZ staining in the 
salivary glands. This showed that the phenotypic and molecular responses to NO are dependent 
on dFOXO. Thor signaling was also reduced when the endogenous dNOS expression was 
reduced using RNAi-NOS. Similarly, expression of Thor-LacZ was further reduced in a 
dFOXO mutant background. When RNAi-NOS was expressed throughout the larvae using a 
tubulin driver, it resulted in an overgrowth phenotype with third instar larvae that never 
pupated. These larvae simply wandered until they died. 
Application of exogenous NO to either S2 tissue culture cells or 3
rd
 instar larvae resulted in a 
drastic inhibition of protein synthesis.  
All work above is from Kimber 2005 (Kimber 2005). A similar NO dependent inhibition of 
translation has been reported where NO treatment on 180-min-old embryos induced a 
reversible arrest of development, gene expression and turnover (Teodoro & O'Farrell 2003). 
 
The results from Kimber 2005 did identify dFOXO as a possible target for the action of NO 
though further work was need to confirm these results and this is discussed below and in 
Chapter 3. 
1.4. Aims of project 
The aim of this research project was to confirm and identify the genetic and molecular 
components of NO signaling in Drosophila melanogaster. Particular emphasis was placed on 
how NOS can affect cell proliferation and/or growth. As previous work in the laboratory had 
identified dFOXO as a possible target for NO, the research was focused on confirming this 
result. As two known targets of dFOXO signaling include regulators of translation, and NO has 
been demonstrated to inhibit protein synthesis, the roles of these dFOXO targets was 
determined. The work also investigated the action of NO in the insulin signaling pathway and 
whether its inhibition of growth may result from action through the known sGC pathway. 
Finally as NO is a known inhibitor of growth, and in mammalian systems it has been shown to 
inhibit growth of tumor cells, this activity was investigated in Drosophila using two known 
and well defined oncogenes. 
An introduction and discussion accompanies each results chapter.  
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Chapter 2:  Material and Methods 
2.1. General 
2.1.1. Fly Husbandry 
Drosophila stocks and crosses were raised on D+ food, in 8cm x 2.5cm plastic vials, stoppered 
with either cotton wool or rayon balls. Flies were raised at either 25
o
C or 18
o
C on a 12 hour 
light-dark cycle, unless otherwise stated. Drosophila were observed using CO2, with a Nikon 
SM2645 dissecting microscope with a Microtec MFO-90 light source. Fly stocks are give in 
Appendix I. 
 
D+ Glucose Food Media   
Agar 40g 
D+ Glucose anhydrous 551g (Fisher Scientific) 
Maize meal 236g 
Yeast 143g 
Sucrose 185g 
Nipagen 10%w/v 82mls 
Propionic acid 25mls 
Water 5500mls 
 
Method 
Yeast and anhydrous D+ Glucose were mixed into a paste using a small amount of water. The 
agar and maize were mixed with the rest of the water and brought to the boil to dissolve. The 
paste was then added and the mixture brought to the boil again. The mixture was allowed to 
cool before pouring into plastic vials or glass bottles.  
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2.1.2. Overexpression using the Gal4-UAS system 
The Gal4-UAS system as described in Brand and Perimon (1993) was utilised for 
overexpression of specific genes. Flies carrying the gene to be expressed linked to an element 
containing multiple UAS sequences, were crossed to flies that carried the Gal4 coding 
sequence fused to a specific promoter. Offspring carrying both the UAS and Gal4 inserts were 
observed.  
To drive expression in salivary glands Gal4 lines AB1 and c147 were exploited. Gal4 
dependent UAS-GFP expression driven by either line was indistinguishable (data not shown). 
NOS2 and dFOXO expression by either Gal4 line either gave similar phenotypes. However, for 
genetic interaction experiments all transgenes were compared through expression driven by 
either AB1 or c147.  
2.1.3. Generating Single Cell Clones  
Single clones were generated using the FLP/FRT technique.  FLP is a site-specific 
recombinase encoded by the S. cerevisiae 2µm plasmid. It efficiently catalyzes recombination 
between two copies of its specific 34 bp recognition site (called the Flp recognition target 
(FRT)). A heat shock FLP construct was used to remove a segment of DNA flanked by FRT 
sites, which lies in the middle of an ActinGal4 transcript preventing its expression. After 
recombination expression of the Gal4 transcript occurs so therefore the UAS will be expressed 
(Struhl & Basler 1993). Recombination was induced at a low level at 24-48 hours of 
development heat shocking for between  4 to 5 and half minutes, after the salivary gland cells 
had been determined (Demerec 1950). This regime produced single cells expressing 
GFP/mRFP as a marker or co-expressing the marker and UAS-NOS2 (or any other 
genes/constructs). The single cells expressing NOS2 produced by this experimental design 
could then be used to assay the molecular and cellular consequences of high levels of NO 
production in otherwise unaffected salivary glands.  
 
 
 34 
 
 
 
Figure 2.1. Schematic diagram of clone generation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.4. G418 selection 
Materials 
G-418 disulphate (Melford Laboratories Ltd.) 
 
Method 
Selection of recombinants was preformed using G418 a selection agent for the neomycin-
resistance FRT sites. Flies were brooded for 24 hours then transferred. The eggs were left for 
approximately 24 hours to allow for hatching and development to 1
st
 instar larvae. 150µl of G-
418- disulphate was then added at 25mg/ml. Larvae were then left to develop to adults and 
recombinant flies were selected. Both positive and negative controls were preformed. 
 
 
 
Gal4 
   y
+ 
FRT 
FRT 
Act5C 
Gal4 
   y+ 
FRT FRT Act5C 
hsFLP induced 
recombination. 
Act5C Gal4 
   y
+ 
Gal4 expression not present, 
as transcription will terminate 
within the y
+
 insert bounded 
by the FRTs. 
Recombination leads to the excision of the 
intervening DNA therefore Gal4 expression 
present as transcription can occur. 
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2.1.5. Drosophila Tissue Culture  
Materials 
S2R+ Drosophila cells (Yanagawa et al 1998) 
Schneider's Drosophila Medium (Gibco BRL, 21720) 
10 % Fetal Bovine Serum (Sigma Aldrich, F-0643) 
10ml Penicillin/Streptomycin solution per 1L (GIBCO BRL, 100ml, 10.000 units/ml Penicillin 
G Sodium and 10.000µg/ml Streptomycin Sulfate in 0.85% saline) 
SNAP (Sigma Aldrich,  N 3398) 
DMSO (Sigma Aldrich) 
 
Method 
S2
R+
 Drosophila cells were grown in Schneider's Drosophila Medium plus 10% FBS and 100 
units per ml Penicillin, 100mg per ml Streptomycin. Cells were routinely cultured. For time 
course cells were grown to a cell density of  1x10
5
 cells/ml in 8-well Culture Slides (BD 
Falcon) containing 500µl/well of above supplemented Schneider's Drosophila Medium. Over 
the time course cells were either treated with 5µl DMSO as a control or 5µl SNAP. After given 
time the cells were Antibody stained as below (2.2.1) and examined on a LSM Zeiss inverted-
LSM 510 META COMBI Confocal Microscope with Coherent Enterprise UV laser using 40x 
water lens. 
Analysis of protein localisation was carried using imaging analysis software Volocity 
(www.improvision.com/products/Volocity/). 
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2.1. Immunohistochemistry 
2.2.1. Antibody staining  
Materials 
1xPBS (10xPBS: 1.37M NaCl, 0.1M Na2HPO4, 0.01M NaH2PO4; pH7.4) 
4% Paraformaldehyde in 1xPBS 
100% Methanol 
PBT (1xPBS, 0.1% Triton X-100, 0.2% BSA) 
Normal Goat sera (Sigma) 
Appropriate primary and secondary antibodies (Section 2.2.2.) 
DAPI  1:20,000 in 1x PBS with 0.1% Triton X-100 
Aquamount (Polyscience) 
 
Method 
Wandering third instar larvae were dissected by inversion and fixed in 4% paraformaldehyde 
for 20 minutes. Tissue was then washed 2x 5min in 1xPBS. If the tissue was to be stored it was 
washed twice in Methanol and stored at –20
o
C in Methanol. The tissue was then washed in 
1xPBS before permeabilization in PBT for 2 x 30 minutes. The tissue was then incubated in 
primary antibody overnight at 4
o
C. Primary antibody was removed and stored, and the tissue 
was washed 4 x 20 minutes in PBT. The tissue was rinsed x 2 in PBT containing 2% goat sera. 
Then incubated with secondary antibody in PBT with 2% goat sera at room temperature for 2 
hours. The tissue was then washed 4 x 15 minutes in PBT.  DAPI staining of tissue was 
performed for 15 min. Tissue was then washed 2x 5minutes in 1xPBS before dissection. The 
required tissues were mounted on a slide in Aquamount and examined on a LSM Zeiss 
inverted-LSM 510 META COMBI Confocal Microscope with Coherent Enterprise UV laser 
using 40x water lens. 
For tissue culture same protocol as above though staining was carried out in 8-well Culture 
Slides (BD Falcon). 
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2.2.2. Primary and Secondary Antibodies  
dFOXO Antibody 
Rabbit dFOXO antibody a kind gift from O.Puig was used at 1:1000 (Puig et al 2003). 
Secondary antibody goat anti-rabbit Cy5 (Jackson ImmunoResearch Laboratories, Inc.) at 
1:100.  
 
β-Gal Antibody  
Rabbit anti-βgal (Jackson ImmunoResearch Laboratories, Inc.) used at 1:5000.  
Secondary antibody goat anti-rabbit Cy5 (Jackson ImmunoResearch Laboratories, Inc.) at 
1:100. 
 
Myc Antibody 
Guinepig anti-dMyc a kind gift from Dr. Marco Milán used at 1:1000 (Herranz et al 2008). 
Secondary antibody goat anti-Guinepig Alexa 555 (Molecular Probes, Invitrogen) at 1:200. 
 
Thor Antibody 
Rabbit anti-Thor a kind gift from Prof. Nahum Sonenberg used at 1:200 (Miron 2001). 
Secondary antibody goat anti-rabbit Cy5 (Jackson ImmunoResearch Laboratories, Inc.) at 
1:100. 
 
 
2.3. Nuclei staining and measuring 
Materials 
1xPBS (10xPBS: 1.37M NaCl, 0.1M Na2HPO4, 0.01M NaH2PO4; pH7.4) 
4% Paraformaldehyde in 1xPBS 
DAPI : 1:20,000 in  1x PBS with 0.1% Triton X-100 
Aquamount (Polysciences) 
 
Method 
Wandering third instar larvae were dissected by inversion and fixed in 4% paraformaldehyde 
for 20 minutes.  Tissue was then washed 2x 5min in 1xPBS. The tissue was then incubated in 
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diluted DAPI staining of tissue was performed for 15 min. Tissue was then washed 2x 5 
minutes in 1xPBS before dissection. The required tissues were mounted on a slide in 
Aquamount and examined on a Zeiss AxioPhot Microscope at 40x unless other wise stated. 
Nuclear diameter was used as a measure of cell growth. Cell diameter and volume have large 
variation (not shown) due to the irregular cell shapes that occur in salivary glands and were 
therefore not used as a measure of size. These volume variabilities are probably also probably 
due to rapid expansion of  cell volume independent of DNA replication during wandering larva 
stage due to accumulation of secretary products in preparation for glueing pupal case to 
vertical substrate. 
 
In order to compare statistically the relative sizes of nuclei within each genotype, data was 
loaded into Minitab version 15 (MINITAB Inc) statistical software package. A histogram of 
residuals was used to show if the nuclei measurement data was normally distributed (graphs 
shown in Appendix II) and a one-way ANOVA, all pairway comparisons (Tukey) was carried 
out.  ANOVA is a post hoc test which are used to identify which conditions are showing 
significant differences (Dytham 2003).  Independence and equal variance across the data set 
were assumed (Dytham 2003). The raw data are recorded within the Appendix II. The P-values  
though are given for each graph. The P-value is the probability of the hypothesis being tested is 
true, the smaller the value the more confident we can be in the conclusions that are drawn for it 
(Dytham 2003).  Using the Tukey 95.0% simultaneous confidence intervals generated for each 
comparison, a punet square was constructed to compare statistical significance across the data 
set which is shown in the Appendix II. Sampling variation from was kept to a minimum. 
Larvae to be compared were kept on the same batch of food plus the number of larvae in the 
vials was restricted to prevent variation in nutrients. The larvae were picked as they started to 
wander to reduce age variation. 
 
 
 
 
 
 
 
 39 
 
 
 
Chapter 3: NO action is through dFOXO 
3.1. Introduction 
3.1.1. Regulation of growth by NO in Drosophila melanogaster 
The identification of the signalling pathway through which NO acts to regulate growth is key 
to the understanding of the effect of NO on growth.  Previous work our the lab has used 
Affymetrix gene arrays to identify any transcriptional changes that were induced in Drosophila 
S2 cells in response to exposure to NO, following treatment with the NO donor, S-nitroso-N-
acetylpenicillamine (SNAP). These data demonstrated that many genes were up regulated in 
response to NO, and that many of these were also targets of the transcription factor dFOXO, 
part of the insulin signalling pathway (discussed in more detail in section 1.3.). Regulation of 
dFOXO activity itself occurs through Akt-dependent phosphorylation following exposure to 
insulin, resulting in dFOXO being retained in the cytoplasm (Puig et al 2003).  
One of the known transcriptional targets of dFOXO found to be up regulated following NO 
treatment was Thor (4E-BP) (discussed in more detail in, section 1.2.3.5.). Thor is a member of 
the 4E-binding protein (4E-BP) family, which controls initiation of translation through the 
binding of eukaryotic initiation factor 4E (eIF4E) (Bernal & Kimbrell 2000). When levels of 
Akt activity are low, dFOXO is not phosphorylated, allowing it to enter the nucleus where it 
promotes transcription of Thor (and other genes) (Puig et al 2003). Thor in turn then binds 
eIF4E preventing initiation of translation and therefore growth is presumably inhibited. 
It has also been demonstrated that Thor, is transcriptionally activated by NO in vivo. 
Expression of an active Nitric Oxide Synthase gene (NOS2) in the larval salivary glands 
resulted in increased expression of a Lac Z reporter construct of Thor. This increased 
expression of Thor in response to NO was shown to be completely suppressed by removal of 
dFOXO using a dFOXO null mutant (Kimber 2005). In the same study, the inhibition of 
growth of these cells by NO was also shown to be suppressed by the genetic removal of 
dFOXO. Therefore it was concluded that growth-inhibitory effects and activation of Thor by 
NO were dependent on dFOXO. 
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3.1.2. Analysis of NO expression in single cells of salivary glands 
Although the above study by Kimber 2005 did identified a molecular target through which NO 
may be acting, the experiments were performed in whole salivary glands. Accordingly they did 
not take into account any physiological affects that the reduced growth may be having on the 
expression of genes, and could not distinguish between the direct consequences of NO 
signalling versus the effects of reduced growth of the cells. It was therefore decided to 
determine if NO signalled autonomously through dFOXO, and whether the apparent increase 
in dFOXO signalling could occur when growth was minimally affected. To achieve this, 
expression of NO would be induced in single cells within the salivary gland rather than in 
whole salivary gland as had been done by Kimber 2005. The expression in single cells would 
also allow any increase in expression of proteins out side of the target cell to be identified 
thereby showing if NO was have a cell autonomous or non-autonomous effect. This was done 
using the FLP/FRT technique.  FLP is a site-specific recombinase encoded by the S. cerevisiae 
2µm plasmid. It efficiently catalyzes recombination between two copies of its specific 34 bp 
recognition site (called the Flp recognition target (FRT)). A heat shock FLP construct was used 
to remove a segment of DNA flanked by FRT sites, which lies in the middle of an Actin 5C 
Gal4 transcript, thereby preventing its expression. Recombination results in expression of the 
Gal4 transcript leading to expression of the UAS (Struhl & Basler 1993). Recombination was 
induced at a low level at 24-48 hours after egg laying (AEL), after the salivary gland cells have 
been determined (Demerec 1950). This methodology produced single cells expressing 
GFP/mRFP as a marker, or co-expressing the marker and UAS-NOS2 (or any other 
genes/constructs). The single cells expressing NOS2 produced by this experimental design 
could then be used to assay the molecular and cellular consequences of high levels of NO 
production in otherwise unaffected salivary glands.  
 
The UAS-NOS2 construct used was that previously used in the lab to drive NOS2 expression 
under the UAS/Gal4 system. The NOS2 gene used, being the mouse macrophage Nitric Oxide 
Synthase gene (Lowenstein et al 1992), which unlike the Drosophila NOS2 gene, is not 
regulated by calcium (Regulski & Tully 1995). Previously, this NOS2 transgene, referred to as 
the mouse NOS2 transgene (Kuzin et al 1996), has been utilised for experiments in Drosophila, 
under the control of a heat shock promoter. NOS2 was cloned into pUAST (Brand & Perrimon 
1993) and four transformants were obtained. These transformants of the UAS - mouse 
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macrophage NOS2 gene, abbreviated here as UAS-NOS2, were mapped to their chromosome 
location by segregation (Kimber 2005). One transformant was obtained on the X chromosome, 
two on the second chromosome and one on the third chromosome. The one used for this study 
was UAS-NOS2, located on the X chromosome, as it gave the highest levels of expression.  
 
 
 
3.2. Results 
3.2.1. Analysis of NOS2 and dFOXO expression in larval salivary glands  
To confirm that NO acts as a negative regulator of growth, UAS-NOS2 was expressed in the 
salivary glands using the GAL4 driver, c147-GAL4. Though some of this work had been 
completed by Kimber 2005 it was not quantified but rather judged by eye therefore to gain 
more detailed information on the effect of NO on cell proliferation and to also compare that 
with expression of dFOXO the experiment below was completed.   The nuclei of wandering 
third instar larvae were measured and data statistically analysed as described in material and 
methods. The raw data are recorded within the appendix in section II. The salivary glands from 
third instar larvae expressing UAS-NOS2 (NOS2) were overall smaller in size than that of the 
wild type control (Fig. 3.1Ai. and 3.1Aii.). The nuclei of the salivary glands expressing UAS-
NOS2 were also smaller than wild type (Fig. 6Bi. and 6Bii.) and upon measurement, it was 
found that the salivary gland nuclei of NOS2 expressing glands were statistically smaller than 
those from the wild type control larvae (Fig. 3.2.). As it was expected that NO may act through 
dFOXO to regulate growth, salivary glands from larvae expressing UAS-dFOXO using the 
c147-GAL4 driver were also examined. The salivary glands expressing UAS-dFOXO were also 
found to be smaller than those from the wild type control (Fig. 3.1Aiii.). The salivary gland 
nuclei were also shown to be statistically smaller than those from the wild type control larvae 
(Fig. 3.2.). Comparison of salivary gland nuclei expressing either UAS-NOS2 or UAS-dFOXO 
showed that the nuclei from dFOXO were statistically smaller than those from NOS2 (Fig. 
3.2.).  
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Figure 3.1. Salivary glands are reduced in size when NOS2 or dFOXO was over expressed. 
A. Salivary glands Ai. Wild type (c147-GAL4/+). Aii. Increased expression of NOS2 (UAS-NOS2; 
c147-GAL4), salivary glands show reduced size. Aiii. Increased expression of dFOXO (c147-
GAL4/UAS-dFOXO) salivary glands show reduced size.  
B. Nuclei of salivary glands stained with DAPI. Bi. Wild type (c147-GAL4/+). Bii. Increased 
expression of NOS2 (UAS-NOS2; c147-GAL4), salivary glands nuclei show reduced size. Biii. 
Increased expression of dFOXO (c147-GAL4/UAS-dFOXO) salivary glands nuclei show reduced size.  
Scale bars shown:  A series, 500µm. and B series, 10µM.  
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Figure 3.2. Average Size of Salivary Gland Nuclei was reduced following NOS2 or dFOXO 
expression. 
c147-GAL4 was used to drive expression of UAS-NOS2 or UAS-dFOXO. WT (c147-GAL4/+), NOS2 
(UAS-NOS2; c147-GAL4) and dFOXO (c147-GAL4/UAS-dFOXO). Error bars represent the standard 
deviation. Both NOS2 and dFOXO nuclei are statistically smaller than those of WT (raw data is given 
in Appendix II.a.). 
 
For WT, data was derived from 696 nuclei from 107 salivary glands. NOS2; 380 nuclei from 77 
salivary glands. dFOXO; 68 nuclei from 8 salivary glands. P-Value = 0.001 
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3.2.2. Thor LacZ expression in NOS2 expressing clones 
The reduced growth phenotype observed following expression of NO is thought to be a result 
of NO acting through the insulin pathway (Kimber 2005). This previous work showed that 
Thor, part of the insulin pathway, was up-regulated upon overexpression of NO. As previously 
mentioned, Thor is transcriptionally regulated by dFOXO, and accordingly the action of 
dFOXO can be monitored through the expression of Thor. The previous work demonstrated an 
increase of Thor by colourimetric monitoring the expression of a reporter of Thor expression 
P{w[+mC]=lacW}Thor[k07736] using β-galactosidase (X-Gal) staining. There was an increase 
in X-Gal staining when NOS2 was overexpressed in the salivary glands (Kimber 2005). This 
increase in Thor LacZ production coincided with a reduced size in the salivary glands. 
However, this increase in staining could have been a reflection of the reduced size of the cells 
and not in an increase in the expression of Thor.  To verify the action of NO on expression of 
Thor, and thereby its action through dFOXO, clones were generated in the salivary glands that 
expressed UAS-NOS2 in single, or small numbers of cells, in larvae carrying the Thor LacZ 
reporter. The expression of Thor was then identified through the expression of Thor LacZ 
reporter, using an anti beta-Gal antibody, and the UAS expression with UAS-GFP.  NOS2 
clones showed an increase in expression of Thor-LacZ reporter in a cell-autonomous (Fig. 
3.3Ai.) or non-autonomous fashion (Fig. 3.3Aii.). 
As well as the in the salivary gland, clones of NOS2 expressing cells were also generated in the 
wing discs of the developing larvae. These clones were much less prevalent, probably due to 
widespread induction of expression of NOS2 causing lethality. The 5 clones that were 
recovered showed varying results. A few did show an increase in Thor-LacZ expression (Fig. 
3.4.), but due to lack of concordance, no real conclusion can be formed. Three clones did show 
an increase in Thor-LacZ expression and in one example it could be seen that the increased 
Thor-LacZ expression was observed with and surrounding the NOS expressing clone (Fig 3.4). 
This indicates that the diffusion of NOS can trigger increases in Thor-LacZ expression in cells 
neighboring those expressing NOS. 
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Ai. Aii. 
 
Figure 3.3. Thor LacZ expression is increased in NOS2 expressing clones in salivary glands. 
Ai and Aii. Clones were generated using a 4min heat shock at 38
o
C between 24-48hr AEL, of animals 
with genotype: UAS- NOS2/hsFLP; Thor LacZ/Act5c>y
+
>Gal4;UAS-GFP/+. Clones are therefore 
marked with GFP. Ai. NOS2 clone showing cell autonomous increase of Thor LacZ expression (arrow). 
Aii. NOS2 clone showing cell non-autonomous increase of Thor LacZ expression (white arrowheads 
show non-autonoumos and purple show clone cells a).    Red: Thor LacZ, Blue: DAPI, Green: GFP 
Scale bar 50µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Thor LacZ expression is increased in NOS2 expressing clones in wing 
imaginal discs. 
Clones were generated using a 4min heat shock at 38
o
C between 12-24hr AEL, of animals with 
genotype: UAS- NOS2/hsFLP; Thor LacZ/Act5c>y
+
>Gal4;UAS-GFP/+. Clones are therefore labeled 
with GFP. Red: Thor LacZ, Blue: DAPI, Green: GFP. White arrow showing clone area. Scale bar 
50µm. 
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3.2.3. Analysis of Thor-YFP expression with NOS2 and dFOXO 
Although LacZ is a commonly used reporter gene, it is only a reporter of a promoter activity 
and does not directly show native protein expression. Therefore we decided the use of a newly 
constructed Thor-YFP protein fusion (Cambridge Protein Tap Insertion Consortium, 
unpublished) would better facilitate the analysis of protein expression rather than just report 
promoter activity. As with the Thor LacZ experiments, both UAS-NOS2 and UAS-dFOXO 
were expressed in the salivary glands using the c147 Gal4 driver in animals carrying the Thor-
YFP fusion. Expression of either UAS-NOS2 or UAS-dFOXO in whole salivary glands resulted 
in an increase in Thor-YFP expression when compared to wild type control (Fig. 3.5.). As with 
the case of Thor LacZ, this increase in expression of Thor-YFP may just have been a 
consequence of the reduced size or growth of the salivary glands. To resolve these issues, 
clones were made within the salivary gland that expressed either UAS-NOS2 or UAS-dFOXO, 
and the expression of Thor-YFP examined. As for the Thor Lac Z clones, an increase in 
expression of Thor-YFP was observed in cells expressing either UAS-NOS2 or UAS-dFOXO, 
compared to surrounding wild type tissue (Fig. 3.6.) The cells expressing Gal4 could be 
identified by the expression of UAS-myr-mRFP which expresses membrane-targeted 
monomeric RFP which also labels cell membranes (Chang 2003). 
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Figure 3.5. Thor-YFP expression in salivary glands over expressing either NOS2 or dFOXO.  
Ai. Wild type (c147-GAL4/Thor-YFP). Aii. Increased expression of NOS2 (UAS-NOS2; c147-
GAL4/Thor-YFP) showing increase in Thor-YFP. Aiii. Increased expression of dFOXO (c147-
GAL4/UAS-dFOXO;Thor-YFP) showing increase in Thor-YFP. Green; Thor-YFP.  Scale bar 200µm. 
Red arrows indicate salivary gland and white arrows fat body.All images acquired and 
processed using identical settings. 
 
 
 
 
 
 
 
 
 
Figure 3.6. Thor-YFP expression is increased in single salivary gland cells expressing either NOS2 
or dFOXO. Clones over expressing either NOS2 or dFOXO were generated using a 4min heat 
shock at 38oC between 24-48hr AEL. Clones are labeled with UAS-myr-mRFP (mRFP). 
Ai. UAS-NOS2 clone (UAS- NOS2/hsFLP; Thor-YFP/mRFP; Act5c>CD>Gal4/+). 
Aii. UAS-dFOXO clone (hsFLP/+; UAS-dFOXO,Thor-YFP/ mRFP; Act5c>CD>Gal4/+).  
Red: UAS-mRFP, Blue: DAPI, Green: Thor-YFP.White arrow showing clone cell.Scale bar 50µm 
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3.2.4. Analysis of Thor protein expression in response to NOS2 expression 
To further investigate the increase in Thor expression in response to NO, an anti-Thor antibody 
was utilised. To first test this antibody for use on tissue, antibody staining was carried out on 
both larvae homozygous for a Thor null allele (Thor
2
) and those expressing UAS-NOS2 in 
clones. The homozygous Thor
2
 larvae showed the same level of staining as wild type larvae 
(Fig. 3.7.). The UAS-NOS2 clones did show an increase in anti-Thor staining compared to that 
of surrounding wild type tissue but only when there was high expression of Gal 4 as indicated 
by very bright GFP expression in clones (Fig. 3.8.). 
 
 
Figure 3.7. Antibody staining of Thor protein in wild type and Thor 2 salivary glands. 
Ai Wild type third instar salivary gland (yw). Aii Thor null salivary gland (yw; Thor 
2
). 
Red: anti-Thor antibody, Blue: DAPI. The anti-Thor antibody Miron et al (2001)(Miron 2001). 
Scale bar 100µm. 
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Figure 3.8. Antibody staining of Thor protein in NOS2 expressing clones in salivary glands. 
Clones were generated using a 4min heat shock at 38
o
C between 24-48hr AEL. Clones are labeled with 
GFP. 
Ai. UAS-NOS2 clone (UAS- NOS2/hsFLP; Thor LacZ/Act5c>y
+
>Gal4;UAS-GFP/+). Scale bar 
200µm. 
Aii. UAS-NOS2 clone close up. Red: anti-Thor antibody, Blue: DAPI, Green: UAS-GFP. The anti-Thor 
antibody is as in Miron et al (2001)(Miron 2001). Scale bar 20µm 
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3.2.5. Analysis of dFOXO expression and localisation 
NO has been shown to increase the expression of Thor in whole salivary glands, and I have 
demonstrated a similar increase in expression of Thor promoter activity, Thor-YFP and Thor 
protein expression in single cells expressing NOS2. Thor expression is known to be regulated 
by the transcription factor dFOXO (Puig et al 2003, Puig & Tjian 2005). It has also been 
shown that both the inhibition of growth and molecular responses to NO in Drosophila larvae 
are dependent on dFOXO (Kimber 2005). The phenotype of reduced size and increased Thor 
expression that is seen when NOS2 is expressed in the salivary glands is not seen when NOS2 
is expressed in animals homozygous for a null allele of dFOXO (Kimber 2005).  
 
To determine if the NO-induced effects on Thor expression in salivary glands were due to 
alterations in the expression of dFOXO, the levels and localization of dFOXO protein were 
determined. It has been shown that the sub-cellular localization, and therefore transcriptional 
activity, of dFOXO is altered by insulin (Puig et al 2003). Thus the localisation of dFOXO may 
change from cytoplasm to nucleus in response to an increase of NO. When dFOXO is located 
in the cytoplasm it is inactive, but when activated it moves in to the nucleus and initiates 
transcription of Thor (Puig et al 2003).  
Expression and localisation of dFOXO was examined in whole salivary glands expressing 
UAS-NOS2 using the c147 Gal4 driver. The data showed that there did not seem to be an 
identifiable change in the nuclear:cytoplasmic ratio of dFOXO distribution as compared to 
wild type cells (Fig. 3.9.). However, there is an apparent increase in the overall levels of 
dFOXO protein (Fig. 3.9.). Nevertheless, it should be noted that the results do show large and 
overlapping standard deviations.  
dFOXO protein localisation was also examined in UAS-NOS2 expressing clones within the 
salivary glands.  A similar result is seen (Fig. 3.10.), with there being no obvious change in the 
nuclear:cytoplasmic ratio of dFOXO expression. However when the overall expression of 
dFOXO is compared to the surrounding wild type tissue there is again an overall increase of 
dFOXO expression within the clones (Fig. 3.10.).   
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Figure 3.9. Distribution of dFOXO expression in whole salivary glands. 
dFOXO expression in the nucleus and the cytoplasm in wild type and UAS-NOS2 expressing salivary 
glands. WT Nuclear dFOXO (+/+;c147/+), WT Cytoplasmic dFOXO (+/+;c147/+), NOS2 Nuclear 
dFOXO (NOS2/+;c147/+) and NOS2 Cytoplasmic dFOXO (NOS2/+;c147/+)  Measurement of dFOXO 
expression was performed using Image J to calculate integrated density. Error bars indicate the standard 
deviation.  
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Figure 3.10.  dFOXO protein expression and subcellular localization in NOS2 expressing cells in 
salivary glands. Clones of NOS2 expressing cells were generated using a 4 min heat shock at 38oC 
between 24 - 48hr AEL of animals with the genotype: UAS- NOS2/hsFLP; Act5c>y+>Gal4;UAS-
GFP/+. Ai and Aii show increase in level but no obvious change in subcellular localisation of dFOXO 
protein in NOS2 expressing clones. Red: dFOXO expression using dFOXO primary antibody and cy5 
secondary antibody, Blue: DAPI, Green: GFP.  Scale bar 50µm 
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3.2.6. Analysis of dFOXO expression and localisation in cell culture 
The previous work showing relocalisation of dFOXO protein was using cell culture (Puig et al 
2003), therefore to examine if any similar effects could be observed in response to NO, S2 
tissue culture cells were employed. The NO donor SNAP (S-nitroso-N-acetyl-penicillamine) 
was applied to S2 cells which were then stained with anti-dFOXO antibody. SNAP produces 
NO immediately upon contact with water, accordingly SNAP must be reconstituted prior to use 
in a non-aqueous solvent (DMSO), allowing the time of the start of NO production to be 
accurately recorded. The biological half-life of SNAP in aqueous media is predicted to be less 
than 30 minutes (Janssen et al 2000). The concentration of SNAP used was 200uM, the 
minimum concentration previously shown to induce cytostasis in S2 cells (Kimber 2005). 
Analysis of dFOXO expression was performed over a few different time-courses. Initial results 
suggested that there was an increase in dFOXO expression (Fig.3.11). The increase of dFOXO 
expression was apparent after 1hour, there seemed to be no effect at 30 min. The increase of 
dFOXO was seen through a six hour time course. Though there was an increase in dFOXO 
expression no consistent alterations to dFOXO localisation could be determined by eye, 
therefore analysis was done using the imaging analysis software Velocity 
(www.improvision.com/products/Volocity/) (Fig 3.12). The results though were highly 
variable, and I was not able to draw any definite conclusions from the data.  
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Figure 3.11. dFOXO protein expression and subcellular localization in S2 cells treated 
with SNAP.  Two images of each treatment time with SNAP are given. Red: dFOXO 
expression using dFOXO primary antibody and cy5 secondary antibody, Blue: DAPI. All 
images acquired and processed using identical settings. Scale Bars 20µm.  
A) Control cells with no SNAP treatment. 
B) Cells after 30min SNAP treatment. dFOXO expression showed no increase compared 
to control. 
C)  Cells after 1hour SNAP treatment. dFOXO expression was increased compared to 
control. 
D) Cells after 2 hours SNAP treatment. dFOXO expression was increased compared to 
control. 
E) Cells after 3hours SNAP treatment. dFOXO expression was increased compared to 
control. 
F) Cells after 4hours SNAP treatment. dFOXO expression was increased compared to 
control. 
G) Cells after 5hours SNAP treatment. dFOXO expression was increased compared to 
control. 
H) Cells after 6hours SNAP treatment. dFOXO expression was increased compared to 
control. 
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Figure 3.11.  
 
 A) No SNAP 
B) SNAP 30min 
C) SNAP 1 hr 
D) SNAP 2 hr 
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E) SNAP 3 hr 
H) SNAP 6hr 
F) SNAP 4 hr 
G) SNAP 5 hr 
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Figure 3.12.  Screen capture showing the use of imaging analysis software Velocity. The software 
was utilised to identify any changed to dFOXO localisation in response to SNAP treatment on S2 cells. 
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3.2.7. Analysis of Thor-YFP expression and localisation in salivary glands in tissue 
culture 
The work done by Kimber et al 2005 in cell culture was looking at expression of the gene 
rather than that of the protein its self, by utilizing the Thor-YFP construct the protein 
expression could be monitored. As seen above in 3.2.3 an increase in expression of Thor-YFP 
was observed in cells or whole salivary glands expressing UAS-NOS2. To identify the time 
frame in which this increase of Thor protein acts it was decided to use a time course of SNAP 
treated salivary glands. This was achieved by dissecting out the salivary glands of wandering 
third instar larvae and separating the pair. One of the pair was placed in tissue culture media 
plus and SNAP. The other gland was placed in tissue culture plus DMSO only. After specific 
incubation times images of both the SNAP treated (experimental) and DMSO treated (control) 
were taken.  Most of the results that were incubated in time periods ranging from 30min to 7 
hours showed increase in Thor-YFP expression when treated with SNAP (Fig. 3.13). Though 
through out the varing time periods the increase in expression was varible. The results that did 
not show increase were ones which had been slightly damaged during the dissection process or 
also glands that overall did not look normal. This result is in keeping with the results already 
shown in this chapter.  
 
 
 
 
 
 
 
 
 
 61 
 
 
 
Figure 3.13. Thor-YFP expression is increased in single salivary gland cells incubated with SNAP. 
All images acquired and processed using identical settings.  
Ai. 1 hour DMSO treated salivary gland 10x.   Aii. 1 hour SNAP treated salivary gland 10x. With 
SNAP treatment Thor-YFP expression increased. Scale Bars 200µm 
 
Bi. 4 hour DMSO treated salivary gland 63x.    Bii. 1 hour SNAP treated salivary gland 63x. With 
SNAP treatment Thor-YFP expression increased. Scale Bars 200µm 
Green: Thor-YFP 
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Thor-YFP 
Thor-YFP 
Bi. DMSO control Bii. SNAP Treated 
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3.2.8. Analysis of DNA synthesis in response to removal of NOS 
 Kuzin et al 1996 investigated how NOS activity affected DNA synthesis. It was found that 
when NOS2 was expressed in the wing disc fewer went through S-phase as identified by there 
being less BrdU labeled cells. In contrast when cells were treated with L-nitroarginine methyl 
ester (L-NAME) a chemical which suppresses NOS activity, there were more BrdU labeled 
cells. Since this original paper a null mutant for NOS has been generated. This means that 
clones which are mutant for dNOS were able to be generated utilizing the dNOSc which is a 
null allele of the dNOS gene (Regulski et al 2004) therefore producing clones that are null 
rather than reduced NOS activity.  Flies were generated to carry a FRT proximal to dNOSc. 
G418 selection was used as these flies inherited the transgenic neomycin resistance from the 
FRT site. Theses flies were then crossed to heat shock Flp stock to generate clones. BrdU (5-
bromo2’-deoxy-uridine) staining was then done this was done because it would allow an 
estimation of the rate of cell division as it measures the number of cells which have proceeded 
through S-phase, which will be compared in dNOSc clones expressing tissue compared to wild 
type tissue. BrdU staining works as BrdU is a synthetic nucleotide which is an analogue of 
thymidine and will be incorporated into DNA in place of thymidine during DNA synthesis. 
Therefore during S-phase, in the presence of BrdU, cells will incorporate BrdU. Cells, which 
have incorporated BrdU into there DNA, can be detected using a monoclonal antibody against 
BrdU.  The results showed that dNOSc clones were able to be generated. The generation of 
wing disc clones expressing NOS2 were as discussed previously were much less prevalent, 
probably due to widespread induction of expression of NOS2 causing lethality so no results 
were clear enough to analysis fully (Fig 3.14). 
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Figure 3.14. BrdU expression in NOS2 clones in wing imaginal discs. 
Clones were generated using a 4min heat shock at 38
o
C between 12-24hr AEL, of animals with 
genotype: UAS- NOS2/hsFLP; Thor LacZ/Act5c>y
+
>Gal4;UAS-GFP/+. Clones are therefore labeled 
with GFP. Red: BrdU, Green: GFP NOS2. Scale bar 50µm 
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3.3 Discussion 
NO is a known regulator of growth. To verify a possible target of NO action, the expression of 
dFOXO was determined in both whole salivary glands and in single cell clones within the 
salivary glands. To first verify the effects of NO reduction on growth, UAS-NOS2 was 
expressed in the salivary glands. NOS2 expression resulted in statistically smaller salivary 
glands and salivary gland nuclei. The same was seen in salivary glands expressing UAS-
dFOXO, although the glands and nuclei were even smaller. These results show that both NO 
and dFOXO can inhibit growth, although dFOXO can achieve this to a higher level. This may 
be because NOS2 expression does not up regulate dFOXO expression/activity to the same level 
that is seen when UAS-dFOXO is driven by Gal4.  
 
3.3.1 Thor expression increases in response to NOS2 
As previously mentioned, it has been shown that Thor expression increases both in vivo and in 
vitro in response to NO treatments. In the in vivo study, NOS2 was expressed in whole salivary 
glands which meant the increase in Thor LacZ expression occurred in the background of a 
reduction in salivary gland size. Accordingly, the observed increase in staining could have 
been a reflection of this change in size, and not as a result of an increase in the expression of 
Thor. To verify the increase in Thor LacZ levels were in response to NOS2 expression, UAS-
NOS2 was expressed in small or single cell clones within the salivary gland. In this case, 
NOS2-expressing clones showed an increase in Thor LacZ as was expected. The clones also 
showed an interesting result in that the expression of NOS2 resulted in cell-autonomous as well 
as a cell non-autonomous action. This result coincides with the fact that NO is known to 
diffuse between cells (Haley 1998). The short-range of non-autonomous effects of NO 
observed are probably due to its half-life of approximately only a few seconds (Haley 1998), 
limiting its diffusion to those cells immediately neighboring the source of NO. 
The increase in Thor expression in response to NOS2 was also observed with both Thor-YFP 
and using Thor antibody staining. These results verify those observed with the LacZ reporter. 
Thereby showing that NOS2 does act to increase the expression of Thor protein.   
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3.3.2. dFOXO expression increases in response to NOS2 activity 
The increase in Thor expression that was found as described above is thought to be due to the 
action of the transcription factor dFOXO. It has been previously shown that reduced salivary 
gland size and increased Thor expression in response to NOS2 activity is dependent on 
dFOXO expression (Kimber 2005). Therefore dFOXO expression in response to NOS2 was 
examined using a dFOXO antibody. Firstly, expression of dFOXO was analysed in whole 
salivary glands in response to NOS2 expression.   It was expected that there would be a change 
in sub-cellular localization from cytoplasm to nucleus, as that has been previously reported in 
vitro in Drosophila as a result of activity of the insulin pathway (Puig et al 2003). When NOS2 
was expressed in the whole salivary gland an overall increase in dFOXO expression was seen 
in both cytoplasm and nucleus compared to wild type glands. The ratio of dFOXO in the 
nucleus to cytoplasm was similar for both wild type and NOS2 expressing salivary glands. 
However, dFOXO expression in response to NOS2 is difficult to determine in whole salivary 
gland due to the NOS2-induced reduction in size. Therefore clones of cells within the salivary 
glands expressing NOS2 were also examined. There was not an obvious change in nuclear to 
cytoplasmic ratio of expression, however, an increase in the amounts of dFOXO present in the 
clones expressing NOS2 was very noticeable. This increase in dFOXO expression in response 
to NOS2 expression may mean that NO acts through dFOXO, but by regulating dFOXO 
activity in different way than simply through modulation of sub-cellular localisation. This 
increase but no apparent sub-cellular localisation change of dFOXO was also observed in cell 
culture with S2 cells were treated with NO. The results also suggested that it took over 30 min 
for the NO to cause an increase in dFOXO expression.  
Due to the lack of sub-cellar movement of dFOXO in response to NO it may mean that NO 
may be acting through different regulatory routes than those previously identified (such as 
through Akt-mediated phosphorylation). Although the increase in protein levels of dFOXO 
may be masking a subtle localisation change so Akt regulation cannot be completely ruled out. 
Other ways in which dFOXO is known to be regulated were mentioned briefly in Chapter 1 
(section 1.2.3.4.). Sub-cellar localisation (through phosphorylation), transcriptional activity and 
protein stability may be ways in which NO is acting to regulate dFOXO and thereby growth. 
As an increase in dFOXO is observed with NOS2 expression it may be that dFOXO protein 
stability is altered by NO, thereby resulting in an increase in dFOXO protein. In a study of 
dFOXO regulators using Drosophila S2 cells, 21 protein were identified that modulated 
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dFOXO transcriptional activity, protein levels and/or sub-cellular localization (Fig. 3.15.) 
(Mattila et al 2008). Of these 21 proteins, 8 have been shown to regulate dFOXO through 
stability (Mattila et al 2008). Therefore these proteins may be of interest for future work to see 
if NO may act by affecting one or more of these proteins to regulate dFOXO and thereby 
growth. It may also be of interested to see if dFOXO mRNA is increased in response to NO. 
This would show that protein levels may be increasing, and increasing because of transcription 
of dFOXO, but this would not eliminate changes due to increased stability of the protein. This 
could be analysed in NOS2 clones using in situ hybridisation to dFOXO mRNA. It may also be 
possible that NO is directly effecting dFOXO through chemical modification such as S-
nitrosylation (Asada et al 2009, Stamler 1994). 
 
 
Figure 3.15.  The identified dFOXO regulators grouped by their regulatory mode of action. 
Eighteen proteins regulate dFOXO dependent transcription, eight regulate its localization, and eight its 
stability. Three proteins have effects in all three readouts. Figure from Mattila et. al. (2008) (Mattila et 
al 2008). 
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3.3.3. In vitro versus in vivo 
In this chapter both in vitro and in vivo techniques were used for looking at both Thor and 
dFOXO expression in response to both NOS expression and SNAP treatment to identify the 
action of NO anti-proliferation effect. Looking first at Thor expression, an increase in Thor 
expression was observed using Thor-LacZ , Thor-YFP and a Thor antibody in the salivary 
glands in response to NOS2 expression. The expression of Thor-YFP was as also looked at in 
response to in vitro expression of SNAP on cultured salivary glands, though results were 
variable in the amount of increase in Thor-YFP expression it did increase.  
The expression of dFOXO was shown to increase in response to NOS2 through the use of 
dFOXO antibody though no sub-cellular localisation change was observed. The dFOXO 
antibody was also used in S2 cells to see if a change in dFOXO localisation could be observed 
in response to SNAP treatment. As for the NOS2 expression an increase in dFOXO was 
observed in response to SNAP treatment. A change in sub-cellular localisation though was not 
observed. Most of the previous work that had observed location change of dFOXO used a 
tagged version of dFOXO protein which would be one way forward. It would also be best to 
use a positive control such as insulin treatment to optimize the procedure to make sure the 
system was working. This was no done during this work as there was a limited supply of 
antibody meant work had to be limited  
 
Together the results from this Chapter confirm NO as a growth regulator in vivo and that its 
action is through dFOXO. To investigate whether NO does act directly on dFOXO or via 
upstream components of the insulin signaling pathway or by other pathways, a genetic analysis 
examining the epistatic relationships between NO and known components of the signaling 
pathway was performed. The results of these experiments are detailed in the following 
chapters. 
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Chapter 4: Analysis of signal transduction required for NO 
dependent growth regulation 
4.1. Introduction 
Although NO has been shown to act through dFOXO, whether it acts directly on dFOXO or 
activates some component of the insulin signaling pathway, or a separate pathway is not 
known. To elucidate if NO acts directly on dFOXO, or if it acts further upstream in the insulin 
pathway or by another pathway, a genetic dissection of the pathway can be performed, 
assaying what components are necessary for the NO signal to be transduced. As the majority of 
the identified members of the insulin signaling pathway are required for viability in the whole 
organism or for tissue growth, a targeted knock down strategy to reduce the amounts of the 
proteins was undertaken. Data which analyses the signal transduction required for NO-
dependent growth regulation will be presented in this chapter. 
 
One way to reduce the expression of proteins is the use of RNA interference (RNAi), this 
allows for a targeted knockdown of protein expression. RNAi is a technique which results in 
specific gene-silencing, initiated by double-stranded RNA (Fire et al 1997). RNAi was first 
demonstrated in Caenorhabditis elegans showing that dsRNA could be used to silence specific 
genes in animals (Fire et al 1997). RNAi is an evolutionary conserved mechanism found in 
fungi, plants and animals. It has been determined that RNAi machinery is also conserved 
across species and that target mRNA degradation is directed by short (21–23-nucleotide) RNA 
fragments derived from long dsRNAs. This cleavage is performed by an RNase III-type 
enzyme, Dicer.  So as well as dsRNA, small interfering (si)RNAs can be used directly as 
triggers to initiate gene silencing by binding to their target-mRNA. Once formed the small 
dsRNAs assemble into the RNA-induced silencing complex (RISC), which then targets the 
complementary mRNA. 
In Drosophila one of the first examples of RNAi use was to demonstrate the actions of genes 
within the wingless pathway (Kennerdell & Carthew 1998). In this work dsRNA was injected 
directly into embryos, although since that study the UAS/Gal4 system has been utilised for 
delivery of the dsRNA. The Vienna Drosophila RNAi Center (VDRC) stock centre provides 
stocks enabling expression of RNAi directed towards 88% of the predicted protein-coding 
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genes in the Drosophila genome (Dietzl 2007). These RNAi constructs are linked to a UAS 
and so their expression is inducible and is able to be targeted with the use of Gal4 drivers.   
To analyze the signal transduction required for NO-dependent growth regulation, RNAi 
knockdown of specific genes was undertaken by expressing suitable constructs along with 
UAS-NOS2 and observing any change to the growth phenotypes observed with UAS-NOS2 
alone. 
Comparing the results of experiments when NOS2 was expressed alone, to the phenotypes 
produced by combinations of transgenes may show if NO is acting upstream or downstream of 
that component of a pathway. This technique is known as epistasis. Epistasis analysis works by 
examining the phenotype of a double mutant to identify if the products of the two mutant genes 
act in the same or independent pathway (Lawrence S. B. Goldstein 1994). 
 
4.1.2. Is NO acting through soluble guanylyl cyclase to regulate growth? 
As previously mentioned, a number of heme containing proteins are controlled by NO (Stamler 
1994). Soluble guanylyl cyclase (sGC) is a heme-containing, heterodimeric NO receptor. The 
basal activity of sGC can be increased up to 200-fold by the binding of NO, but the resulting 
NO-heme complex has a half-life of only around 0.2s (Bruckdorfer 2005). sGC forms cyclic 
GMP from the nucleotide GTP. cGMP acts a secondary messenger, which can signal through 
cGMP-dependent protein kinases (PKGs). Active forms of PKG can phosphorylate many 
substrates including the IP3 receptor and subunits of myosin light chain phosphatase 
(Krumenacker et al 2004). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. The guanylate cyclase 
reaction and NO signal transduction 
adapted from (Denningera & Marletta 
1999). 
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The Drosophila genome contains 5 genes that code for sGC subunits – with different NO 
induced activities (Morton et al 2005). Two of these genes are Gycα-99B and Gycβ-100B, the 
α and β subunits that form a conventional, NO-sensitive heterodimeric sGC (Shah & Hyde 
1995). Although several combinations of subunits exhibit sGC activity the majority of hetero- 
and homodimeric combinations are not greatly (only approximately  4 fold) stimulated by NO 
(Morton et al 2005). Only sGC complexes containing the Gycα-99B subunit are highly 
stimulated (30 fold) by NO (Morton et al 2005). Genetic removal of the Gycα-99B subunit has 
also been demonstrated to abolish any detectable increase in NO-induced increases in cGMP 
levels (Gibbs et al 2001). In Drosophila, NO has been shown to act through the interaction 
with sGC (as discussed in Chapter 1 section 1.1.4.). If NO signals to regulate growth via sGC, 
then the removal or reduction in the amount of NO-sensitive sGC should restrict the growth 
inhibition caused by NO signalling. To determine if this was so, a UAS-RNAi-Gycα-99B 
transgene obtained from VDRC was utilised. Co-expression of this UAS-RNAi-Gycα-99B with 
UAS-NOS2 would determine whether NO regulation of growth was dependent on sGC 
expression, thereby indicating whether NO acted through sGC to regulate growth.  
 
4.1.3. What components of the Insulin Signalling Pathway is NO affecting? 
To determine what components of the insulin signaling pathway other than dFOXO, are 
required for NO-dependent growth inhibition, a similar RNAi-dependent knockdown approach 
was undertaken. The experiments performed were the co-expression of RNAi-NOS or NOS2 
with components of the insulin pathway using epistasis analysis. For example, if NO activates 
dAkt, knockdown of any components of the pathway above dAkt would not suppress the 
phenotype associated with increased NO production. However, RNAi induced knockdown of 
components downstream (and including dAkt) should suppress the phenotypes in an analogous 
way to the genetic removal of dFOXO. As previously discussed in Chapter 1 section 1.3. an 
increased growth phenotype is produced by expression of UAS- RNAi-NOS with the tubulin-
Gal4 driver. The expression of this construct under tubulin–Gal4 control results in an 
approximately 90% reduction in NOS protein levels (Kimber 2005). A selection of UAS-RNAi 
stocks from the VDRC stock centre were exploited to allow the knockdown of various specific 
components of the insulin signaling pathway (Fig. 4.2.). 
As well as this genetic dissection of the proteins required for NO growth inhibition, a cellular 
analysis of the activation of the insulin signaling pathway was undertaken.  
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PI3K is upstream of dFOXO in the insulin signaling pathway (Fig. 4.2.) PI3K activity can be 
assayed in vivo by examining the localisation of a ß-tubulin promoter driven GFP-PH fusion 
(tGPH) (Britton et al 2002). tGPH works through the pleckstrin homology (PH) domain of the 
Drosophila homolog of the general receptor for phosphoinositides-1 (GRP1) being fused to 
GFP. This tagged receptor will bind specifically to phosphatidylinositol-3,4,5-P3 (PIP3), the 
secondary messenger generated by PI3K. PIP3 generally resides in lipid membranes, 
particularly the plasma membrane. GRP1 is recruited to membranes when PI3K activity raises 
the cellular levels of PIP3. Thus the fusion proteins containing the GRP1 PH domain will also 
be recruited to plasma membranes by binding PIP3, and therefore serve as a reporter for PI3K 
activity (Britton et al 2002). tGPH has been shown to respond to increases or decreases in 
dPI3K signaling in vivo by increasing or decreasing its localization at the cell membrane 
(Britton et al 2002). Thus, this allows analysis of the effects of NO expression on dPI3K 
activity. Activated PI3K expression will be used as a positive control to show increased tGPH 
signal at cell membranes (Britton et al 2002, Wittwer et al 2005). If localisation of tGPH at the 
cell membrane decreases, this will suggest that the action of NO is not acting directly on 
dFOXO, but is instead acting further up the insulin pathway to reduce the activity of PI3K and 
thereby causing the increase in dFOXO. Conversely, if no change in the localisation of tGPH is 
observed, this will indicate that NO acts downstream of PI3K in this signaling cascade. 
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Figure 4.2. Insulin signalling pathway (adapted from (Puig et al 2003)) (      indicates components of 
the pathway tested with RNAi). 
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4.2. Results 
4.2.1. Analysis of the requirement of sGC subunit- Gycα-99B for NO-dependent 
inhibition of growth  
To determine if NO was acting through sGC to regulate growth, epistasis analysis was 
performed with targeted RNAi towards Gycα-99B which codes for the NO sensitive α subunit 
of  soluble guanylyl cyclase (Shah & Hyde 1995). The c147-Gal4 driver was used to express 
UAS-RNAi-Gycα-99B and UAS-NOS2 individually or together. Salivary gland nuclei of third 
instar larvae expressing UAS-RNAi-Gycα-99B were seen to be comparable in size to that of 
wild type larvae (Fig. 4.3.). Expression of UAS-NOS2 showed the expected small nuclei when 
driven with c147-Gal4 (Fig. 4.3.). When UAS-RNAi-Gycα-99B and UAS-NOS2 were co-
expressed in the salivary gland, the salivary gland nuclei exhibited the reduced growth 
phenotype in a statistically similar way to that resulting from UAS-NOS2 expression alone 
(Fig. 4.3.).  
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Figure 4.3. Average size of salivary gland nuclei expressing RNAi-Gycα-99B and NOS2. 
c147 was used to drive expression UAS-RNAi- Gycα-99B, UAS-NOS2 and both together. WT 
(+/+;c147-Gal4/+;+/+),  RNAi-Gycα-99B (+/+;c147-Gal4/UAS-RNAi-Gycα-99B;+/+), NOS2 (UAS-
NOS2/+;c147-Gal4/+;+/+) and  NOS2 RNAi-Gycα-99B (UAS-NOS2/+;c147-Gal4/UAS-RNAi-Gycα-
99B;+/+). Error bars represent the standard deviation (raw data is given in Appendix II.b.). 
 
For WT, data was derived from 203 nuclei from 20 salivary glands. RNAi-Gycα-99B; 214 nuclei from 
20 salivary glands. NOS2; 218 nuclei from 19 salivary glands. NOS2 RNAi-Gycα-99B; 265 nuclei 
from 21 salivary glands.  
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4.2.2. Analysis of interaction between RNAi-NOS expression and components of the 
insulin signalling pathway 
The RNAi stocks from VDRC that were used in this part of the study were: UAS-RNAi-dInR 
and UAS-RNAi-Pi3K p110, both of which are components of the insulin pathway (Fig. 4.2.) 
and were expected to inhibit growth. Firstly, to verify the efficacy of the UAS-RNAi-dInR and 
UAS-RNAi-Pi3K transgenes, they were driven with the c147 salivary gland driver. As 
expected, the knockdown of positive components of the insulin pathway resulted in an overall 
reduction in size of salivary glands (Table 4.1). The lethality or growth phenotypes caused by 
the expression of these RNAi constructs when driven by tub-Gal4 was then determined (Table 
4.1.).  Expression via tubulin Gal4 driver of UAS-RNAi-dInR and UAS-RNAi-Pi3K p110 
resulted in larval lethality before 3
rd
 instar. When animals expressed either of these two RNAi 
constructs with RNAi NOS, again no 3
rd
 instar larvae were recovered (Table 4.1.). 
Unfortunately as the RNAi-NOS dependent phenotype is only seen in 3rd instar larvae no 
conclusions about the interaction of NO and insulin signaling dependent growth could be 
drawn from these experiments. 
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Table 4.1. Size of salivary glands expressing RNAi-NOS and RNAi against insulin signalling 
pathway components. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UAS 
 
Gal4 Driver 
 
Genotype 
 
3
rd
 instar 
Salivary Gland 
size 
UAS-RNAi-dInR 
 
 
 
 c147-Gal4 
 
+/+; c147-Gal4/+; UAS-RNAi-
dInR/+ 
 
 
very small 
 
 
tub-Gal4 
+/+; +/+; UAS-RNAi-dInR/tub-
Gal4 
 
 
2
nd
 instar lethal 
UAS-RNAi-Pi3K 
p110 
 
 
 c147-Gal4 
+/+; c147-Gal4/+; UAS-RNAi-
Pi3K p110/+ 
 
 
small  
 
tub-Gal4 
+/+; +/+; UAS-RNAi-Pi3K 
p110/tub-Gal4 
 
 
2
nd
 instar lethal 
UAS-RNAi-dInR 
and 
UAS-RNAi-NOS 
 
 
tub-Gal4 
UAS-RNAi-NOS/+; +/+; UAS-
RNAi-dInR/tub-Gal4 
 
 
2nd instar lethal 
UAS-RNAi-Pi3K 
p110 
and 
UAS-RNAi-NOS 
 
 
tub-Gal4 
 
UAS-RNAi-NOS /+; +/+; UAS-
RNAi-Pi3K p110/tub-Gal4 
 
 
2
nd
 instar lethal 
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4.2.3.  Analysis of interactions between NOS2 expression and components of the insulin 
signalling pathway 
An inhibition in growth phenotype was observed when UAS-NOS2 was driven in the salivary 
gland by either c147-Gal4 or AB1-Gal4.  The c147-Gal4 driven expression of UAS-RNAi-Thor 
transgene did not result in any observable change in salivary gland growth (Table 4.2.). 
Efficiency of the UAS-RNAi-Thor was assayed by examining expression of an endogenously 
expressed YFP tagged Thor protein. There appeared to be no reduction in expression of the 
YFP even with very high levels of RNAi-Thor expression driven by tubulin Gal4. Therefore no 
further work was undertaken with the UAS-RNAi-Thor stock. Expression of the UAS-RNAi-
dFOXO with a salivary gland-specific Gal4, resulted in very small salivary glands that were 
smaller that those produced with either UAS-NOS2 or the UAS-dFOXO with the same driver.  
 
 
Table 4.2. Size of salivary glands expressing RNAi constructs targeted to Thor or dFOXO. 
 
UAS 
 
Gal4 
Driver 
 
Genotype 
 
3rd instar 
Salivary Gland 
UAS-RNAi-Thor c147-Gal4 +/+;c147/+; UAS-RNAi-  wild type 
 
UAS-RNAi-dFOXO 
 
c147-Gal4 
 
+/+;c147/ UAS-RNAi-
dFOXO; +/+ 
very small 
 
 
 
The inhibition of growth due to RNAi-dFOXO expression was not be expected, partly as null 
mutants of dFOXO are viable with no obvious growth phenotypes (Jünger et al 2003), and 
knockdown of dFOXO would decrease the expression of Thor and other negative regulators of 
growth. The reason for the observed reduction in growth may be due to the reported feed back 
loop of dFOXO signaling (Puig et al 2003, Puig & Tjian 2005). In situations where nutrients 
are limited, the insulin signaling pathway becomes inactivated, so dFOXO is not inhibited and 
is able to activate expression of genes. One of the genes targeted and up regulated by dFOXO 
when nutrients are limited, is dInR. Up regulating dInR expression allows cells to accumulate 
higher levels of dInR in the membrane, and thus they are more sensitive to any changes in 
DILP levels. Accordingly, cells with reduced levels of dFOXO may express lower levels of 
dInR compared to surrounding wild type tissues. These affected cells maybe unable to compete 
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for DILPs and thus have reduced growth. It may also be possible that UAS-RNAi-dFOXO could 
be affecting expression of other genes, this is known as off-target RNAi and can occur where 
there is a degree of target sequence conservation in other genes (Saxena et al 2003). To further 
investigate the reduced growth phenotype caused by expression of UAS-RNAi-dFOXO, co-
expression of wild type UAS-dInR (wt) and activated UAS-dInR* was induced to determine if 
the small salivary gland phenotype could be rescued by dFOXO-independent expression of the 
dInR. Phenotypes caused by expression of wild type UAS-dInR (wt) or activated UAS-dInR* 
and if their expression could modify the reduced growth phenotype associated with UAS-NOS2 
expression was also examined. It was determined if the reduced growth phenotype observed 
with NOS2 expression also occurred when RNAi-dFOXO was co-expressed, co-expression of 
UAS-NOS2 and UAS-RNAi-dFOXO under c147-Gal4 control resulted in reduced salivary gland 
growth in 3
rd
 instar larvae compared to wild types. The size of the nuclei of these salivary 
glands was not determined due to the very small size of the cells making measurements 
unreliable. However comparison by eye of both the salivary glands and the nuclei of these 
animals did not indicate any significant difference in size to those of animals expressing UAS-
RNAi-dFOXO alone.  
The co-expression of dInR with either UAS-RNAi-dFOXO or UAS-NOS2 was performed using 
the salivary gland driver, AB1-Gal4. Animals co-expressing UAS-RNAi-dFOXO and either 
wild type UAS-dInR or activated UAS-dInR*, exhibited small salivary glands that did not differ 
in size to those of UAS-RNAi-dFOXO expressing animals. As above, because of the resulting 
small gland size, it was not possible to take accurate measurements.. 
NOS2 expression with either wild type UAS-dInR or activated UAS-dInR* (Fig. 4.4.) resulted 
in a decrease in growth compared to wild type UAS-dInR or activated UAS-dInR* expression 
alone.  
 
 
 79 
 
 
 
 
 
Figure 4.4. Average size of salivary gland nuclei expressing dInR and NOS2. 
AB1-GAL4 was used to drive expression UAS-dInR wild type or UAS-dInR* activated, NOS2 and both 
together. WT (+/+;+/+;AB1-GAL4/+),  InR (UAS-dInR wt/+;+/+;AB1-GAL4/+), InR* (UAS-dInR 
activated/+;+/+;AB1-Gal4/+), NOS2 (UAS-NOS2/+;+/+;AB1-GAL4/+), NOS2 InR(UAS-NOS2/UAS-
dInRwt;+/+; AB1-Gal4/+) and NOS2 InR* (UAS-NOS2/UAS-dInR activated;+/+; AB1-Gal4/+).  Error 
bars indicate the standard deviation. (raw data is given in Appendix II.c.). P-Value= 0.001 
 
For WT, data was derived from 206 nuclei from 20 salivary glands. InR; 260 nuclei from 25 salivary 
glands. InR
*
; 269 nuclei from 22 salivary glands. NOS2; 315 nuclei from 26 salivary glands. NOS2 
InR; 317 nuclei from 24 salivary glands. NOS2 InR
*
; 317 nuclei from 24 salivary glands.  
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4.2.4. Localisation of tGPH reporter 
To test if NO was affecting dPI3K activity, NOS2 was expressed in salivary glands using the 
salivary gland GAL4 driver c147 in larvae ubiquitously expressing the reporter of PI3 kinase 
activity, tGPH. UAS-PI3K-CAAX an activated, membrane-associated form of Pi3K92E, was 
used as a positive control (Leevers et al 1996). The expression of UAS-PI3K-CAAX resulted in 
an increase, compared to wild type, in tGPH localisation at the membranes of salivary gland 
cells (Fig. 4.5Aii.). There was also an increase in cell size which is expected with expression of 
UAS-PI3K-CAAX (Leevers et al 1996). Due to the small size of cells produced, the effects of 
UAS-NOS2 expression in all cells of the salivary gland on the localization of tGPH were 
unclear. Therefore the FLP/FRT Gal4 technique was utilised to allow the localization of tGPH 
to be determined in single cells expressing NOS2. The tGPH localisation could be compared to 
that of surrounding wild type cells in the same salivary gland. The cells expressing Gal4 could 
be identified by the expression of UAS-myr-mRFP which expresses membrane-targeted 
monomeric RFP which also labels cell membranes (Chang 2003). Single salivary glands cells 
expressing only UAS-myr-mRFP (as a control) showed no change in tGPH localisation (Fig 
4.6Ai. and Aii.). As expected, when UAS-PI3K-CAAX was expressed in single cells within the 
salivary gland an increase in tGPH localisation at the membranes was observed compared to 
surrounding wild type cells (Fig. 4.6Bi.). The PI3K-CAAX expressing cells were also larger in 
size compared to wild type cells. Expression of dFOXO in single cells resulted, in most cases, 
with increased localisation of tGPH to the membranes (Fig. 4.7A.i.and A.ii.). However this 
was not always the case, as no significant changes in localisation were observed in a few 
clones. NOS2 expression in single salivary gland cells showed variable results, with tGPH 
localisation increased at the membrane in some cells, and sometimes not in others (Fig. 4.8A.i., 
Aii. and A.iii.).  
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Figure 4.5. Localisation of tGPH in wild type and PI3K-CAAX expressing salivary glands.  
Ai. Wild type (c147-GAL4/tGPH). Aii. Expression of PI3K-CAAX ( c147-GAL4/tGPH; UAS-PI3K-
CAAX). Blue; DAPI Green; tGPH. Scale bar 50µm. All images acquired and processed using identical 
settings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ai. Aii. 
tGPH DAPI tGPH DAPI 
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Ai. Aii. 
mRFP mRFP 
tGPH DAPI DAPI 
Figure 4.6. Localisation of tGPH in wild type and 
PI3K-CAAX expressing clones in salivary glands. 
Wild type and positive control clones for tGPH. Clones 
were generated using a 4 and half min heat shock at 
38oC between 24-48hr AEL. Clones are labeled with 
mRFP. Scale bars 50µm. 
 
Ai. and Aii. Wild type controls (hsFLP/+; UAS-myr-
mRFP/+; tGPH/Act5C>CD>Gal4). 
Blue; DAPI. Green; tGPH   Red; myr-mRFP 
 
 
Bi. PI3K CAAX positive control (hsFLP/+;UAS-myr-
mRFP/tGPH; UAS-PI3K CAAX/ Act5C>CD>Gal4). 
Blue; DAPI. Green; tGPH   Red; myr-mRFP+ PI3K 
CAAX.  
tGPH 
Bi. 
DAPI 
mRFP + P13KCAAX 
tGPH 
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mRFP + dFOXO mRFP + dFOXO 
tGPH tGPH 
Figure 4.7. Localisation of tGPH in salivary gland 
cell clones over expressing dFOXO. 
Clones were generated using a 4 and half min heat 
shock at 38
o
C between 24-48hr AEL. Clones are 
labeled with mRFP. Scale bars 50µm. 
Ai., Aii. and Aiii. dFOXO  (hsFLP/+; UAS-
dFOXO/ UAS-myr-
mRFP;tGPH/Act5C>CD>Gal4). 
Blue; DAPI. Green; tGPH   Red; myr-mRFP + 
dFOXO) 
 
 
Ai. Aii. 
Aiii. 
DAPI DAPI 
DAPI 
mRFP + dFOXO 
tGPH 
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mRFP + NOS2 
Figure 4.8. Localisation of tGPH in NOS2 
expressing salivary gland cell clones. 
Clones were generated using a 4 and half min heat 
shock at 38oC between 24-48hr AEL. Clones are 
labeled with mRFP.Scale bars 50µm. 
Ai., Aii. and Aiii. NOS2 (hsFLP/UAS-NOS2; / 
UAS-myr-mRFP;tGPH/Act5C>CD>Gal4). 
Blue; DAPI. Green; tGPH   Red; myr-mRFP + 
NOS2) 
 
 
mRFP + NOS2 
mRFP + NOS2 
tGPH tGPH 
tGPH 
Aii. Ai. 
Aiii. 
DAPI 
DAPI DAPI 
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Figure 4.9. Localisation of tGPH in fat body cell 
clones over expressing dFOXO. 
Clones were generated using a 4 and half min heat 
shock at 38
o
C between 24-48hr AEL. Clones are 
labeled with mRFP. Scale bars 50µm. 
Ai., Aii. and Aiii. dFOXO  (hsFLP/+; UAS-
dFOXO/ UAS-myr-
mRFP;tGPH/Act5C>CD>Gal4). 
Blue; DAPI. Green; tGPH   Red; myr-mRFP + 
dFOXO) 
 
 
As well as the results shown for tGPH in the salivary glands in response to dFOXO, the fat 
body was also observed, results though were much more variable. In figures 4.9 it can be seen 
that in dFOXO expression clones in fat body does result in an increase in tGPH localisation at 
the membrane. This though didn’t always occur in dFOXO clones and as it can be seen from 
figures 4.10 it did very in the intensity of expression at memebrane. The Movemnt of tGPH 
though  was never observed in NOS2 clones in the fat body.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ai. Aii. 
Aiii. 
mRFP + dFOXO 
mRFP + dFOXO 
mRFP + dFOXO 
DAPI 
DAPI 
DAPI tGPH tGPH 
tGPH 
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4.3. Discussion 
The data presented in this Chapter have helped determine the role of sGC and components of 
the insulin signaling pathway in NO signaling. The expression of RNAi was utilised to 
genetically dissect the signaling pathway through the targeted knockdown of specific genes 
involved in the pathway. When combined with the study of other relevant mutations or 
overexpression of genes, this strategy allows the dissection of a pathway by showing which 
genes are genetically up or downstream of each other. The Gycα-99B subunit of sGC is a 
known target of NO. To assess if NO dependent growth regulation is acting through sGC, its 
expression was reduced via RNAi and the consequences of overexpression of NO was 
examined.  As it was expected that NO may be acting within the insulin signaling pathway to 
regulate growth, a number of insulin pathway transgenes were selected to knockdown or 
increase signaling from parts of this pathway, while either increasing or reducing NO levels by 
expressing UAS-NOS2 or UAS-RNAi-NOS.  
As well as assaying the genetic requirements of NO signaling by knocking down parts of the 
insulin pathway, the cellular response to NO expression was determined by assaying the 
activity of PI3K by following tGPH localisation. 
4.3.1. NO regulation of growth does not act through sGC subunit- Gycα-99B 
Gycα-99B, an σ subunit of Drosophila sGC, is a known target for NO signaling (Morton et al 
2005, Shah & Hyde 1995). To determine if NO regulates growth through sGC, UAS-RNAi-
Gycα-99B was co-expressed with UAS-NOS2 and the size of the salivary gland nuclei 
measured. Expression of RNAi-Gycα-99B in otherwise wild type animals had no observable 
effect on growth. The salivary gland nuclei in animals co-expressing UAS-RNAi-Gycα-99B and 
UAS-NOS2 exhibited that same reduced size phenotype as that seen with expression of UAS-
NOS2 alone. This result indicates that NO-dependent regulation of growth does not act through 
the sGC subunit- Gycα-99B. It has to be noted though that the results from the use of UAS-
RNAi-Gycα-99B can not be relyed upon until the RNAi its self is tested. This could be done 
using an anti-Gyc-99B or by anti-cGMP to clarify that the RNAi is actually having an effect.  
NO signaling has also been shown to act independently of sGC signaling in a number of ways 
including S-nitrosylation of target proteins  (Asada et al 2009), through cytochrome oxidase 
(Cooper 2002) and through Metallothionein (St. Croix et al 2002), accordingly it is possible 
that NO is acting via one of these other pathways to regulate growth. 
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4.3.2. Interaction between RNAi-NOS expression and inhibition of insulin signaling  
To try and determine the nature of the interaction between NOS signalling and insulin 
signaling to regulate growth, dNOS activity was reduced via the expression of RNAi-NOS, 
while the activity of the insulin signaling pathway was inhibited via the RNAi knockdown of 
activating components of the insulin signaling pathway. Co-expression of RNAi-NOS with 
either UAS-RNAi-dInR or UAS-RNAi-Pi3K p110 would demonstrate if NO was acting 
downstream of either dInR or Pi3K p110. Expression of either UAS-RNAi-dInR or UAS-RNAi-
Pi3K p110 using c147 Gal4 resulted in reduced growth, but when expressed with tubulin Gal4 
they were both 2
nd
 instar lethal. The lethality with tubulin Gal4 is most likely due to their 
requirement throughout growth. The larvae co-expressing RNAi-NOS with either UAS-RNAi-
dInR or UAS-RNAi-Pi3K p110 were also 2
nd
 instar lethal. Therefore the knockdown of NOS 
was unable to suppress the 2
nd
 instar lethality seen with both UAS-RNAi-dInR and UAS-RNAi-
Pi3K p110 expression. It cannot be deduced from this result if this due to NO action not being 
downstream of dInR or Pi3k, or if it is the case that both signalling pathways are so vital for 
growth the animal cannot survive when they are both knocked down.  
 
4.3.3. Interaction between NOS2 expression and inhibition and activation of insulin 
signaling  
To determine if the growth regulation seen with NO expression is dependent on proteins within 
the insulin pathway, UAS-NOS2 was co-expressed with transgenes to knockdown specific 
components of the pathway. dFOXO and Thor were chosen as they are proteins known to be 
negative regulators of growth, and have been shown to respond to NO expression. Expression 
of RNAi-Thor was shown not to reduce YFP tagged endogenous Thor expression, so no 
further work was carried out with this RNAi construct. There was an initially unexpected result 
when UAS-RNAi-dFOXO was driven in the salivary gland with c147-Gal4. In this instance, 
RNAi-dFOXO expression resulted in very small salivary glands which were smaller than those 
resulting from expression of either UAS-NOS2 or UAS-dFOXO. This may be due to the 
reported feed-back loop where expression of dFOXO is required for full expression of dInR 
(Puig & Tjian 2005). To assess this, dFOXO-independent expression of dInR was induced in 
animals expressing RNAi-dFOXO. Expression of wild type UAS-dInR (wt) or activated UAS-
dInR* were unable to rescue the small salivary gland phenotype seen with expression of RNAi-
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dFOXO. However, expression of wild type or activated UAS-dInR alone was able to increase 
growth in the salivary gland cells.  An explanation for these data is that in the absence of 
dFOXO, insulin signaling cannot promote growth. Alternatively, the RNAi-dFOXO construct 
may target the degradation of other mRNA(s) required for growth. 
The co-expression of UAS-NOS2 with UAS-RNAi-dFOXO in the salivary gland resulted in very 
small glands that showed no significant difference in size to that of expression of UAS-RNAi-
dFOXO alone. This finding does not agree with the results seen by Kimber (Kimber 2005) 
where the small salivary gland phenotype due to expression of NOS2 was suppressed in 
dFOXO null larvae. However, dFOXO null larvae do not show any growth phenotype unlike 
the expression of RNAi-dFOXO in salivary glands. To determine if the reduced growth 
phenotype caused by NOS2 expression, could be rescued by either wild type UAS-dInR or 
activated UAS-dInR* co-expression of these constructs was undertaken. Expression of UAS-
NOS2 with either wild type or activated UAS-dInR resulted in decreased growth compared to 
expression of wild type or activated UAS-dInR alone. Thus NO-induced reduction of growth 
could not be rescued by the expression of either wild type or activated UAS-dInR. These data 
are consistent with NO acting genetically downstream or alongside of the insulin receptor. 
 
4.3.4. tGPH localisation can be affected by NOS2 or dFOXO expression  
To assess the cellular response of NO on the insulin pathway, the PI3K activity reporter, tGPH 
was utilised (Britton et al 2002).  It was expected that NO would either have no effect on tGPH 
localisation, therefore indicating activity below dPI3K in the insulin pathway, or that the tGPH 
signal would decrease at the membrane suggesting that NO was acting above dPI3K. The 
initial experiments performed with tGPH were to use whole salivary glands using the Gal4 
driver c147 to express UAS-NOS2 or a positive control, the activated PI3K, UAS-PI3K-CAAX. 
The positive control worked as expected with increased growth of these cells and increased 
tGPH localisation at cell membranes. Thus tGPH localisation is capable of indicating increased 
PI3K activity due, in this case, to the expression of this constitutively active PI3K protein. 
However, when UAS-NOS2 was expressed the results were less definitive. The salivary glands 
produced were much smaller than those of the controls making it hard to determine if there was 
any change in tGPH localisation. To circumvent this, the FLP/FRT Gal4 system was exploited 
to express the genes of interest in single cells of the salivary glands. As in the whole salivary 
glands, the expression of UAS-PI3K-CAAX in single cells showed an increase in size and tGPH 
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localisation at the membrane of those cells. The expression of UAS-dFOXO in single cells also 
resulted in increased tGPH signal at cell membranes. This result with UAS-dFOXO expression 
is consistent with the fact that changes in dFOXO activity are thought to feedback on the 
pathway by activating the expression of the insulin receptor (Puig et al 2003, Puig & Tjian 
2005). However the result with UAS-NOS2 expression was not as clear. The localisation of 
tGPH in the cells expressing NOS2 varied. This variability could be due to the increased levels 
of dInR due to increased dFOXO expression (Puig et al 2003, Puig & Tjian 2005) and 
temporal variability in this feedback. The feedback will allow the expression of NOS2 to affect 
tGPH localisation as a consequence of altering dFOXO activity. The extent of the feedback 
(dInR expression) will be dependent on how long the cells have been expressing NO and 
therefore there may be a lag in the activity of dFOXO dependent genes (e.g. dInR), their 
translation and the activation of the pathway. 
 
The data presented in this chapter support the role of NO acting to regulate growth by 
inhibiting the insulin signaling pathway below or in parallel with the insulin receptor, dInR, but 
at or above the level of dFOXO activity. The work also confirms the known feedback 
mechanism involving dFOXO activity to regulate dInR expression (Puig et al 2003, Puig & 
Tjian 2005). Here I have demonstrated this feedback at the cellular level in the salivary gland 
through the localisation of tGPH reporter. Feedback at this cellular level has not been 
previously been demonstrated. 
The molecular targets of dFOXO activation required for NO induced growth inhibition will be 
investigated in the following chapter.      
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Chapter 5:  Genetic analysis of dFOXO transcriptional targets as 
possible growth inhibitors    
5. Introduction 
NO has been shown to act through the transcription factor dFOXO, and dFOXO itself has been 
shown to activate the transcription of many genes (Puig et al 2003, Teleman et al 2008).  Some 
of these genes encode proteins that do, or can have, growth inhibitory effects. Data, intended to  
better define the roles of some of these potential effectors of the growth inhibitory phenotypes 
of NOS2 and dFOXO will be presented in this chapter. 
NO can affect translation (Kimber 2005, Teodoro & O'Farrell 2003), and some of the dFOXO 
targets proteins are known regulators of translation. Accordingly we investigated whether it 
was NO modulation of these dFOXO target proteins that was responsible for the NO effect on 
translation. Given previous research in this area (as discussed in the introduction), the most 
likely candidates that may be required for both growth inhibition through the activity of 
dFOXO, and the reduced levels of translation induced by NO, are Thor and Lk6, both of which 
regulate the activity of the translation factor eIF4E. Genetic manipulation of these genes was 
undertaken to test the role of each of these genes in the regulation of growth by NO. The 
genetic manipulation undertaken and the rationale for selection of each gene is briefly 
explained below. 
5.1. Thor  
It has previously been shown that NO acts through dFOXO to regulate growth. One of the 
transcriptional targets that has been shown to have increased expression due to NO, via 
dFOXO, is Thor, indeed, Thor expression has been used as a reporter in studies as an indicator 
of dFOXO activity (Wittwer et al 2005).  
It is thought that Thor may act to inhibit growth via its binding to the translation initiation 
factor eIF4E (Bernal & Kimbrell 2000).  However, although Thor is considered to be a 
regulator of growth, this may not be the only way in which NO is acting, via dFOXO, to inhibit 
growth, as dFOXO has many transcriptional targets (Puig et al 2003, Teleman et al 2008). To 
test whether expression of Thor alone was sufficient for the growth phenotype observed with 
expression of either UAS-NOS or UAS-dFOXO (Chapter 3) a constitutively active form of 
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Thor, Thor
LL
 was expressed in the salivary gland.  To determine if Thor is necessary for the 
action of NO, a null allele of Thor (Thor
2
) (Bernal & Kimbrell 2000) was used. Thor
2
, is a null 
mutant which has part of the promoter region, the translation site and a substantial part of the 
coding region deleted (Teleman et al 2005). 
5.2. Lk6 and eIF4E 
Another candidate effector protein for the growth inhibitory effects of NO is Lk6, the 
functional homolog of the mammalian Mnk kinases (Arquier et al 2005). Like Thor, it is an 
known transcriptional target of dFOXO (Teleman et al 2008) and has also been shown to 
regulate the activity of translation initiation factor eIF4E (Arquier et al 2005, Parra-Palau et al 
2005, Reiling et al 2005). The regulation of eIF4E through Lk6 phosphorylation has been 
demonstrated (Arquier et al 2005, Reiling et al 2005), although the exact role of this 
phosphorylation event on eIF4E activity is unclear and will be discussed below. Lk6 has been 
shown in one study to be vital for normal growth and development (Arquier et al 2005). Lk6 
null mutants exhibited reduced viability, slower development and reduced adult size (Arquier 
et al 2005). These results were comparable to those seen in animals expressing a non-
phosphorylatable form of eIF4E (Lachance et al 2002) where expression caused delayed 
development and flies were smaller in overall size. These data suggest that Lk6 acts to 
positively phosphorylate eIF4E which is then able to activate protein synthesis. In contrast 
however, results in mammalian studies have been contradictory, with it being shown that 
phosphorylation of eIF4E reduces its affinity for the capped mRNA (Scheper et al 2002). 
Moreover, it has also to be noted that even in the studies in which it was shown that 
phosphorylation of eIF4E through Lk6 acted to activate translation (Arquier et al 2005), Lk6 
overexpression in the eye disc resulted in subtle growth impairments (Arquier et al 2005). 
Accordingly, even in studies where Lk6-mediated activation of translation is seen, the opposite 
effect was also observed in some tissues. Growth inhibition due to Lk6 overexpression in an 
eIF4E phosphorylation-dependent manner was also seen in another study (Reiling et al 2005). 
This work however, also produced contradictory results to those of Arquier et al, as Reiling et 
al found that their Lk6 nulls were viable, and fertile flies without obvious growth defects were 
produced when grown under standard conditions. However Reiling et al also found that when 
Lk6 null mutants were raised under conditions of poor nutrient supply a reduction in size of 
flies was observed. The reduction in the amino acid supply also abolished the negative effects 
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of Lk6 overexpression on growth, which suggested that the activity of Lk6 was also regulated 
in response to nutrients.  
Together these results show that Lk6 activity and its downstream effects are dependent on a 
variety of factors (nutrient availability and level of phosphorylation) and changing them will 
result in either to growth stimulation or growth inhibition (Reiling et al 2005) (Fig. 5.1.).   
Thus it may be that if dFOXO acts to upregulate Lk6 as a result of NO expression, it may then 
result in Lk6-mediated phosphorylation of eIF4E, which in turn would result in the inhibition 
of translation. To test this hypothesis both Lk6 nulls and non-phosphorylatable form of eIF4E 
were utilised.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Effect of Diet and Lk6 Dosage on Growth. 
In wild type, TOR activity is stimulated under rich nutrient conditions (high amino acids), resulting in 
the phosphorylation of Thor. This leads to an increase in the pool of free eIF4E (represented by circles), 
which assembles into functional translation initiation complexes. The translation efficiency is further 
modulated by phosphorylation of eIF4E by Lk6 (blue circles represents phosphorylated eIF4E). A high 
level of Lk6 results in complete phosphorylation of eIF4E and impairs growth because of premature 
eIF4E phosphorylation and/or a reduction of the affinity of phosphorylated eIF4E to capped mRNA. On 
the other hand, the loss of Lk6 is without impact on translation initiation under favorable conditions, 
because phosphorylation of eIF4E is not essential as long as the pool of free eIF4E is sufficiently large. 
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Under low amino acids conditions, however, the absence of Lk6 leads to impaired translation 
efficiency. Lk6 activity is presumably also regulated in response to amino acid availability. Figure 
adapted from Reiling et. al. (Reiling et al 2005). 
 
5.2. Results 
5.2.1. Is Thor sufficient for NO induced growth inhibition? 
Thor has been shown to respond to the action of NO, so further investigation into this action 
was undertaken. Expression of an active form of Thor (UAS-ThorLL) and a Thor null mutant 
(Thor
2
) were exploited. Thor
LL
 is an active form of Thor that binds deIF4E strongly (Miron 
2001). This stronger binding of Thor
LL 
to
  
deIF4E would result in deIF4E being unable to be 
recruited to the translation initiation complex and thereby inhibition of translation. Expression 
of UAS-Thor
LL
 within the wing-imaginal disc has been shown to decrease wing size. This 
reduction in size was not seen if wild type Thor was expressed (UAS-Thor) (Miron 2001).  
Expression of NO in the salivary glands using UAS-NOS2 resulted in reduced salivary gland 
and nuclei size, and expression of UAS-dFOXO produced similar results (Chapter 3. Fig. 3.2.). 
It is thought that NO may be acting through dFOXO to increase transcription of Thor which 
thereby results in reduced growth.  To see if expression of an active form of Thor would result 
in the same reduced growth in salivary glands, the salivary gland Gal4 driver c147 was utilised. 
The active form of UAS-Thor was chosen as previous work had demonstrated that wild type 
UAS-Thor did not cause any change in growth (Miron 2001). The expression of Thor
LL
 in the 
salivary glands did not show the same reduced nuclei size that was seen with UAS-NOS2 or 
UAS-dFOXO. There was a small reduction when compared to the wild type (Fig. 5.2.) but this 
difference was not statistically significant (Appendix II. d.).  
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Figure 5.2. Average Size of Salivary Gland Nuclei expressing Thor
LL
. 
c147-GAL4 was used to drive expression UAS-Thor
LL
. WT (c147-GAL4/+) and Thor
LL
 (c147-
GAL4/UAS-Thor
LL
). Error bars indicate the standard deviation. Wt; 209 nuclei of 19 salivary glands. 
ThorLL; 193 nuclei of 21 salivary glands (raw data in Appendix II.d.). P-Value=0.001 
 
For WT, data was derived from 209 nuclei from 19 salivary glands. Thor
LL
; 198 nuclei from 21 salivary 
glands.  
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5.2.2. Is Thor necessary for NO induced growth inhibition? 
dFOXO has many transcriptional targets, with Thor being just one of them. To identify if the 
reduced growth phenotype seen with NO is solely due to an increase in Thor levels, the Thor 
null mutant, Thor
2
, was used. Thor
2
 null mutant animals are homozygous viable and fertile 
(Bernal & Kimbrell 2000), and show no growth defects under normal conditions (Teleman et al 
2005). However, Thor
2
 null mutant larvae were found to have an impaired response to nutrient 
deprivation, thought to be due to an impaired ability to reduce energy burn rate (Teleman et al 
2005). The salivary gland Gal4 driver AB1 was used to drive UAS-NOS2 expression in the 
background of Thor null larvae. The nuclei of Thor
2
 homozygous larvae were slightly bigger 
than wild type nuclei in size (Fig. 5.3.) but this effect was not statistically significant. The 
expression of UAS-NOS2 in a Thor null background had little effect on the reduced growth 
phenotype seen with NO expression (Fig. 5.3.) with nuclei from larvae expressing UAS-NOS2 
in a wild type or a Thor2 background being statistically similar (Appendix II. e.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 96 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Average Size of Salivary Gland Nuclei in Thor null larvae. 
AB1-GAL4 was used to drive expression NOS2 in salivary glands of Thor null larvae (Thor
2
). WT 
(+/+; +/+; AB1-Gal4/+), Thor
2
 (+/+;Thor
2
; AB1-Gal4/+), NOS2 (UAS-NOS2/+; +/+ ;AB1-GAL4/+) 
and NOS2 Thor
2
 (UAS-NOS2/+;Thor
2
 ;AB1-GAL4/+). Error bars indicate the standard deviation (raw 
data in Appendix II.e.). P-value= 0.001 
 
For WT, data was derived from 216 nuclei from 21 salivary glands. Thor
2
; 288 nuclei from 24 salivary 
glands. NOS2; 203 nuclei from 20 salivary glands. NOS2 Thor
2
; 304 nuclei from 24 salivary glands.  
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5.2.3. Are Lk6 or the phosphorylation of eIF4E necessary for NO induced growth 
inhibition?  
NO has been shown to inhibit growth through dFOXO. Thor is one of the transcriptional 
targets of dFOXO shown to be upregulated by NO through dFOXO, but as dFOXO is known 
to have many translational targets (Puig et al 2003) it may be that expression of Thor is not the 
target through which NO acts to regulate growth. Another candidate for NO action on growth 
through dFOXO is Lk6. Lk6 is of interest as it is a known transcriptional target of dFOXO and 
it also regulates the activity of the same translation factor, eIF4E. To investigate if NO may be 
acting via dFOXO on Lk6 to regulate growth, Lk6 null mutations were utilised as well as a 
non-phosphorylatable form of eIF4E.  
To generate Lk6 null a loss-of-function animals, alleles of Lk6 (Lk615and Lk638) were used, 
which were kind gift from Prof. Ernst Hafen (Reiling et al 2005). It has previously been shown 
that this mutant combination gave rise to viable and fertile flies without obvious growth defects 
(Reiling et al 2005). However, as with Thor , under conditions of limited nutrients Lk6 is 
required for normal growth (Reiling et al 2005). The salivary gland nuclei of third instar larvae 
of Lk6 null animals were not different in size to that of wild type (Fig. 5.4.). To ascertain if NO 
was acting through Lk6, UAS-NOS2 was expressed using the salivary gland Gal4 driver c147. 
The expression of UAS-NOS2 in a Lk6 null background did not show any rescue of the growth 
inhibition as was seen with UAS-NOS2 alone (Fig. 5.4.).  
A separate analysis to determine whether NO-reduced growth required Lk6 dependent 
phosphorlylation was also undertaken. A non-phosphorylatable form of eIF4E was utilised to 
show if phosphorylation of eIF4E was vital for the inhibition of growth by NO (presumably 
through Lk6 or other kinases). The UAS-eIF4E
Ser251Ala
 construct allows expression of a non-
phosphorylatable form of eIF4E (Lachance et al 2002), and flies that express this construct in 
eIF4E mutant background
 
are delayed in development and are smaller than control
 
animals 
(Lachance et al 2002). As has already been discussed, the phosphorylation of eIF4E may act to 
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either activate or inhibit translation, but as it is expected that if dFOXO does act through Lk6 
this would result in hyperphosphorylation of eIF4E and therefore inhibition of translation. An 
investigation whether expression of eIF4E
S251A
 can prevent the growth reduction seen with 
UAS-NOS2 expression would determine if phosphorlylation (by Lk6 or other kinases) was 
necessary for the growth inhibition caused by NO. In this study, the salivary gland nuclei of 
third instar larvae expressing UAS-eIF4E
S251A
 did not appear different in size to wild type (Fig. 
5.5.). To ascertain if NO was acting through Lk6, and therefore phosphorylation of eIF4E was 
inhibiting growth, UAS-NOS2 was expressed using the salivary gland Gal4 driver c147 along 
with UAS-eIF4ES251A. The expression of UAS-NOS2 with UAS-eIF4ES251A in the salivary gland 
did not show any rescue of the growth inhibition seen with UAS-NOS2 alone, with the nuclei 
being slightly smaller in size to those produced as a result of UAS-NOS2 alone, although this 
difference was not statistically significant (Fig. 5.5.).  
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Figure 5.4. Average Size of Salivary Gland Nuclei NOS2 expression in Lk6 null larvae. 
c147-GAL4 was used to drive expression UAS-NOS2 in Lk6 null larvae. WT (+/+;c147/+;+/+), Lk6 null 
(+/+;c147/+;Lk6
15
/Lk6
38
), NOS2 (UAS-NOS2/ +;c147/+;+/+), NOS2 Lk6 null 
(NOS2/+;c147/+;Lk6
15
/Lk6
38
). Error bars indicate the standard deviation (raw data is given in Appendix 
II. f.) P-Value= 0.001 
 
For WT, data was derived from 247 nuclei from 20 salivary glands. Lk6; 245 nuclei from 24 salivary 
glands. NOS2; 186 nuclei from 15 salivary glands. NOS2 Lk6; 261 nuclei from 20 salivary glands.  
 
 
 
 
 
 
Average Size of Salivary Gland Nuclei
0
5
10
15
20
25
30
35
WT Lk6 null NOS2 NOS2 Lk6 null
S
iz
e
 u
m
 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. Average Size of Salivary Gland Nuclei expressing eIF4E
S251A
 and NOS2. 
c147-GAL4 was used to drive expression UAS- eIF4E
S251A
, NOS2 and both together. WT (c147-
GAL4/+), eIF4E* (c147-GAL4/+; UAS- eIF4E
S251A
 /+), NOS2 (NOS2/+;c147-GAL4/+) and NOS2 
eIF4E* (NOS2/+;c147-GAL4/+; UAS- eIF4E
S251A
 /+). Error bars indicate  the standard deviation (raw 
data is given in Appendix II. g.). P-Value = 0.001 
 
For WT, data was derived from 210 nuclei from 20 salivary glands. eIF4E*; 225 nuclei from 20 
salivary glands. NOS2; 223 nuclei from 20 salivary glands. NOS2 eIF4E*; 224 nuclei from 20 salivary 
glands.  
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5.2.4. Are Thor and Lk6 required for NO induced growth inhibition? 
Neither Thor nor Lk6 alone were shown to be individually required for the inhibition of growth 
seen with UAS-NOS2 expression in the salivary gland. However it has been proposed (Reiling 
et al 2005) that Thor and Lk6 may be acting in partnership to control translation (Reiling et al 
2005).Both these genes are targets of dFOXO (Teleman et al 2008). To test whether they are 
required for the signal transduction, UAS-NOS2 was expressed in the salivary glands using a 
first chromosome Gal4 driver A9 in animals doubly mutant for Thor
2
 and Lk6
15
/Lk6
38
. In these 
double null mutant animals, where both Thor and Lk6 were null mutants, the average nuclei 
size was slightly smaller than wild type, although this difference was not statistically 
significant (Fig. 5.6.) (Appendix II. h.). When UAS-NOS2 was driven in the salivary glands of 
double null mutants there was no change in the average size of nuclei when compared to UAS-
NOS2 expression alone (Fig. 5.6.).  
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Figure 5.6. Average Size of Salivary Gland Nuclei NOS2 expression in Thor and Lk6 null larvae. 
A9-GAL4 was used to drive expression UAS-NOS2 in Thor and Lk6 null larvae. WT (A9-
Gal4/+;+/+;+/+), NOS2 (UAS-NOS2/ A9-Gal4;+/+;+/+), NOS2 Thor
2 
Lk6
15/38
 (UAS-NOS2/ A9-
GAL4;Thor
2 
/ Thor
2
; Lk6
15
/Lk6
38
), Thor
2 
Lk6
15/38
 (A9-GAL4/+; Thor
2 
/ Thor
2
; Lk6
15
/Lk6
38
) and NOS2 
Thor
2
/+
 
Lk6
15
/+ (UAS-NOS2/ A9-GAL4;Thor
2 
/ +; Lk6
15
/+). Error bars indicate standard deviation (raw 
data in Appendix II. h.). P-Value=0.001. 
 
For WT, data was derived from 211 nuclei from 20 salivary glands. NOS2; 223 nuclei from 20 salivary 
glands. NOS2 Thor
2 
Lk6
15/38
; 241 nuclei from 21 salivary glands. Thor
2 
Lk6
15/38
; 230 nuclei from 20 
salivary glands. NOS2 Thor
2
/+
 
Lk6
15
/+; 246 nuclei from 20 salivary glands.  
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5.3. Discussion 
5.3.1. Thor is not necessary or sufficient for NO induced growth inhibition. 
To investigate how NO may inhibit growth through the action of the insulin pathway, 
components of the pathway that may act as negative regulators of growth were analysed more 
closely. NO has been shown to effect Thor expression. To test whether Thor was sufficient for 
the growth inhibition induced by NO, an high affinity active form of Thor (UAS-Thor
LL
) was 
expressed in salivary glands. To determine whether Thor was necessary for the phenotype, a 
Thor null (Thor
2
) was utilised. As dFOXO is known to upregulate the transcription of Thor 
(Puig et al 2003), it was hypothesised that expression of an active form of Thor may inhibit the 
size of the salivary gland nuclei that were observed with either UAS-NOS2 or UAS-dFOXO. 
This was not the case with targeted expression of Thor
LL 
to the salivary glands. This resulted in 
salivary gland nuclei that were not significantly different in size from that of wild type. This 
may be due to increased Thor expression not being the only way in which NO, acting through 
dFOXO, is inhibiting growth of these cells. It may also be that although ThorLL binds to 
deIF4E more strongly, this is not having the same growth inhibitory effect that is caused by the 
large increase in normal Thor expression that occurs when NO is expressed. Nevrtheless, it 
should be noted that ThorLL has been shown in wing dics to reduce growth in wing discs 
(Miron 2001). 
To further investigate if the action of NO is specifically through Thor via dFOXO, NO was 
expressed in Thor null mutant animals to test if the reduced growth phenotype was Thor 
dependent. The reduced growth phenotype was still observed following NO expression in Thor 
null homozygous larvae. However, this is in contrast to the results of a similar experiment 
previously observed in our laboratory showing that dFOXO nulls abolish the growth inhibitory 
effects of NO (Kimber 2005). Thus, although the action of NO has been shown to increase 
Thor expression through dFOXO, this increase does not appear necessary for NO to regulate 
growth. Taken together these data imply that there may be other transcriptional targets of 
dFOXO whose modulation is required to reduce growth.  
5.3.2. Lk6 or eIF4E phosphorylation are not required for NO-induced growth inhibition 
Lk6 is another transcriptional target of dFOXO (Teleman et al 2008) that has been previously 
shown to be a regulator of the translation factor eIF4E (Arquier et al 2005, Parra-Palau et al 
2005, Reiling et al 2005) and thus may be responsible for dFOXO regulated growth. The Lk6-
 105 
 
dependent regulation of eIF4E is thought to be both inhibitory and activating (Arquier et al 
2005, Reiling et al 2005). It was hypothesised that if NO acted through Lk6 (via dFOXO) it 
would be due to the increase in Lk6 expression resulting in hyperphosphorylation of eIF4E 
reducing its affinity for capped mRNA. However, it was found that neither complete loss of 
Lk6, or expression of a non-phosphorylatable form of eIF4E (eIF4E
S251A
),was able to suppress 
the reduced growth phenotype observed with NO expression in the salivary gland. Thus neither 
Lk6 nor other kinases which may phosphorylate eIF4E are responsible for the reduced growth 
of the salivary gland caused by NO. 
5.3.3. Thor and Lk6 are not required for NO induced growth inhibition 
It is has been suggested that translational control through the dFOXO branch of the insulin 
pathway acts directly via parallel, independent targets (Lk6 and Thor) to regulate protein 
translation (Teleman et al 2008). Therefore although Thor null and Lk6 nulls alone were unable 
to suppress the reduced growth seen following expression of NO, it may be that removal of 
both simultaneously would prevent NO-dependent growth inhibition.   
However, it was found that despite removing both Thor and Lk6 at the same time, NO was still 
able to inhibit growth. Therefore NO growth inhibition through dFOXO does not require either 
Thor, Lk6, or a combination of the two. Thus, although I have demonstrated some evidence for 
the proposed parallel independent functions in growth regulation by Thor and Lk6 (the slightly 
reduced growth of Thor2; Lk6 doubly mutants animals), there is no evidence that either of 
these regulators of translation (either separately, or redundantly in parallel) are required for the 
inhibition of growth caused by NO. Therefore, although dFOXO is necessary (and sufficient) 
for growth inhibition of the salivary glands, the biologically relevant targets of this 
transcription factor have yet to be identified.  
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Chapter 6: Oncogenes and NO 
6.1. Introduction 
Nitric Oxide is known to have an antiproliferative activity (Kuzin et al 1996, Peunova & 
Enikolopov 1995, Peunova et al 2001), and FOXO, a target of NO,  has been linked to cell-
cycle arrest and apoptosis in mammalian studies (Zanella et al 2008). These observations 
suggest that NO may have a function as a tumor suppressor, having anti-oncogenic effects.  
To test this, two known oncogenes, Ras and Myc, were analysed with respect to their response 
to NO. Although both Ras and Myc were discussed in Chapter 1, they are briefly discussed 
again below. 
6.1.2. Ras 
Ras is a guanine nucleotide binding protein, a GTPase, and is controlled by the GDP/GTP
 
cycle. Ras is inactive when bound to GDP, but becomes active when bound to GTP. Ras in the 
active GTP-bound form acts in signal transduction pathways to transmit extracellular signals 
from receptor tyrosine kinases to downstream serine/threonine kinase targets. (Vojtek & Der 
1998).  
The microarray data produced from NO donor treated Drosophila S2 cells versus untreated S2 
cells (Kimber 2005), was compared to that from microarray analysis of hemocytes expressing 
activated Ras (Ras
V12
) versus hemocytes expressing wild type Ras
 
(Asha et al 2003). There is 
an inverse correlation in the up and down regulation of transcripts identified from these data 
sets. In the hemocyte data, 1286 genes were found to be up regulated in association with the 
expression of activated Ras
V12
. When compared to the data for S2 cells derived 12 hours after 
NO, 83 genes of those 1286 were found to be downregulated. Analysis of these 83 common 
genes revealed that those most upregulated by expression of Ras
V12 
are in turn the most 
downregulated genes following NO treatment (Kimber 2005). These results give an indication 
that the proliferation control produced by NO may work in an opposite way to that of the 
overproliferation induced by Ras. This was tested in this study, by co-expression of Ras
V12
 
with NO to see if NOS2 could suppress the overgrowth seen with Ras
V12
 alone. 
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6.1.3. Myc 
Myc is part of a network of transcription factors which act to regulate a wide variety of 
processes including growth and proliferation, differentiation, apoptosis and oncogenesis 
(Pierce et al 2004). This transcription network, known as the Max transcription factor network, 
it is made up of a group transcription factors which share two common features. They contain a 
basic-helix-loop-helix-leucine zipper (bHLHZ) motif which mediates in protein-protein 
binding and DNA binding (Grandori et al 2000). They also form individual heterodimers with 
Max, which is also a bHLHZ protein (Grandori et al 2000). Drosophila has one ortholog to the 
mammalian Myc transcription factor dMyc.  
To test if NO was able to suppress the overgrowth induced by Myc, NOS2 and Myc were also 
co-expressed in the same manner as NOS2 and Ras
V12
. 
Myc is also an interesting potential target for NO signaling as myc has been identified as a 
direct and also indirect target of dFOXO, with myc mRNA levels being controlled by dFOXO 
in a tissue specific manner. dFOXO can inhibit or increase dMyc expression (Teleman et al 
2008). FOXO has been shown to suppress Myc driven proliferation (Bouchard et al 2007) and 
Myc dependent gene expression in cell culture (Delpuech et al 2007). The FOXO-dependent 
nature of Myc induced transformation has demonstrated cooperativity between Myc and Ras 
(Bouchard et al., 2004). 
To investigate if NO can effect expression of Myc, possibly through dFOXO, Myc protein 
levels were also examined in salivary gland clones expressing NOS2 compared to the 
surrounding wild type salivary gland tissue. 
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6.2. Results 
6.2.1. Interaction between Ras and NOS-controlled cell proliferation 
To examine whether Ras-induced over proliferation could be suppressed by NOS2, an 
activated form of Ras, RasV12, was expressed in the larval salivary gland using the salivary 
gland GAL4 driver c147, both alone and in combination with UAS-NOS2. 
The late third instar larvae which were expressing just the UAS- Ras
V12
, had salivary glands 
which showed a marked increase in overall size (Fig. 6.1.). The nuclei in the salivary glands 
expressing the UAS- Ras
V12
 were also much larger than the control nuclei in wild type controls 
(Fig. 6.1. and 6.2.). In contrast, when both UAS- RasV12 and UAS-NOS2 were co-expressed in 
the salivary gland, the salivary glands showed a marked decrease in size compared to wild 
type, looking closer in size to NOS2 expressing salivary glands (Fig. 6.1. and 6.2.). Co-
expression of UAS- RasV12 and UAS-NOS2 resulted in a decrease in the size of the nuclei when 
compared to those expressing Ras
V12 
alone. There was a range of nuclear sizes but all were 
smaller than nuclei expressing RasV12 alone (Fig. 6.1. and 6.2). 
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Figure 6.1. Salivary glands and salivary gland nuclei expressing Ras
V12
.  
c147-Gal4 was used to drive the expression of Ras
V12 
 alone (A,C), and in the presence of UAS-NOS2 
(D). (A) c147-GAL4/UAS-Ras
V12
 salivary gland pair and c147-GAL4/+ salivary gland. Scale bar 
200µm (B) c147-GAL4/UAS-Ras
V12
 salivary gland nucleus. (C) c147-GAL4/+ salivary gland nucleus. 
(D) NOS2/+;c147-GAL4/+ salivary gland nucleus. (E) NOS2/+;c147-GAL4/UAS-Ras
V12
 salivary gland 
nucleus. Scale bars 20µm. 
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Figure 6.2. Average size of salivary gland nuclei expressing Ras
V12
 and NOS2. 
c147-GAL4 was used to drive expression UAS-Ras
V12
, NOS2 and both together. WT (c147-GAL4/+), 
RasV12 (c147-GAL4/UAS-Ras
V12
), NOS2 (NOS2/+;c147-GAL4/+) and NOS2 Ras
V12
 (NOS2/+;c147-
GAL4/UAS-Ras
V12
). Error bars indicate the standard deviation (raw data is presented in Appendix II.i.). 
P-Value=0.001 
 
For WT, data was derived from 223 nuclei from 20 salivary glands. Ras
V12
; 236 nuclei from 20 salivary 
glands. NOS2; 282 nuclei from 21 salivary glands. NOS2 Ras
V12
; 246 nuclei from 22 salivary glands.  
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6.2.2. Interaction between dMyc and NOS controlled proliferation  
To examine whether dMyc-induced growth could be suppressed by NOS2 expression, dMyc 
was overexpressed in the larval salivary gland using the salivary gland GAL4 driver c147, both 
alone and in combination with UAS-NOS2. 
Late third instar larvae which were expressing just UAS-dMyc had salivary glands which 
showed a marked increase in overall size (Fig. 6.3.). The nuclei in the salivary glands 
expressing UAS-dMyc were much larger than nuclei in wild type controls (Fig. 6.3.). When 
both UAS-dMyc and UAS-NOS2 were co-expressed in the salivary gland, the salivary glands 
showed a marked decrease in size when compared to glands in which just UAS-dMyc was 
overexpressed (Fig. 6.3.). The size of the nuclei co-expressing dMyc and NOS2 was also 
decreased when compared to those expressing dMyc
 
alone, although co-expression resulted in 
a range of nuclei sizes, all were smaller than nuclei expressing dMyc alone, which was very 
similar to that of wild type nuclei (Fig. 6.3.). 
 
To examine if NO is able to not only suppress the overgrowth phenotype seen with UAS-dMyc 
expression, but also to regulate expression of dMyc, salivary glands expressing NOS in single 
cell clones were stained with a dMyc antibody to examine for any change in dMyc expression.  
The antibody was shown to be specific as tested in wing discs. UAS-dMyc expression was 
driven using a Gal4, which drove expression in a specific pattern in the wing discs (Dpp 
pattern). When dMyc antibody stained the discs showed uniform weak expression as well as 
increased staining in the specific pattern of Dpp expression. The level of Myc expression was 
analysed in salivary glands containing small clones of cells expressing NOS2. In 17 clones 
studied in salivary glands, 10 showed a slight increase in dMyc expression (Fig. 6.4.), 5 
showed no increase and in the remaining 2, the staining was not clear enough to make a 
judgement. The clones which did show an increase demonstrated both cell-autonomous and 
non-autonomous up regulation.  
 
 
 
 
 
 
 112 
 
 
 
 
 
 
Figure 6.3. Average size of salivary gland nuclei expressing dMyc and NOS2. 
c147-GAL4 was used to drive expression UAS-Myc, NOS2 and both together. WT (c147-GAL4/+), 
Myc (c147-GAL4/+; UAS-dMyc/+), NOS2 (NOS2/+;c147-GAL4/+) and NOS2 Myc (NOS2/+;c147-
GAL4/+;UAS-dMyc/+). Error bars indicate the standard deviation. (raw data is given in Appendix II.j.) 
P-Value= 0.001 
 
For WT, data was derived from 286 nuclei from 26 salivary glands. Myc; 319 nuclei from 26 salivary 
glands. NOS2; 223 nuclei from 20 salivary glands. NOS2 Myc; 376 nuclei from 26 salivary glands. 
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Figure 6.4. dMyc expression in NOS2 expressing 
clones in salivary glands. 
Clones were generated using a 4 and half min heat 
shock at 38
o
C between 24-48hr AEL. Clones are 
marked with GFP. Scale bars 50µm. 
Ai., Aii. and Aiii. NOS2; UAS- NOS2/hsFLP; 
+/Act5c>y
+
>Gal4;UAS-GFP/+. Red; dMyc  Green; 
GFP + NOS2  Blue; DAPI. 
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6.3. Discussion 
6.3.1. Ras 
NO has been shown to have antiproliferative activity (Kuzin et al 1996, Peunova & Enikolopov 
1995, Peunova et al 2001and this thesis). To determine if Ras-induced overproliferation could 
be suppressed by NO, an activated Ras
V12
 protein was co-expressed with NOS2. Expression of 
activated RasV12 in salivary glands results in increased of both the overall salivary gland size 
and the nuclear size. This increase in size is consistent with results seen from overexpression of 
Ras
V12
 in other Drosophila tissues as well as the results seen by Berry & Baehrecke 2007 
where expression of Ras
V12
 in the salivary glands resulted in increased growth. It should be 
noted that in Berry & Baehrecke 2007 growth was measured by cell area measurements on 
Drosophila 13.5 hours after puparium formation, whereas I was examining nuclear size of late 
third instar larvae although the results are similar. When Ras
V12
 was co-expressed with NOS2, 
NOS2 was able to rescue the overproliferation effects of increased nuclear size induced by 
Ras
V12
 alone. The average nuclear size of salivary glands expressing both NOS2 and Ras
V12
 
was smaller than in wild type salivary glands, but larger than in glands expressing NOS2 alone. 
Thus NOS2 is capable of suppressing the RasV12 overgrowth phenotype, but in turn RasV12 can 
suppress, to some degree, the small salivary gland phenotype of NOS2. This supports the 
molecular data showing they have opposing effects on the regulation of many genes (Kimber 
2005). 
These data also show that NOS2 expression is capable of suppressing Ras
 V12
 induced 
overproliferation supporting the idea of NOS as a tumour suppressor, having anti-oncogenic 
effects. As dFOXO is a proposed target for NO, that has been linked to cell-cycle arrest and 
apoptosis in mammalian studies (Zanella et al 2008), it suggests that NO may be acting 
through dFOXO to exert  its anti-oncogenic effects. To further investigate this it would be 
necessary to repeat the experiment, but in animals homozygous for dFOXO null mutations. 
Activated RasV12 is known to act through PI3K, a component of the insulin pathway, to 
increase growth, and NO is thought to act in this pathway to suppress growth. It is interesting 
to note that NOS2 can suppress Ras
V12
 induced overproliferation.  
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6.3.2. Myc 
As with Ras
V12
, NOS2 was able to suppress the overgrowth phenotype resulting from dMyc 
expression. This overgrowth phenotype was similar to previous studies where dMyc is 
overexpressed in Drosophila, resulting in an increase in the size of cells, with both mitotic and 
endoreplicating cells (including those of the salivary gland) being larger than normal (Grewal 
et al 2005, Neufeld et al 1998, Pierce et al 2004). NOS2 co-expression with dMyc results in 
salivary gland nuclei which were statistically similar to that of wild type salivary glands.  
I was unsure what levels of dMyc expression would be observed in NOS2 expressing clones, 
but was surprised when in more than half, an obvious increase was apparent, given that 
dFOXO expression can inhibit dMyc expression in Drosophila muscle (Demontis & Perrimon 
2009) and inhibition of N-Myc expression by NO has been reported neuroblastoma cells (Ciani 
et al 2004).  
 However it should be noted that in some clones no change in dMyc expression was observed 
and the background in the staining was relatively high, accordingly in future verification 
studies this would need to be optimised. dMyc has been identified as a direct and also indirect 
target for the transcription factor dFOXO, with dMyc mRNA levels being controlled by 
dFOXO in a tissue-specific manner. dFOXO can inhibit or increase dMyc expression (Teleman 
et al 2008).  
In vertebrates FOXO has been shown to suppress Myc-driven proliferation (Bouchard et al 
2007) and Myc-dependent gene expression in cell culture (Delpuech et al 2007), and in 
Drosophila, dFOXO has been shown to inhibit dMyc function (Demontis & Perrimon 2009). 
Thus, although increased Myc expression is usually associated with increased growth and 
proliferation, the activity of dMyc in these NOS2 expressing cells may be suppressed by the 
increased dFOXO activity in these same cells. Alternatively, the increase in dMyc expression 
may reveal a control mechanism whereby once dFOXO expression reaches specific levels in 
the cell, this activates dMyc expression, therefore preventing over inhibition of proliferation. 
 
Overall the data presented in this Chapter demonstrates that NO can suppress the increased 
growth of salivary gland cells expressing ectopic Myc or activated Ras, thereby supporting the 
possible use of NO-donating compounds in the treatment of misregulated growth. 
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Chapter 7: Discussion 
7.1. Introduction 
The work presented in this thesis has confirmed the role Nitric Oxide in the inhibition of 
growth in Drosophila and demonstrated a potential molecular mechanism for its action. NO 
was also shown to be able to not only regulate normal growth in Drosophila but also to inhibit 
misregulated overgrowth. The mechanism as to how NO functions in regulating growth 
elucidated through the data presented in this thesis, as well as possible lines worthy of further 
investigation, are discussed below. 
7.2. Expression of NOS in Drosophila 
Nitric Oxide levels were controlled via expression of NOS2, a constitutively active mouse 
macrophage nitric oxide synthase gene, under the control of GAL4 (section, 3.2.1.). The 
ectopic expression of NOS2 in the salivary glands was achieved by using either c147 or AB1 
Gal4 as the driver. Expression of NOS2 in the salivary glands resulted in a reduced growth 
phenotype (section 3.2.1.). This reduced growth phenotype was similar to that following 
overexpression of dFOXO (section 3.2.1.). The transcription factor dFOXO, which is part of 
the insulin signaling pathway, has previously been identified as a possible target for NO 
signaling (Kimber 2005), and was also shown to be necessary for NO action in inhibiting 
growth (Kimber 2005). The data presented in this thesis confirm these initial findings and 
further demonstrate that NO can upregulate the protein levels of dFOXO. However it is not 
clear how NO has this effect. It is speculated that it may be post transcriptionally as no changes 
in dFOXO mRNA levels were observed in NO treated tissue culture cells (Kimber 2005).  
7.2.1. Thor expression in NOS2 expressing larvae 
To confirm the role of dFOXO as a target for NO signaling in Drosophila, the expression of 
one known dFOXO transcriptional target, Thor, was studied. This allowed the activity of 
dFOXO to be monitored, albeit indirectly. The expression of Thor, and thereby dFOXO 
activity, was examined in three ways: through the use of a LacZ promoter fusion, a YFP 
protein fusion and via antibody staining of the endogenous Thor protein. In the previous in vivo 
study of Kimber et al. NOS2 was expressed in whole salivary glands which resulted in the 
increase in Thor LacZ expression, coinciding with a reduction in the size of the salivary glands 
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(Kimber 2005). However, the observed increase in LacZ staining may have been a reflection of 
this change in size and not in an increase in the expression of Thor.  
To verify the apparent increase of Thor LacZ reporter levels in response to NOS2 expression, 
NOS2 was expressed in small or single cell clones within the salivary gland. NOS2 expressing 
clones showed an increase in Thor LacZ levels confirming the direct effect of NO on Thor 
expression. Interestingly, the clones also demonstrated that the expression of NOS resulted in 
cell non-autonomous as well as cell autonomous effects. These non-autonomous effects are 
consistent with the fact that NO is known to diffuse between cells (Haley 1998). The short-
range of the non-autonomous effects of NO are probably due to its half-life of approximately 
only a few seconds (Haley 1998) limiting its diffusion to those cells immediately neighboring 
the source of NO. 
As the Thor LacZ is only a reporter of the Thor promoter activity and does not directly reflect 
protein levels, a Thor-YFP protein fusion was also utilised to observe the behavior of Thor 
protein itself to increased levels of NO. This construct comprises an insertion of a YFP protein 
trap construct into the coding region of the Thor locus. Thus it reflects the expression of the 
endogenous protein rather the just activity of the promoter. Experiments using the Thor-YFP 
fusion also indicated an increase in expression in response to expression of NOS2 in whole 
salivary glands, and in single salivary gland cells.  
To validate expression of Thor-YFP as an indicator of increased dFOXO activity, UAS-dFOXO 
was also expressed in whole salivary glands and in single salivary gland cells. The results from 
this, was as expected, showing an increase in Thor-YFP expression. The final verification was 
achieved using antibody raised against Thor. Although this antibody was later identified not to 
be specific for only Thor protein, this was probably due to being from an early bleed as the 
original purified antibody had run out.  The antibody though did show that there was an 
increase in Thor protein expression in response to NOS2. Taken together these data strongly 
suggests that NO can increase Thor expression through what is thought to be increased dFOXO 
activity.  
7.2.2. dFOXO expression in response to NOS2 expression 
To confirm that the NOS2-induced increase in Thor expression was affected through an 
increase in dFOXO activity, the expression of dFOXO was analysed in response to NOS2 
expression. dFOXO activity has been previously been shown to be regulated by localisation 
(Jünger et al 2003, Puig et al 2003). The phosphorylation of dFOXO by Akt causes it to be 
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retained in the cytoplasm, and thereby unable to act as a transcription factor (Jünger et al 2003, 
Puig et al 2003). Therefore to study dFOXO activity, the localisation of dFOXO protein was 
examined in salivary glands using an antibody specific to dFOXO. A change in localisation of 
dFOXO in response to NOS2 expression in whole salivary glands was not observed, although 
an overall increase in dFOXO expression was detected. To test that this increase in expression 
was not a consequence of reduced cell size, dFOXO expression was analysed in single cells 
expressing NOS2. These single cells also showed an increase in dFOXO protein levels in both 
the cytoplasm and nuclei. Accordingly, it is suggested that NO acts on dFOXO by increasing 
its expression. The regulation of dFOXO expression has been suggested to play a role in its 
activity, and I have shown that increased expression of dFOXO can mimic the effects of NO. 
In a study of dFOXO regulators using Drosophila S2 cells, 21 proteins were identified that 
modulated dFOXO transcriptional activity, protein levels and/or sub-cellular localization 
(Mattila et al 2008). Of these 21 proteins, 8 were shown to regulate dFOXO stability (Mattila 
et al 2008). Therefore, these proteins may be of interest for future work to examine if NO may 
act by affecting one or more of these proteins to regulate dFOXO stability and thereby growth. 
It may also be worthwhile to determine if dFOXO mRNA levels are increased in response to 
NO. This would show that protein levels may be increasing due to increased transcription of 
dFOXO, although of course this would not exclude changes due also to other factors such as 
changes in the stability of the protein and splice variants, as well as other post transcriptional 
modifications. This analysis could be performed in NOS2 expressing clones using in situ 
hybridisation to dFOXO mRNA or real-time PCR could be utilised.  
7.2.3. NOS acts in the insulin signalling pathway 
It was shown that NO was acting within the insulin signalling pathway through dFOXO, but 
not whether this was a direct action. Therefore the effects of NO on components of the insulin 
signaling pathway, above dFOXO, were also investigated.  
We first examined whether knocking out parts of the pathway (which result in reduced growth) 
had any effect on NOS signaling. This part of the study was attempted using RNAi to 
knockdown dNOS expression, along with dInR or PI3K p110. However, no results were 
obtained because of the lethality that resulted. 
To verify the previous data demonstrating that NOS2-induced growth inhibition was dFOXO-
dependent (Kimber 2005), a new RNAi-dFOXO transgene was utilised. Expression of this 
RNAi-dFOXO transgene induced a reduced growth phenotype in the salivary glands, 
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producing glands that were smaller than those resulting from expression of either UAS-NOS2 
or UAS-dFOXO alone. However, it is possible that this reduced growth may be due to the 
known feedback loop, whereby dFOXO acts to regulate expression of dInR (Puig & Tjian 
2005). In this case, it could mean that although dFOXO is known to act in this feedback loop 
where it is thought to function to regulate sensitivity to insulin, acting as an insulin sensor to 
activate insulin signaling, thereby allowing a fast response to the hormone after each meal 
(Puig & Tjian 2005). It may be the case that dFOXO is needed for further expression of dInR 
during development as well, so when dFOXO is not there to modulate dInR expression, 
reduced growth is observed as is seen with RNAi-dFOXO. 
There is a caveat to this theory, as dFOXO null mutants are viable and do not show reduced 
growth (Jünger et al 2003). To address this, dFOXO-independent expression of dInR was 
examined by expressing UAS-dInR, and co-expressing it with UAS-RNAi-dFOXO. Expression 
of wild type UAS-dInR (wt) or activated UAS-dInR* was unable to rescue the small salivary 
gland phenotype seen with UAS-RNAi-dFOXO. However, expression of wild type or activated 
UAS-dInR alone was able to increase growth of salivary gland cells.  An explanation for these 
observations is that in the absence of dFOXO, insulin signaling cannot promote growth. 
Alternatively, the RNAi-dFOXO construct may target the degradation of other mRNA(s) 
required for growth, so called ‘off-targets’ (Saxena et al 2003). It may be worth determining if 
RNAi-dFOXO expression does reduce dFOXO protein levels however this would not exclude 
the possibility of off-targets causing the observed effects. It would be also interesting to 
examine dInR proteins levels in animals expressing RNAi-dFOXO, or in dFOXO nulls to 
determine if there is reduced expression of dInR. The discrepancy between salivary gland 
growth in dFOXO null animals compared to those expressing RNAi-dFOXO may be due to 
competition for insulin. For example, cells expressing RNAi-dFOXO are likely to have 
reduced expression of dInR compared to wild type cells and thus will be at a growth 
disadvantage, whereas in dFOXO null animals, all cells will be expressing equally low levels 
of dInR.   
7.2.4. NO acts downstream of dInR   
To determine if the reduced growth phenotype caused by NOS2 expression could be rescued 
by either wild type UAS-dInR or activated UAS-dInR, epistasis analysis was undertaken. Co-
expression of UAS-NOS2 with either wild type or activated UAS-dInR resulted in decreased 
growth compared to that of wild type or with activated UAS-dInR expression alone. Thus NO-
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induced reduction of growth was unable to be rescued by the expression of either wild type or 
activated UAS-dInR. These data are consistent with NO acting genetically downstream of, or in 
parallel to, the insulin receptor. 
To further examine where NO may be acting in the insulin signalling pathway, a reporter of 
PI3K activity was utilised. This reporter, known as tGPH, responds to PIP3 levels, a secondary 
messenger in the pathway, which increases as a result of active PI3K phosphorylation of 
phosphatidylinositol-4,5-P2  (PIP 2).. tGPH is recruited to plasma membranes by binding PIP3, 
and therefore serves as a reporter for PI3K activity (Britton et al 2002).  
As NOS signalling was shown to act through dFOXO, and dFOXO is known to be part of a 
feedback loop, the localization of tGPH in single cells of the salivary glands expressing 
dFOXO or NOS2 was determined. Single cells expressing dFOXO showed increased 
localisation of tGPH to the cell membrane when compared to wild type cells. This result is 
consistent with the fact that changes in dFOXO activity are thought to feedback on the pathway 
by activating the expression of the insulin receptor (Puig et al 2003, Puig & Tjian 2005), but 
this is the first demonstration of this feedback loop in salivary gland cells. 
However, the data obtained with NOS2 expression were not as clear. The localisation of the 
tGPH in cells expressing NOS2 showed some variation. Mostly, as for dFOXO, tGPH was 
observed at higher levels at the cell membranes. However, in a minority of cases there was no 
alteration in tGPH localisation. This variability could be due to the feedback were dFOXO acts 
to increase expression of the insulin receptor although the extent of this feedback will be 
dependent on how long the cells have been expressing NO. There may also be a lag in the 
activity of dFOXO dependent genes, their translation and the activation of the pathway. Thus, 
although clones are induced at 24 –28 hours AEL, there may be slight differences in the level 
and time of NO expression in these cells which results in the perceived variability in 
expression of dFOXO and thereby its feedback loop. Indeed, when levels of dFOXO were 
determined directly in single cells expressing NOS2, there were noticeable differences between 
individual cells. This explanation could be tested by directly correlating levels of dFOXO 
expression and tGPH localisation simultaneously in clones of cells expressing NOS2 using the 
FLP/FRT technique. 
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7.2.5. NO inhibition of growth does not require soluble Guanyl Cyclase (sGC) 
The activity of sGC is known to be regulated directly by NO in Drosophila (Gibbs et al 2001). 
To determine if NO was regulating growth through sGC, the effects of NO were determined in 
animals with reduced sGC expression. sGC was knocked down via expression of RNAi-Gycα-
99B. There was no obvious change in the growth inhibition induced by NOS2 when expression 
of this sGC was reduced. Indeed, there were no observed changes in growth of cells expressing 
RNAi-Gycα-99B, indicating that cGMP levels are not controlling growth. These data indicate 
that NO dependent regulation of growth does not act through sGC. This is not the first instance 
where NO signaling has been shown to act independently of sGC signalling. Other examples of 
sGC-independent NO signaling have also been identified including by S-nitrosylation (Asada 
et al 2009), through cytochrome oxidase activity (Cooper 2002) and through Metallothionein 
(St. Croix et al 2002), so it may be that NO is acting via one of these other pathways to 
regulate growth.  
However, it has to be noted that the Drosophila genome contains 5 genes that code for soluble 
guanylyl cyclase subunits. Each subunit is differently activated by NO (Morton et al 2005). 
The only subunit targeted by RNAi was Gycα-99B (the α subunit). This subunit along with the 
β subunit, Gycβ-100B, form a conventional, NO-sensitive heterodimeric soluble guanylyl 
cyclase (Dietzl 2007, Shah & Hyde 1995).  Only sGC complexes containing the Gycα-99B 
subunit are highly stimulated (approx. 30 fold) by NO (Morton et al 2005), and the genetic 
removal of the Gycα-99B subunit has also been demonstrated to abolish detectable increase in 
NO induced increases in cGMP levels (Gibbs et al 2001). Thus although Gycα-99B is the only 
likely sGC that can be responding to NO  it is possible that other sGCs may function 
independently of Gycα-99B and these can be stimulated to increase cGMP levels by NO. To 
further investigate the possible role(s) of sGC, if any, in NO inhibition of growth, the levels of 
cGMP could be directly observed using anti-cGMP antibodies. However, any change observed 
in cGMP levels would still not conclusively demonstrate whether cGMP was required for NO 
dependent growth inhibition. To definitively test the role of sGC and cGMP the simultaneous 
knock down of all sGC genes would be required. 
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7.2.6. dFOXO transcriptional targets: roles in NO signalling 
dFOXO was shown to be vital for NO signaling and thus an analysis of the roles of some of its 
transcriptional targets was undertaken.  As mentioned above, an increase in Thor expression 
was identified in response to NO.  
To identify if expression of Thor alone was acting to regulate growth due to NO via dFOXO, 
expression of an active form of Thor (Thor
LL
) was utilised to see if Thor expression would be 
able to induce the  reduced growth seen with either NOS2 or dFOXO expression. In this study, 
the expression of ThorLL resulted in a small reduction in growth, but this difference was not 
statistically significant. This may be due to increased Thor expression not being the only way 
in which NO, acting through dFOXO, is inhibiting growth of these cells. It may also be that 
although Thor
LL
 binds to deIF4E more strongly, this is not having the same growth-inhibitory 
effect that is caused by the large increase in Thor expression that occurs when NO is expressed. 
Therefore further investigation was required. 
To test if the increase in Thor was required for NO inhibition of growth, a null mutation of 
Thor was utilised. When NOS2 was expressed in this Thor null background, a reduction of 
growth was still observed. Thus Thor is not required for NO induced inhibition of growth.  
Another transcriptional target of dFOXO examined was Lk6. Like Thor, Lk6 is also known to 
regulate the activity of the translation initiation factor, eIF4E. Lk6 is also a target of dFOXO 
transcriptional regulation. The activity of Lk6 in response to NO expression was studied via 
two routes: firstly through the expression of NO in an Lk6 mutant null background, and 
secondly by regulation of eIF4E. Expression of NO in Lk6 null animals did not alter the ability 
of NO to inhibit growth. These data indicate that neither Lk6 nor Thor are required 
individually for NO controlled growth. However it has been proposed that Thor and Lk6 may 
act in partnership to regulate translation (Reiling et al 2005). Thus they may have redundant 
roles in growth regulation. To test any redundant roles, double mutant animals were 
constructed. NOS2 expression in these double mutants still resulted in growth inhibition. Thus 
there is no evidence that either of these regulators of translation (separately or in parallel) are 
required for the inhibition of growth caused by NO. Although no role for Lk6 was revealed, it 
is still possible that other kinase(s) may regulate the activity of its substrate, eIF4E, in response 
to NO. The role of phosphorylation of eIF4E in NO dependent growth control was tested using 
a non-phosphorylatable form of eIF4E (eIF4E
Ser251Ala
). Expression of eIF4E
Ser251Ala
  in parallel 
with NOS2 was however unable to suppresses the NO-inhibition of the growth phenotype. 
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Thus there is no evidence that NO-induced growth inhibition is dependent on Thor, Lk6 or 
their effector, eIF4E. Accordingly, although dFOXO is necessary (and sufficient) for growth 
inhibition of the salivary glands, the biologically relevant targets of this transcription factor 
have yet to be identified and this may be of interest for further study.   
7.2.7. NO acts as an inhibitor of misregulated growth 
Nitric Oxide is known to have an antiproliferative activity (Kuzin et al 1996, Peunova & 
Enikolopov 1995, Peunova et al 2001) and FOXO, a target for NO,  has been linked to cell-
cycle arrest and apoptosis in mammalian studies (Zanella et al 2008), this suggests that NO 
may function as a tumor suppressor, with anti-oncogenic effects.  
To test this in Drosophila, the interaction of NO signaling with two known and well-defined 
oncogenes, Ras and dMyc, was analysed. 
Both Ras and dMyc induced overgrowth were shown to be inhibited by co-expression of 
NOS2.  
The expression levels of dMyc in response to NOS2 expression were examined as FOXO has 
been shown to suppress Myc driven proliferation (Bouchard et al 2007), and Myc dependent 
gene expression in cell culture (Delpuech et al 2007). In Drosophila Telman et. al. 2008 have 
also shown that dFOXO does not only act indirectly to inhibit dMyc expression but it may also 
act directly to maintain constant levels of dMyc in the adipose tissue upon fasting. In my 
studies dMyc protein levels often increased in response to NOS2 expression. However in some 
instances dMyc levels appeared unaltered. The increased dMyc levels in these growth-inhibited 
cells is somewhat counterintuitive as increased dMyc is normally associated with increased 
growth. However, FOXO can inhibit the function of Myc (Bouchard et al 2007, Delpuech et al 
2007), and thus the effects of increased dMyc expression (usually associated with increased 
growth and proliferation) may be being suppressed by the increased dFOXO activity in these 
cells.   
Alternatively the observed increase in dMyc expression may indicate a control mechanism, 
whereby once dFOXO expression (induced by NO) reaches a specific level in the cell, dMyc 
expression is activated thereby preventing the over-inhibition of growth. This hypothesis could 
be tested by examining dMyc expression as well as dFOXO expression levels in clones 
overexpressing dFOXO. Slight over expression of dFOXO might be predicted to result in a 
decrease in dMyc expression, whereas high levels of dFOXO could result in an increase of 
dMyc. 
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7.3. Further work 
As well as the specific lines of enquiry that have been discussed above, several other aspects of 
interest that may be worth investigating are noted below. 
dFOXO has been shown to act as a key effector of NO signalling in this thesis as well as in 
previous work (Kimber 2005), therefore it would be revealing to investigate how NO acts on 
dFOXO by examining a known regulator of dFOXO activity, dAkt. Although the data 
presented in this thesis indicates that levels dFOXO are regulated by NO, changes due to 
alterations to the localisation of dFOXO cannot be eliminated. Accordingly it may prove useful 
to determine whether dAkt activity is altered in response to NO. It is also relevant to point out 
a study in which NO was shown to inhibit proliferation of hematopoietic cells (Wang et al 
2007). This work provides evidence that NO-induced G0/G1 arrest is mediated through the 
regulation of cell cycle related proteins, which may be depend on Akt deactivation by NO 
(Wang et al 2007).  
There is also a mammalian cell line which has been utilised to analysis FOXO nuclear-
cytoplasmic shuttling in response to chemical stimuli. This cell line expresses a GFP-FOXO3a 
fusion protein and has previously been used to test the ability of compounds to alter FOXO3a 
localisation (Zanella et al 2008). It would be interesting to determine if NO could alter 
localisation of this mammalian FOXO by using a NO donor such as SNAP. This would allow 
the analysis of mammalian FOXO in response to NO treatment and in turn it may demonstrate 
that NO can effect FOXO localisation. This work in tissue culture would back up work that 
could be continued with the tagged version of dFOXO in cell culture in response to SNAP 
treatment. 
 
The use of Thor-YFP in this study has also identified a method for being able to identify 
proteins which maybe part of the NO signalling pathway using cultured salivary glands and 
SNAP treatment. The Cambridge Protein Trap YFP Insertion stocks can be utilised to identify 
NO responsive proteins. The YFP-protein fusions are expressed at endogenous levels so that 
both localization and protein complexes are likely to reflect the normal cellular physiological 
condition. It must be noted that though SNAP treatment on cultured salivary gland did result in 
the expected increase in Thor-YFP expression, the results were variable. So though this method 
may prove to be a way to quickly screen and identify proteins that may respond to NO and 
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there by be part of NO signalling pathway, care must be taken to then do further work to verify 
those findings.  
A method that could be used to identify genes required for NO induced cytostasis is that of 
RNAi screens in cell culture. Cells could be cultured in the presence of SNAP at a 
concentration that inhibits cell division (200µm (Kimber thesis 2005)) and it could be 
determined if any single RNAi suppressed this growth inhibition. The localisation of dFOXO 
in these cells could also be determined.  
The model proposed in this thesis of NO signalling to FOXO to inhibit growth eliminates sGC 
(upstream of FOXO) and Thor and Lk6 as molecules required for this pathway. However, the 
RNAi screens referred to above may reveal critical molecules required for this signalling.  
A specific protein who’s role in NO signalling that has not been investigated in this work was 
that of AKT. AKT has been identified in previous studies to firstly have a role in the insulin 
pathway acting to inhibit dFOXO (ref). Secondly it has been also identified as a target for NO 
whereby NO acts to inhibited AKT by preventing its phosphorylation. To identify if a similar 
mechanism is occurring in Drosophila the amount of phosphorylated Akt could be determined 
after NO treatment by using antibodies that recognise the phosphorylated form of the protein 
(Torroglosa et al 2007). Additionally, activated Akt could be co-expressed with NOS2 to test 
whether activated Akt could rescue the NOS induced phenotypes.  
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Appendices 
I. Fly stocks used  
Table 1. Bloomington stocks, http://flystocks.bio.indiana.edu/   
 
 
 
 
 
 
 
 
Stock 
# Geneotype Comments 
1824 y[1] w[*]; P{w[+mW.hs]=GawB}AB1 GAL4 in salivary gland, basal expression of P{GawB} 
4780 y[1] w[*]; P{w[+mC]=GAL4-Act5C(FRT.CD2).P}S Ubiquitous expression of GAL4 in FLP-generated clones 
4847 w[1118]; P{w[+mC]=UAS-Ras85D.V12}TL1 Expresses activated Ras 
6979 w[1118]; P{w[+mW.hs]=GawB}C147 GAL4 expressed in larval brain and salivary glands. 
7012 
y[1] w[*] P{ry[+t7.2]=hsFLP}1; P{w[+mC]=UAS-
Tor.WT}III Wild type Tor expressed under the control of UAS 
7118 w[1118]; P{w[+mC]=UAS-myr-mRFP}1 
P{UAS-myr-mRFP} expresses membrane-targeted monomeric 
RFP 
7119 w[1118]; P{w[+mC]=UAS-myr-mRFP}2/TM6B, Tb[1] 
P{UAS-myr-mRFP} expresses membrane-targeted monomeric 
RFP 
8163 w[118]; P{w[+mC]=tGPH}2; Sb[1]/TM3, Ser[1] 
Expresses a fusion protein composed of GFP and the pleckstrin 
homology domain. 
8262 y[1] w[1118]; P{w[+mC]=UAS-InR.Exel}2 Expresses wild type InR under the control of UAS 
8263 y[1] w[1118]; P{w[+mC]=UAS-InR.A1325D}2 Expresses a constitutively active InR under the control of UAS 
8294 P{w[+mC]=UAS-Pi3K92E.CAAX}1, y[1] w[1118] 
Expresses a constitutively active Pi3K92E with a farnesylation 
signal (CAAX) appended to the C terminus. 
8651 
w[1118]; P{w[+mC]=UAS-p35.H}BH1; 
P{w[+mC]=UAS-Thor.LL}s 
Expresses a mutant Thor protein that cannot bind eIF-4E 
effectively under the control of UAS 
8708 w[1118]; P{w[+mC]=UAS-Lk6.A}1/TM6B, Tb[1] Wild type Lk6 expressed under the control of UAS 
8709 w[1118]; P{w[+mC]=UAS-Lk6.T424D}6 Constitutively-active Lk6 expressed under the control of UAS 
8711 w[1118]; P{w[+mC]=UAS-eIF-4E.S251A}8 
Non-phosphorylatable eIF-4E expressed under the control of 
UAS 
8761 P{w[+m*]=GAL4}A9, w[*] 
Expresses GAL4 in the wing and haltere discs. Also weak 
salivary gland expression observed. 
9559 y[1] w[*]; Thor[2] Thor loss of function mutants 
9575 y[1] w[*]; P{w[+mC]=UAS-foxo.P}2 Expresses wild type dfoxo under UAS control 
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Table 2. Vienna Drosophila RNAi Center (VDRC), http://stockcenter.vdrc.at/control/main 
  
 
  
 
 
Table 3. Fly stocks from other sources. 
 
 
 
 
 
 
 
 
 
 
 
 
Stock # Genotype Chromosome  CG number of Gene effected 
 
992 UAS-RNAi-dInR 3 CG18402 
30556 UAS-RNAi-dFOXO       2 CG3143 
38985 UAS-RNAi-Thor 3 CG8846 
38985 UASRNAi-dPI3K p110 3 CG4141 
43711 UAS-RNAi-Gycα-99B 2 CG1912 
Genotype  Chromosome Comments and Reference 
Lk6[15] 3 Lk6 null mutant. A kind gift from Prof. Ernst Hafen (Reiling et al 2005) 
Lk6[38] 3 Lk6 null mutant. A kind gift from Prof. Ernst Hafen (Reiling et al 2005) 
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II. Raw Data from Statistical Analysis of Salivary Gland Nuclei 
measurements 
II. a.  Wild type, NOS2 and dFOXO expression 
 
 
86420-2-4-6
70
60
50
40
30
20
10
0
Residual
Fr
e
q
u
e
n
c
y
Histogram
(response is DATA)
 
 
 
 
Genes  1  WT  
  2  NOS2 
  3  dFOXO 
 
One-way ANOVA: DATA versus GENES  
 
Source   DF        SS       MS        F      P 
GENES     2  11668.31  5834.16  1381.55  0.001 
Error   553   2335.26     4.22 
Total   555  14003.57 
 
S = 2.055   R-Sq = 83.32%   R-Sq(adj) = 83.26% 
 
                           Individual 95% CIs For Mean Based on 
                           Pooled StDev 
Level    N    Mean  StDev   -+---------+---------+---------+-------- 
1      108  22.964  2.664                                        (*) 
2      380  12.711  1.888               (* 
3       68   8.098  1.835   (*) 
                            -+---------+---------+---------+-------- 
                           8.0      12.0      16.0      20.0 
 
Pooled StDev = 2.055 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of GENES 
 
Individual confidence level = 98.04% 
 129 
 
 
 
 
GENES = 1 subtracted from: 
 
GENES    Lower   Center    Upper  ------+---------+---------+---------+--- 
2      -10.778  -10.253   -9.729          (*) 
3      -15.611  -14.866  -14.122  (*) 
                                  ------+---------+---------+---------+--- 
                                    -12.0      -6.0       0.0       6.0 
 
 
 
 
GENES = 2 subtracted from: 
 
GENES   Lower  Center   Upper  ------+---------+---------+---------+--- 
3      -5.246  -4.613  -3.980                   (*) 
                               ------+---------+---------+---------+--- 
                                 -12.0      -6.0       0.0       6.0 
 
 
Genes 1 WT 2 NOS2 3 UAS-dFOXO 
1 WT - - - 
2 NOS2 SD- smaller - - 
3 UAS-dFOXO SD- smaller SD- smaller - 
 
Columns are compared to rows. SD- statistically different  
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II. b.  Wild type, NOS2 and dFOXO expression 
4.53.01.50.0-1.5-3.0-4.5
120
100
80
60
40
20
0
Residual
Fr
e
q
u
e
n
c
y
Histogram
(response is DATA)
 
 
 
 
Genes  1 WT 
  2  RNAi-Gycα-99B 
  3  NOS2 
  4 NOS2 RNAi-Gycα-99B 
 
One-way ANOVA: DATA versus GENES  
 
Source   DF        SS       MS        F      P 
GENES     3  20042.25  6680.75  2781.42  0.001 
Error   896   2152.12     2.40 
Total   899  22194.37 
 
S = 1.550   R-Sq = 90.30%   R-Sq(adj) = 90.27% 
 
 
                           Individual 95% CIs For Mean Based on 
                           Pooled StDev 
Level    N    Mean  StDev  ----+---------+---------+---------+----- 
1      203  23.539  1.749                                  *) 
2      214  24.000  1.443                                   (*) 
3      218  14.029  1.690  (* 
4      265  14.569  1.335    (* 
                           ----+---------+---------+---------+----- 
                            15.0      18.0      21.0      24.0 
 
Pooled StDev = 1.550 
 
 
 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of GENES 
 
Individual confidence level = 98.96% 
 
 
GENES = 1 subtracted from: 
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GENES   Lower  Center   Upper  -------+---------+---------+---------+-- 
2       0.071   0.461   0.851                   (* 
3      -9.898  -9.510  -9.122   *) 
4      -9.341  -8.970  -8.599   (*) 
                               -------+---------+---------+---------+-- 
                                   -6.0       0.0       6.0      12.0 
 
 
GENES = 2 subtracted from: 
 
GENES    Lower  Center   Upper  -------+---------+---------+---------+-- 
3      -10.353  -9.971  -9.588  *) 
4       -9.796  -9.431  -9.065   *) 
                                -------+---------+---------+---------+-- 
                                    -6.0       0.0       6.0      12.0 
 
 
GENES = 3 subtracted from: 
 
GENES  Lower  Center  Upper  -------+---------+---------+---------+-- 
4      0.176   0.540  0.903                   (*) 
                             -------+---------+---------+---------+-- 
                                 -6.0       0.0       6.0      12.0 
 
  
 
 
 
 
 
 
 
 
 
Columns are compared to rows. SD- statistically different. ND- statistically not 
different.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genes 1 2 3 4 
1 WT -    
2 RNAi-Gycα-99B ND -   
3 NOS2 SD-smaller SD –smaller -  
4 NOS2 RNAi-Gycα-
99B 
SD- smaller SD- smaller ND - 
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II. c.  Wild type, NOS2 and dInR expression 
 
15129630-3-6
400
300
200
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0
Residual
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Histogram
(response is DATA)
 
 
 
 
Genes  1 WT 
2 dInR 
3 dInR* 
4 NOS2 
5 NOS2 dInR 
6 NOS2 dInR* 
 
 
One-way ANOVA: DATA versus GENES  
 
Source    DF        SS        MS        F      P 
GENES      5  82469.37  16493.87  3053.76  0.001 
Error   1659   8960.55      5.40 
Total   1664  91429.92 
 
S = 2.324   R-Sq = 90.20%   R-Sq(adj) = 90.17% 
 
 
                           Individual 95% CIs For Mean Based on 
                           Pooled StDev 
Level    N    Mean  StDev  ---+---------+---------+---------+------ 
1      209  23.497  2.344                     (*) 
2      260  27.218  2.233                             *) 
3      269  31.763  4.028                                      (* 
4      315  13.706  1.129  *) 
5      317  14.504  1.938   (*) 
6      295  15.025  1.416     *) 
                           ---+---------+---------+---------+------ 
                           15.0      20.0      25.0      30.0 
 
Pooled StDev = 2.324 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of GENES 
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Individual confidence level = 99.56% 
 
 
GENES = 1 subtracted from: 
 
GENES    Lower  Center   Upper  ---------+---------+---------+---------+ 
2        3.106   3.721   4.336                        (* 
3        7.655   8.266   8.876                             *) 
4      -10.381  -9.790  -9.200           *) 
5       -9.583  -8.993  -8.403           (*) 
6       -9.070  -8.471  -7.873            (* 
                                ---------+---------+---------+---------+ 
                                       -10         0        10        20 
 
 
GENES = 2 subtracted from: 
 
GENES    Lower   Center    Upper  ---------+---------+---------+---------+ 
3        3.969    4.545    5.121                         (* 
4      -14.066  -13.511  -12.956       *) 
5      -13.268  -12.714  -12.160        *) 
6      -12.755  -12.192  -11.629        (* 
                                  ---------+---------+---------+---------+ 
                                         -10         0        10        20 
 
 
GENES = 3 subtracted from: 
 
GENES    Lower   Center    Upper  ---------+---------+---------+---------+ 
4      -18.606  -18.056  -17.506  (* 
5      -17.808  -17.259  -16.710   (* 
6      -17.295  -16.737  -16.179    *) 
                                  ---------+---------+---------+---------+ 
                                         -10         0        10        20 
 
 
GENES = 4 subtracted from: 
 
GENES  Lower  Center  Upper  ---------+---------+---------+---------+ 
5      0.271   0.798  1.324                     (* 
6      0.783   1.319  1.856                      *) 
                             ---------+---------+---------+---------+ 
                                    -10         0        10        20 
 
 
GENES = 5 subtracted from: 
 
GENES   Lower  Center  Upper  ---------+---------+---------+---------+ 
6      -0.014   0.522  1.057                     (* 
                              ---------+---------+---------+---------+ 
                                     -10         0        10        20 
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Genes 1 2 3 4 5 6 
1 Wt       
2 dInR SD-
greater 
     
3 dInR* SD-
greater 
SD-
greater 
    
4 NOS2 SD- 
smaller 
SD- 
smaller 
SD- 
smaller 
   
5 NOS2 dInR SD- 
smaller 
SD- 
smaller 
SD- 
smaller 
ND   
6 NOS2 dInR* SD-
smaller 
SD- 
smaller 
SD- 
smaller 
ND ND  
 
Columns are compared to rows. SD- statistically different. ND- statistically not 
different.  
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II. d.  Wild type and Thor
LL
 expression 
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(response is DATA)
 
 
 
Genes 1 WT 
2 Thor L.L. 
 
 
One-way ANOVA: DATA versus GENES  
 
Source   DF       SS      MS      F      P 
GENES     1   354.79  354.79  65.62  0.001 
Error   400  2162.74    5.41 
Total   401  2517.53 
 
S = 2.325   R-Sq = 14.09%   R-Sq(adj) = 13.88% 
 
 
                           Individual 95% CIs For Mean Based on 
                           Pooled StDev 
Level    N    Mean  StDev  ----+---------+---------+---------+----- 
1      209  23.653  2.556                             (----*---) 
2      193  21.772  2.046  (----*----) 
                           ----+---------+---------+---------+----- 
                            21.70     22.40     23.10     23.80 
 
Pooled StDev = 2.325 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of GENES 
 
Individual confidence level = 95.00% 
 
 
GENES = 1 subtracted from: 
 
GENES   Lower  Center   Upper  ---------+---------+---------+---------+ 
2      -2.337  -1.880  -1.424  (----*-----) 
                               ---------+---------+---------+---------+ 
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                                     -1.60     -0.80     -0.00      0.80 
 
  
 
 
 
 
 
 
 
Colum
ns are compared to rows. SD- statistically different. ND- statistically not 
different.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genes 1 2 
1 Wt -  
2 Thor L.L SD- slightly  smaller  - 
 137 
 
II. e.  Wild type, NOS2 and Thor null larvae 
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Genes  1 WT  
2 Thor[2] 
3 NOS2 
4 NOS2 Thor[2] 
 
 
One-way ANOVA: DATA versus GENES  
 
Source    DF        SS       MS        F      P 
GENES      3  24838.42  8279.47  2714.92  0.001 
Error   1005   3064.87     3.05 
Total   1008  27903.29 
 
S = 1.746   R-Sq = 89.02%   R-Sq(adj) = 88.98% 
 
 
                           Individual 95% CIs For Mean Based on 
                           Pooled StDev 
Level    N    Mean  StDev  ---------+---------+---------+---------+ 
1      216  22.399  2.228                                   (* 
2      288  23.431  1.706                                      (*) 
3      203  12.627  1.533  (*) 
4      302  13.432  1.512     (* 
                           ---------+---------+---------+---------+ 
                                 15.0      18.0      21.0      24.0 
 
Pooled StDev = 1.746 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of GENES 
 
Individual confidence level = 98.96% 
 
 
 138 
 
GENES = 1 subtracted from: 
 
GENES    Lower  Center   Upper  ---------+---------+---------+---------+ 
2        0.629   1.032   1.436                      (* 
3      -10.211  -9.773  -9.334    (* 
4       -9.367  -8.968  -8.568     (*) 
                                ---------+---------+---------+---------+ 
                                      -6.0       0.0       6.0      12.0 
 
 
GENES = 2 subtracted from: 
 
GENES    Lower   Center    Upper  ---------+---------+---------+---------+ 
3      -11.216  -10.805  -10.394  (*) 
4      -10.369  -10.000   -9.631    *) 
                                  ---------+---------+---------+---------+ 
                                        -6.0       0.0       6.0      12.0 
 
 
GENES = 3 subtracted from: 
 
GENES  Lower  Center  Upper  ---------+---------+---------+---------+ 
4      0.398   0.805  1.212                      *) 
                             ---------+---------+---------+---------+ 
                                   -6.0       0.0       6.0      12.0 
 
  
 
 
 
 
Genes 1 2 3 4 
1 Wt -    
2 Thor 2 ND -   
3 NOS2 SD smaller SD smaller -  
4 NOS2 Thor2  SD smaller SD smaller ND - 
 
 
Columns are compared to rows. SD- statistically different. ND- statistically not 
different.  
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II. f.  Wild type, NOS2 and Lk6 null larvae 
 
6.04.53.01.50.0-1.5-3.0-4.5
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Genes  1 WT  
2 LK6[15/38] 
3 NOS2 
4 NOS2 LK6[15/38] 
 
 
One-way ANOVA: DATA versus GENES  
 
Source   DF        SS       MS        F      P 
GENES     3  19331.37  6443.79  2537.68  0.001 
Error   935   2374.20     2.54 
Total   938  21705.56 
 
S = 1.594   R-Sq = 89.06%   R-Sq(adj) = 89.03% 
 
 
                           Individual 95% CIs For Mean Based on 
                           Pooled StDev 
Level    N    Mean  StDev  ---+---------+---------+---------+------ 
1      247  23.582  1.884                                       *) 
2      245  23.607  1.791                                       *) 
3      186  14.625  1.382   *) 
4      261  14.428  1.185  (* 
                           ---+---------+---------+---------+------ 
                           15.0      17.5      20.0      22.5 
 
Pooled StDev = 1.594 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of GENES 
 
Individual confidence level = 98.96% 
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GENES = 1 subtracted from: 
 
GENES   Lower  Center   Upper  ---------+---------+---------+---------+ 
2      -0.344   0.025   0.394                    (*) 
3      -9.354  -8.957  -8.560  (*) 
4      -9.516  -9.153  -8.790  (* 
                               ---------+---------+---------+---------+ 
                                     -5.0       0.0       5.0      10.0 
 
 
GENES = 2 subtracted from: 
 
GENES   Lower  Center   Upper  ---------+---------+---------+---------+ 
3      -9.380  -8.982  -8.584  (*) 
4      -9.542  -9.178  -8.814  (* 
                               ---------+---------+---------+---------+ 
                                     -5.0       0.0       5.0      10.0 
 
 
GENES = 3 subtracted from: 
 
GENES   Lower  Center  Upper  ---------+---------+---------+---------+ 
4      -0.589  -0.196  0.196                    (* 
                              ---------+---------+---------+---------+ 
                                    -5.0       0.0       5.0      10.0 
 
  
 
 
Genes  1 2 3 4 
1 WT -    
2 LK6 null ND -   
3 NOS2 SD- smaller SD- smaller -  
4 NOS2 LK6 null SD- smaller SD- smaller ND - 
 
 
Columns are compared to rows. SD- statistically different. ND- statistically not 
different.  
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II. g.  Wild type, NOS2 and eIF4E larvae 
 
 
4.53.01.50.0-1.5-3.0-4.5
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Genes  1 WT  
5 eIF4E* 
6 NOS2 
7 NOS2 eIF4E* 
 
 
One-way ANOVA: DATA versus GENES  
 
Source   DF        SS       MS        F      P 
GENES     3  21899.50  7299.83  2914.70  0.001 
Error   878   2198.94     2.50 
Total   881  24098.45 
 
S = 1.583   R-Sq = 90.88%   R-Sq(adj) = 90.84% 
 
 
                           Individual 95% CIs For Mean Based on 
                           Pooled StDev 
Level    N    Mean  StDev  -----+---------+---------+---------+---- 
1      210  24.055  1.689                                    (*) 
2      225  24.372  1.608                                      *) 
3      223  14.700  1.517     (*) 
4      224  13.848  1.516  (*) 
                           -----+---------+---------+---------+---- 
                             15.0      18.0      21.0      24.0 
 
Pooled StDev = 1.583 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of GENES 
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Individual confidence level = 98.96% 
 
 
GENES = 1 subtracted from: 
 
GENES    Lower   Center   Upper  --------+---------+---------+---------+- 
2       -0.073    0.317   0.707                    (* 
3       -9.746   -9.355  -8.964    *) 
4      -10.597  -10.207  -9.817  (*) 
                                 --------+---------+---------+---------+- 
                                      -6.0       0.0       6.0      12.0 
 
 
GENES = 2 subtracted from: 
 
GENES    Lower   Center    Upper  --------+---------+---------+---------+- 
3      -10.056   -9.672   -9.288   (*) 
4      -10.907  -10.524  -10.140  *) 
                                  --------+---------+---------+---------+- 
                                       -6.0       0.0       6.0      12.0 
 
 
GENES = 3 subtracted from: 
 
GENES   Lower  Center   Upper  --------+---------+---------+---------+- 
4      -1.236  -0.852  -0.468                  (* 
                               --------+---------+---------+---------+- 
                                    -6.0       0.0       6.0      12.0 
 
  
 
 
 
 
 
 
 
 
 
 
Columns are compared to rows. SD- statistically different. ND- statistically not 
different.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Genes 1 2 3 4 
1 WT -    
2 eIF4E* ND -   
3 NOS2 SD-smaller SD- smaller -  
4 NOS2 eIF4E* SD- smaller SD- smaller ND - 
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II. h.  Wild type, NOS2, Thor null and Lk6 null larvae 
 
 
4.83.21.60.0-1.6-3.2-4.8
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Genes  1 Wt 
2 NOS2 
3 NOS2 Thor[2] LK6[15/38] 
4 Thor[2] LK6[15/38] 
5 NOS2 Thor[2]/+ LK6[15]/+ 
 
One-way ANOVA: DATA versus GENES  
 
Source    DF        SS       MS        F      P 
GENES      4  14412.50  3603.12  1252.85  0.001 
Error   1146   3295.84     2.88 
Total   1150  17708.34 
 
S = 1.696   R-Sq = 81.39%   R-Sq(adj) = 81.32% 
 
 
                           Individual 95% CIs For Mean Based on Pooled StDev 
Level    N    Mean  StDev    -+---------+---------+---------+-------- 
1      211  23.745  1.778                                       (*) 
2      223  14.999  1.853    (*) 
3      241  14.895  1.459    (* 
4      230  20.173  1.410                         (*) 
5      246  15.008  1.921    (*) 
                             -+---------+---------+---------+-------- 
                           15.0      17.5      20.0      22.5 
 
Pooled StDev = 1.696 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of GENES 
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Individual confidence level = 99.36% 
 
 
GENES = 1 subtracted from: 
 
GENES   Lower  Center   Upper  ---+---------+---------+---------+------ 
2      -9.190  -8.745  -8.300  (*) 
3      -9.286  -8.850  -8.413  (*) 
4      -4.013  -3.571  -3.130               (*) 
5      -9.170  -8.736  -8.302  (*) 
                               ---+---------+---------+---------+------ 
                               -8.0      -4.0       0.0       4.0 
 
 
GENES = 2 subtracted from: 
 
GENES   Lower  Center  Upper  ---+---------+---------+---------+------ 
3      -0.535  -0.104  0.326                        (*) 
4       4.739   5.174  5.609                                     (*) 
5      -0.419   0.009  0.437                        (*) 
                              ---+---------+---------+---------+------ 
                              -8.0      -4.0       0.0       4.0 
 
 
GENES = 3 subtracted from: 
 
GENES   Lower  Center  Upper  ---+---------+---------+---------+------ 
4       4.851   5.278  5.705                                     (*) 
5      -0.306   0.113  0.533                        (*) 
                              ---+---------+---------+---------+------ 
                              -8.0      -4.0       0.0       4.0 
 
 
GENES = 4 subtracted from: 
 
GENES   Lower  Center   Upper  ---+---------+---------+---------+------ 
5      -5.589  -5.165  -4.740           (*) 
                               ---+---------+---------+---------+------ 
                               -8.0      -4.0       0.0       4.0 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Columns are compared to rows. SD- statistically different. ND- statistically not 
different.  
 
 
Genes 1 2 3 4 5 
1 WT -     
2 NOS2 SD-
smaller 
-    
3 NOS2  THOR2  LK6null SD-
Smaller 
ND -   
4 THOR 2  LK6 null SD- 
smaller 
SD-
greater 
SD- 
greater 
-  
5  NOS2 Thor[2]/+ 
LK6[15]/+ 
SD-
Smaller 
ND ND SD- 
smaller  
- 
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II. i.  Wild type, NOS2, and Ras
V12
 expression  
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(response is data)
 
 
 
Gene   1  WT 
             2 RASV12 
  3 NOS2  
  4 NOS2 RASV12 
 
 
 
One-way ANOVA: data versus genes  
 
Source    DF        SS        MS        F      P 
genes      3  48131.13  16043.71  2228.14  0.001 
Error   1156   8323.79      7.20 
Total   1159  56454.91 
 
S = 2.683   R-Sq = 85.26%   R-Sq(adj) = 85.22% 
 
 
                           Individual 95% CIs For Mean Based on 
                           Pooled StDev 
Level    N    Mean  StDev  ----+---------+---------+---------+----- 
1      396  20.951  1.512                 (* 
2      236  32.416  3.749                                        (*) 
3      282  13.476  1.479  (*) 
4      246  18.607  3.782             *) 
                           ----+---------+---------+---------+----- 
                            15.0      20.0      25.0      30.0 
 
Pooled StDev = 2.683 
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Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of genes 
 
Individual confidence level = 98.96% 
 
 
genes = 1 subtracted from: 
 
genes   Lower  Center   Upper    +---------+---------+---------+--------- 
2      10.899  11.465  12.032                                   *) 
3      -8.012  -7.475  -6.938                (* 
4      -2.903  -2.344  -1.785                     (* 
                                 +---------+---------+---------+--------- 
                               -20       -10         0        10 
 
 
genes = 2 subtracted from: 
 
genes    Lower   Center    Upper    +---------+---------+---------+--------- 
3      -19.548  -18.940  -18.333    (*) 
4      -14.437  -13.809  -13.182          *) 
                                    +---------+---------+---------+--------- 
                                  -20       -10         0        10 
 
 
genes = 3 subtracted from: 
 
genes  Lower  Center  Upper    +---------+---------+---------+--------- 
4      4.530   5.131  5.732                             *) 
                               +---------+---------+---------+--------- 
                             -20       -10         0        10 
 
 
 
 
 
 
 
 
Columns are compared to rows. SD- statistically different. ND- statistically not 
different.  
Genes  1 2 3 4 
1 WT -    
2 Ras V12 SD- greater -   
3 NOS2 SD- smaller SD- smaller -  
4 NOS2 Ras V12 SD smaller SD- smaller SD- greater - 
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II. j. Wild type, NOS2 and dMyc expression 
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Genes  1 Wt 
2 Myc 
3 NOS2 
4 NOS2 Myc 
 
 
One-way ANOVA: DATA versus GENES  
 
Source    DF        SS        MS        F      P 
GENES      3  44832.26  14944.09  2096.24  0.001 
Error   1200   8554.81      7.13 
Total   1203  53387.07 
 
S = 2.670   R-Sq = 83.98%   R-Sq(adj) = 83.94% 
 
 
                           Individual 95% CIs For Mean Based on Pooled StDev 
Level    N    Mean  StDev    -+---------+---------+---------+-------- 
1      286  23.927  1.936                      (* 
2      319  33.046  3.391                                         *) 
3      223  14.900  1.483    (*) 
4      376  22.940  2.985                    (* 
                             -+---------+---------+---------+-------- 
                           15.0      20.0      25.0      30.0 
 
Pooled StDev = 2.670 
 
 
Tukey 95% Simultaneous Confidence Intervals 
All Pairwise Comparisons among Levels of GENES 
 
Individual confidence level = 98.96% 
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GENES = 1 subtracted from: 
 
GENES   Lower  Center   Upper  ---------+---------+---------+---------+ 
2       8.560   9.118   9.677                              *) 
3      -9.639  -9.027  -8.414           (*) 
4      -1.525  -0.988  -0.450                   (*) 
                               ---------+---------+---------+---------+ 
                                      -10         0        10        20 
 
 
GENES = 2 subtracted from: 
 
GENES    Lower   Center    Upper  ---------+---------+---------+---------+ 
3      -18.743  -18.145  -17.547  (* 
4      -10.628  -10.106   -9.584          (* 
                                  ---------+---------+---------+---------+ 
                                         -10         0        10        20 
 
 
GENES = 3 subtracted from: 
 
GENES  Lower  Center  Upper  ---------+---------+---------+---------+ 
4      7.460   8.039  8.618                            (*) 
                             ---------+---------+---------+---------+ 
                                    -10         0        10        20 
 
  
 
 
 
 
 
 
 
 
 
 
Columns are compared to rows. SD- statistically different. ND- statistically not 
different.  
Genes  1 2 3 4 
1 WT -    
2 MYC SD- greater -   
3 NOS2 SD- smaller SD-smaller -  
4 NOS2 Myc ND SD-smaller SD- greater - 
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